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Summary
Over the last years, ground-breaking success has been achieved in the ﬁeld of human gene
therapy (i.e., the correction of diseases at the genetic level), culminating in the approval of the
ﬁrst gene therapeutic drug Glybera® in the Western world in 2012. Glybera® is based on
Adeno-associated viruses (AAV) which currently form the basis for one of the most promising
therapeutic vectors. Their advantages over other vectors are their apathogenicity in humans,
the ability to achieve long-term gene expression in non-dividing cells due to episomal persis-
tence, and the limited immune response after vector administration. Moreover, they exhibit
a broad natural tropism for a variety of cell types. Still, some tissues cannot be transduced
by AAVs and are thus refractory to AAV gene therapies. Vice versa, the broad tropism can
lead to non-speciﬁc oﬀ-target expression of the delivered transgene. Consequently, there is a
strong need for new AAV capsid variants which can overcome these hurdles.
One way to improve AAV properties is to modify the virus capsid via DNA family shuing
(DFS). This method is based on partial fragmentation of cap genes of several AAV serotypes
and their homology-based re-assembly into chimeras. Since this process is highly error-prone,
a ﬁrst goal in this work was to optimize DFS on the technical and molecular levels. To this end,
we aimed to improve the critical step of DNA fragmentation and hence compared standard
DNaseI digestion with DNA shearing by ultrasonication. Of note, albeit the latter was more
robust, it was outperformed by DNaseI in terms of shuing eﬃciency and crossover forma-
tion. Secondly, we noted a dependency of recombination eﬃciencies on input DNA homologies
that was most evident for the diverse cap genes of AAV4 and 5. We thus re-synthesized these
variants and adapted their sequence to that of AAV2. The resulting 13 % homology increase
translated into 2.5 x more crossovers per clone in an AAV2-4-5 cap library containing the new
sequences as compared to its wild-type counterpart. These beneﬁts were further validated
with higher complexity libraries including larger numbers of AAV serotypes.
In addition, we investigated the role of the recently discovered, essential assembly-activating
protein AAP on the outcome of the DFS method. As AAP is fully encoded in the AAV cap
gene and was shown to be necessary for capsid assembly, we hypothesized that AAV shuing
may disrupt AAP integrity. To investigate this theory, we created assembly-deﬁcient AAP
knock-out mutants of AAV serotypes 1  9 and rh10. Notably, generation of functional par-
ticles could be restored in all cases by supplying AAP expression plasmids in trans during
virus production. We furthermore tested 46 shued and randomly chosen AAPs from dif-
ferent AAV cap libraries in our new model system. Remarkably, 39 (84.8 %) were able to
rescue the AAP knock-out, to extents varying from 5 to 100 %. Of note, most of the deﬁcient
AAPs originated from shued libraries containing AAV4 or 5 capsid genes. We thus produced
virus particles from a shued capsid library of AAV2-4-5-8-9 in the presence or absence of
a mixture of all corresponding AAP expression plasmids. Strikingly, AAP addition had no
eﬀect on virus titers albeit 60 % of the encoded AAPs were predicted to be non-functional due
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to inadvertent recombination or disruption during shuing. As a whole, our data strongly
suggest that fortunately, unintended AAP shuing is no major limiting factor for DFS-based
generation of new AAV capsids.
Finally, our AAP knock-out constructs and a newly produced anti-AAP2 polyclonal antibody
allowed us to study AAP biology in greater detail. Surprisingly, we detected an inﬂuence
of AAP2 on viral cap protein (VP) stability, indicating the occurrence of post-translational
VP modiﬁcations. Moreover, we studied AAP2 expression by microscopy and compared it
to AAPs of other serotypes. Conspicuously, cellular localization varied between the AAPs,
implying unique hotspots of viral capsid assembly.
Collectively, the work presented here has substantially improved the method of AAV DFS
and should thus contribute to a much wider use of this powerful technology in the future.
Concomitantly, our data provide novel insights into AAP biology and, together with our new
constructs and models, open up a multitude of avenues for future research into the fundamen-
tal and applied aspects of AAV.
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Zusammenfassung
Innerhalb der letzten Jahre konnten im Bereich der humanen Gentherapie (d.h. der Behand-
lung von Krankheiten auf genetischer Ebene) bahnbrechende Erfolge erzielt werden. Diese
gipfelten 2012 in der Zulassung des ersten gentherapeutischen Medikamentes (Glybera®)
in der westlichen Welt. Glybera® basiert auf Adeno-assoziierten Viren (AAV), welche die
Grundlage für einen der momentan vielversprechendsten therapeutischen Vektoren bilden.
Die Vorteile von AAVs gegenüber anderen Vektoren liegen in ihrer fehlenden Pathogenität im
Menschen, einer beschränkten Immunreaktion nach Vektor-Verabreichung sowie der Fähigkeit,
eine Langzeit-Expression in sich nicht-teilenden Zellen auf Grund von episomaler Persistenz
zu erzielen. Zudem zeichnen sie sich durch einen natürlichen, breiten Tropismus in einer Viel-
zahl von Zellen aus. Dennoch können einige Gewebe nicht mit AAVs transduziert werden und
sind deshalb von einer AAV-basierten Gentherapie ausgeschlossen. Umgekehrt kann der brei-
te Tropismus zu einer unspeziﬁschen, fehlgeleiteten Expression des transportierten Transgens
führen. Infolgedessen existiert ein großer Bedarf an neuen AAV Kapsid-Varianten, die diese
Hürden überwinden können.
Ein Weg, um die Eigenschaften von AAVs zu verbessern, ist die Modiﬁkation des Virus-
Kapsides durch DNA family shuing (DFS). Diese Methode basiert auf der partiellen Frag-
mentierung von Kapsid-Genen verschiedener AAV-Serotypen sowie deren Homologie-basierter
Rekombination zu Chimären. Da dieser Prozess sehr fehleranfällig ist, war das erste Ziel der
vorliegenden Arbeit, eine Optimierung von DFS auf technischer sowie molekularer Ebene zu
erreichen. Insbesondere sollte der kritische Schritt der DNA-Fragmentierung verbessert wer-
den. Dazu wurde der standardmäßig durchgeführte DNaseI-Verdau mit der DNA-Scherung
durch Ultraschall verglichen. Obwohl sich dabei die letztere Methode als deutlich robuster her-
ausstellte, übertraf der DNase-Verdau diese hinsichtlich der Erzeugung von Serotyp-Wechseln
(Crossovers) sowie Shuing-Eﬃzienz. Darüber hinaus konnte festgestellt werden, dass die
Rekombinations-Eﬃzienz unmittelbar von der Homologie der eingebrachten DNA abhängt.
Dies oﬀenbarte sich besonders deutlich bei den unterschiedlichen Kapsid-Genen von AAV4 und
5, weshalb beide neu synthetisiert und ihre Sequenzen an die von AAV2 adaptiert wurden.
Daraus resultierte eine Homologie-Steigerung von 13 %. Der direkte Vergleich einer Kapsid-
Bibliothek aus AAV2-4-5, welche die neuen Sequenzen beinhaltete, mit ihrem ursprünglichen
Gegenstück zeigte daraufhin eine 2,5-fach höhere Zahl an Crossovers pro Klon. Auch in kom-
plexeren Bibliotheken mit einer größeren Menge an AAV-Serotypen konnten diese Verbesse-
rungen beobachtet werden.
Des Weiteren wurde in dieser Arbeit die Rolle des kürzlich entdeckten, essentiellen AAV-
Proteins AAP (assembly-activating protein) auf den Erfolg der Methode des DFS unter-
sucht. AAP ist vollständig im Kapsid-Gen kodiert und wird für die Kapsid-Zusammensetzung
benötigt. Es wurde deshalb vermutet, dass AAV-Shuing möglicherweise die Integrität von
AAP zerstören könnte. Um diese Theorie zu untersuchen, wurden AAP-Mutationen in die
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AAV-Serotypen 1  9 sowie rh10 eingefügt. Diese waren daraufhin nicht mehr in der Lage,
Kapside auszubilden. Die Erzeugung funktioneller Partikel konnte in allen Fällen durch die
Zugabe von AAP-Expressionsplasmiden während der Virusproduktion wiederhergestellt wer-
den. Als nächstes wurden 46 geshuﬀelte und zufällig ausgewählte AAPs aus verschiedenen
AAV-Kapsid-Bibliotheken mit diesem Modell-System getestet. Bemerkenswerterweise waren
39 davon (84,8 %) in der Lage, den AAP-Defekt zu 5  100 % zu kompensieren. Der Großteil
der nicht funktionierenden AAPs stammte dabei aus Kapsid-Bibliotheken, welche AAV4 und
5 enthielten. Dies wurde zum Anlass genommen, Viruspartikel einer Kapsid-Bibliothek mit
AAV2-4-5-8-9 in der An- sowie Abwesenheit einer AAP-Plasmid-Mischung der verwendeten
Serotypen zu produzieren. Interessanterweise hatte die Zugabe von AAP keinen Eﬀekt auf die
Virus-Titer obwohl 60 % der kodierten AAPs auf Grund von Mutationen oder Beeinträch-
tigungen durch Shuing als nicht-funktional klassiﬁziert wurden. Insgesamt weisen diese
Daten darauf hin, dass unbeabsichtigtes AAP-Shuing glücklicherweise keine wesentliche
Beeinträchtigung für die DFS-basierte Generierung von neuen AAV-Kapsiden darstellt.
Zum Abschluss erlaubten die generierten AAV-AAP-Mutanten sowie ein neu produzierter, po-
lyklonaler anti-AAP2 Antikörper tiefere Einblicke in die AAP-Biologie. Überraschenderweise
wurde hierbei ein Einﬂuss von AAP2 auf die Stabilität der AAV2-Kapsid-Proteine festgestellt,
was auf eine posttranslationale Modiﬁkation dieser Proteine schließen lässt. Weiterhin wurde
die Expression von AAP2 mikroskopisch untersucht und mit AAPs anderer Serotypen vergli-
chen. Auﬀällig war dabei, dass die zelluläre Lokalisation zwischen den verschiedenen AAPs
variierte, was speziﬁsche Orte für die virale Kapsid-Zusammensetzung impliziert.
Zusammenfassend verbessert die hier präsentierte Arbeit die Methode des AAV-Shuings
substantiell und wird daher zu einer breiteren Nutzung dieser Technologie in der Zukunft
beitragen. Gleichzeitig liefern die vorgestellten Daten neue Einblicke in die AAP-Biologie und
eröﬀnen zusammen mit den hergestellten Konstrukten und neuen Modellen eine Vielzahl an
Wegen für die zukünftige Erforschung grundlegender sowie angewandter Aspekte von AAV.
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Introduction
Over the last years, gene therapy approaches for the treatment of diseases like hemophilia,
cancer, congenital blindness or central nervous system and immunodeﬁciency disorders were
extensively developed and tested in numerous clinical studies. These types of therapies are
characterized by the introduction of nucleic acids into patient cells to knock down, add or
modify genes [1]. In order to deliver recombinant DNA, RNA or editing enzymes to the cells
or organs of interest physical, chemical or biological methods can be selected [2]. However,
physical treatment (e.g. electroporation) and chemical modiﬁcations (e.g. cationic lipids) are
limited in in vivo applications and/or eﬃciency [3]. Therefore, most of the reported clinical
trials chose viral vectors as a delivery tool for their transgene into the target cells. Widely
used vector systems are gammaretro- and lentiviral vectors (both belong to the family of
retroviruses), adenoviruses and Adeno-associated viruses (AAV) [4]. Retroviruses are mainly
used for applications which require a stable integration of the transgene into the host genome
to maintain protein expression. In addition to gammaretroviral vectors, lentiviruses can also
infect non-dividing cells and therefore broaden the range of cell types for gene therapy [5]. One
example for successful gene therapy with retroviruses is the treatment of patients suﬀering
from SCID (severe combined immunodeﬁciency). In detail, haematopoietic stem cells were
isolated from these patients, transduced ex vivo for the introduction of the transgene and
transplanted back into the patient. The advantage of this treatment is ascribed to less oﬀ-
targeting compared to an in vivo application and is more unlikely to trigger immune responses.
Clinical trials conducted so far reported stable transgene expression for more than 10 months
[6,7]. However, some of the treated individuals developed acute lymphoblastic leukemia caused
by integration of the delivered transgene into a proto-oncogenic locus [8, 9] which represents
the major drawback of retroviral vectors. In contrast to retroviruses, adenoviral vectors and
AAVs (mainly) persist episomally in the cell nucleus [5]. Thus, negative side eﬀects due to
integration events in regulatory regions or active genes are less likely to occur. Adenoviruses
are valued therapeutic tools in terms of delivery eﬃciency and transgenic expression. On
the other hand they can cause very strong immune reactions after systemic administration
which unfortunately resulted in the death of at least one patient [10]. New vector generations
already led to an improvement of immunogenicity, but applications are restricted to e.g.
cancer gene therapy where immune stimulation is advantageous [2, 5]. Therefore, one of the
most aspiring gene therapeutic vectors are AAVs since they are not associated with a disease,
mediate long-term transgenic expression due to episomal persistence in non-dividing tissue
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and do not induce acute inﬂammatory responses since engineered vectors lack endogenous
viral protein expression (see also chapter 1.2) [1, 2, 5]. Their great promise is supported by
the ﬁrst AAV-based gene therapy approved in Europe in 2012 (known as Glybera®) which
is designed for patients with lipoprotein lipase deﬁciency (LPLD) [11]. Next to the successful
approval of Glybera®, numerous clinical trials for treatment of e.g. hemophilia, congenital
blindness or heart failure are currently ongoing [12] and underline the relevance of the AAV
vector system for gene therapy. Thus, the following chapters will provide more details on
AAV biology, life cycle and vector engineering which can be used for the generation of new,
highly eﬃcient AAV variants.
1.1 Adeno-associated virus (AAV)
1.1.1 AAV classiﬁcation and genome organization
AAVs are small non-pathogenic viruses which belong to the family of Parvoviridae and the
genus of Dependoviruses. The classiﬁcation already implies the need of AAVs for a helper
virus in order to undergo a complete replication cycle. Hence it is not surprising that they
were discovered as contaminant of an Adenovirus preparation ∼ 50 years ago [13]. Next to
Adenovirus also herpes simplex virus (HSV) or human papillomavirus (HPV) can mediate
helper functions for eﬃcient AAV replication [1416].
As is typical for parvoviruses, the genome of AAVs consists of single-stranded (ss) DNA
with a length of ∼ 4700 nucleotides (nt). The coding region of the genome is ﬂanked by two
identical palindromic regions (ITRs  inverted terminal repeats) that form a T-shaped hairpin-
like structure [17], serve as viral DNA replication initiators [18] and possess transcriptional
activity [19,20]. Besides the two ITRs, AAVs contain a rep and a cap gene which encode non-
structural and structural proteins, respectively (see ﬁgure 1.1). These genes are driven by
three promoters, namely p5, p19 and p40, and are terminated by the same polyA signal 3' of
cap [21]. In detail, rep encodes four proteins [22] involved in viral DNA replication, integration
and packaging (see also section 1.1.2). Two of them are transcribed from the p5 promoter
(Rep78 and Rep68) whereas the other two start at the p19 promoter (Rep52 and Rep40).
All of the transcripts contain an intron which is spliced out via one donor and one of two
existing acceptor sites (A1 and A2). Unspliced transcripts lead to Rep78 and Rep52 proteins,
spliced variants to Rep68 and Rep40, respectively [21]. The cap gene is transcribed from the
p40 promoter resulting in a RNA that also contains the abovementioned intron. The RNA
variant spliced through A1 (A1-RNA) encodes for structural protein VP1 while A2-spliced
variants (A2-RNA) encode VP2 and VP3 [23, 24] (ﬁgure 1.1). Notably, A1-RNA generation
seldom occurs compared to A2-RNA splicing and thus determines the relative protein ratio
of VP1:VP2:VP3 with 1:1:10. In addition, VP2 is initiated by the non-consensus start codon
ACG and therefore less frequently translated than VP3 with the conventional start codon
AUG. In 2010, an additional protein was discovered to be translated from the p40-transcribed
2
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Figure 1.1: Genome organization and mRNA transcripts of AAV. The structure of the
complete AAV genome is depicted on top and shows the two genes rep (blue) and cap (orange) ﬂanked
by the ITRs. The colors of the viral promoters p5, p19 and p40 indicate the transcription of the
assigned genes. Viral transcripts for rep and cap are displayed below. All of them contain one splice
donor site (D) and two acceptor sites (A1 and A2). In case of rep transcription, splicing results in two
shorter proteins (Rep68 and Rep40) independent of the acceptor site used. In contrast, cap transcript
splicing determines the ratio of viral capsid protein translation since A1 spliced RNA (encodes for
VP1) appears less frequently than A2 spliced RNA (encodes for VP2 and VP3). Moreover, VP2
is driven by the non-conventional start codon ACG. Next to the VPs, cap also encodes AAP in its
second ORF (grey) which is initiated by a CTG start codon. AAP = assembly-activating protein,
ORF = open-reading frame, D = splice donor, A = splice acceptor.
RNA [25]. In contrast to VP1-VP3, it is encoded in the second open-reading frame (ORF) of
the cap gene and utilizes the non-conventional initiation codon CUG which is located between
the VP2 and VP3 start codons. The protein was named assembly-activating protein (AAP)
and is reported to be required for capsid assembly (see section 1.1.2.3 for more details).
1.1.2 AAV life cycle
1.1.2.1 Cell entry, intracellular traﬃcking and nuclear transport
At the beginning of the AAV life cycle the non-enveloped AAV capsid binds to a cell-surface
receptor and initiates endocytosis. This process is based on the diﬀerent capsid structures
and their diverse receptor binding capabilities (see chapter 1.1.3.2 for details). Depending on
the bound receptor diﬀerent routes of capsid internalization are activated. Although many
studies have been conducted so far the process of AAV endocytosis is not fully understood.
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Usually, AAV serotype 2 was used for cell entry studies and therefore is the best investigated
AAV. It was shown that AAV2 can utilize at least two routes of infection which are clathrin-
mediated endocytosis [26, 27] and the CLIC/GEEC pathway [28]. Other serotypes such as
AAV5 can also internalize through caveolar endocytosis [29]. Generally, it is suggested that
AAVs can enter the host cell through diﬀerent pathways which can then direct the particles
to an infectious (nuclear translocation) or non-infectious pathway (lysosomal / proteasomal
degradation) [30]. Indeed, addition of proteasome inhibitors results in an enhanced transduc-
tion [3133] which is associated with a prevention of capsid degradation potentially mediated
by phosphorylation and ubiquitination [31, 34, 35]. However, this eﬀect was cell-type speciﬁc
and so far only shown for AAV serotypes 2, 5, 7 and 8.
Successful AAV infection requires not only eﬃcient endocyctosis but also eﬀective intracel-
lular transport to the nucleus. It was shown that AAV2 traﬃcks through late and recycling
endosomes towards the nucleus [36]. During this transport AAV2 particles undergo a confor-
mational change in the internalized endosomes [27,32] and thereby expose their VP1 and VP2
N-termini to the outer capsid [37]. This process is required for eﬃcient transduction and is
based on the phospholipase A2 (PLA2) domain located in the VP1 protein sequence [38,39].
In detail, the PLA2 domain leads to an endosomal escape of the virions from the golgi appa-
ratus or the endoplasmic reticulum (ER) [4043]. Moreover, VP1/2 N-termini contain basic
regions which act as nuclear localization signals. They are responsible for the translocation
of viral particles from the cytoplasm to the nucleus after endosomal escape [43, 44]. The
transport of AAVs into the nucleus happens through the nuclear pore complex (NPC) from
where the virions pass the nucleoplasm in direction to the nucleoli [27,45,46]. Intact particles
are preserved until they escape again from the nucleoli and release their viral DNA.
1.1.2.2 Uncoating, integration and DNA replication
Previous reports have shown that AAV particles which enter the nucleus are intact and translo-
cate to the nucleoli (see previous section). While the process of uncoating and viral genome
release has not been completely elucidated so far, it is assumed that DNA release takes place in
the nucleoplasm and is not dependent on the complete disassembly of the particle [45,47,48].
Once the viral DNA is unpackaged it has to be transformed from a ss to a ds (double-stranded)
form prior to transcription. This can happen through annealing of positive and negative DNA
strands which are packaged as single copies in the AAV capsid [49]. On the other hand, com-
plementary strand synthesis occurs and is initiated from the free 3' hydroxyl group of the ITR
which serves as primer for the host DNA polymerase [50]. During this process AAV DNA
is also replicated for virus particle production. This so-called rolling hairpin replication is
depicted in more detail in ﬁgure 1.2. Importantly, the process of AAV replication and tran-
scription is dependent on the presence of a helper virus. In the absence of e.g. adenovirus,
AAV integrates into the host genome which requires the AAV ITRs and one of the viral pro-
teins Rep78 or Rep68. In detail, AAV Rep binds simultaneously to sequences in the ITR and
in the AAVS1 locus of human chromosome 19 and thereby tethers the AAV genome to its
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Figure 1.2: Schematic depiction of the
AAV genome rolling hairpin replica-
tion (Chandler, M. et al., 2013 [51]).
Viral replication starts at the free 3' hy-
droxyl group of the ITR which serves as
primer for the host DNA polymerase (a).
Elongation continues to the 5' end of the ss
DNA (b, c) followed by the recruitment of
Rep proteins to the 3'ITR (d) where they
bind to the Rep binding element (RBE)
and the Rep binding site (RBS) site (Rep
interaction sites are marked with blue cir-
cles in the close-up picture on top of the
ﬁgure). The interaction of Rep and ITR
is assumed to induce a conformational
change resulting in the nick of the DNA at
the terminal resultion site (trs) mediated
by Rep (e) and thereby allows replication
of the 3' ITR (f). Subsequently, ITRs re-
fold (g) and single-stranded DNA is dis-
placed resulting in two copies of ss viral
DNA which provide new free 3' OH groups
for a next replication cycle (h). Note that
introduction of a mutation in the trs of
one ITR leads to a failure of Rep nick-
ing and to dimer formation [52, 53]. As
a result self-complementary AAV genomes
are generated and packaged (not depicted
here, see chapter 1.2.1 for more details and
ﬁgure 1.5 for the resulting genome confor-
mation).
The parental DNA strand is marked in
green, the newly synthesized strand in red.
ITRs are displayed as T-shaped struc-
tures.
integration site [5456]. Once the host cell is infected with a helper virus, latent AAV copies
are activated and replication can start in order to produce new viral particles.
1.1.2.3 Protein expression, virus assembly and the involvement of AAP
Immediately after viral ds DNA is synthesized, protein expression can occur. First, viral
Rep proteins are translated since they regulate DNA replication, gene expression and viral
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integration. Subsequently, structural proteins VP1-VP3 are expressed and virus particles
assemble [57]. Since 2010 it has been known that an additional protein (named AAP) is
required for the assembly process [25]. AAP is also encoded in the cap gene (see section 1.1.1)
and is highly conserved among the diﬀerent AAV serotypes. Typically, AAV2-AAP (AAP2)
localizes in the cell nucleoli as it contains nuclear and nucleolar localization signals [58].
Moreover, it targets the VPs to this organelle where particle assembly takes place. It has
been suggested that AAP acts as a scaﬀold or a chaperone for the VPs in order to allow viral
capsid formation. Probably also intracellular proteins like nucleophosmin or nucleolin are
involved in this process [59, 60]. After the capsid has been formed, large Rep proteins target
the ss viral DNA by simultaneous binding of ITRs and VPs to the particle [61]. Rep40 and
Rep52 helicase activities are further required for translocation of the DNA through the pores
at the ﬁve-fold symmetry axes of the capsid [62, 63]. During this procedure only one copy of
ss DNA (either plus or minus strand) is packaged per particle. Finally, newly formed AAV
viruses spread from the nucleus throughout the cell [57] and are released from the cell due to
lysis which occurs in the context of helper virus co-infection.
1.1.3 AAV capsid characteristics
1.1.3.1 Capsid structure
The AAV capsid consists of 60 VP units and forms a ∼ 18  26 nm icosahedral particle with
a T=1 symmetry (ﬁgure 1.3b) [64, 65]. Each particle encapsidates one copy of ss viral DNA
(either plus or minus strand). The diﬀerent cap proteins VP1, VP2 and VP3 are represented
in the capsid in a ratio of 1:1:10 which is determined by the RNA splicing frequency and
the relative translation eﬃciency due to alternative start codons (see also section 1.1.1). VP
amino acid (aa) sequences overlap completely in the C terminus; hence the VP3 sequence is
fully included in VP1 and VP2. VP1/2 share additional 65 aa. Moreover, VP1 comprises a
137 aa unique N-terminal region which mediates the phospholipase A2 activity mentioned in
section 1.1.2. Crystal structures, cryo-electron microscopy studies and image reconstructions
of diﬀerent AAV capsids have shown that only the shared aa residues of all VPs constitute
the outer capsid surface. N-terminal extensions of VP1 and VP2 as well as the ﬁrst ∼ 15 aa
of VP3 could not be resolved and are hidden in the inner particle. So far structures of nine
AAV serotypes (AAV1  AAV9) have been determined in detail, with AAV2 remaining the
best characterized [6676].
Within the particle the single VP subunits are arranged in a two-, three- and ﬁve-fold sym-
metry which results in the characteristic AAV capsid surface composed of cylindrical channels
surrounded by canyons at the ﬁve-fold axes, protrusions at the three-fold axes and depres-
sions at the two-fold axes (see ﬁgure 1.3b). The three-fold protrusions are spike-like structures
formed by exposed loops from the VP subunits. Each of these subunits contains one conserved
α-helix and one β-barrel with eight anti-parallel β-sheets (βB  βI) connected by large loops
(ﬁgure 1.3a) [66, 67]. Loops are named according to their ﬂanking β-sheets, e.g. HI-loop.
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Figure 1.3: AAV2 capsid structure
and variable regions (Tseng, M.
& Agbandje-McKenna, M., 2014
[79]). a) Ribbon structure of the
resolved overlapping AAV VP3 C-
terminus. The protein contains one
conserved α-helix (αA), one single β-
sheet (βA) and one β-barrel with eight
anti-parallel β-sheets (βB  βI) con-
nected by large loops. Loop structures
encompass the nine identiﬁed variable
regions (VRs) and are named accord-
ing to their ﬂanking β-sheets (loop DE
or HI are labeled as examples). Vari-
able regions are colored as follows: VR-
I = purple, VR-II = blue, VR-III =
yellow, VR-IV = red, VR-V = black,
VR-VI = pink, VR-VII = cyan, VR-
VIII = green, VR-IX = brown, HI loop
= wheat. N- and C-terminal ends are
marked with N and C, respectively.
Two-, three- and ﬁve-fold symmetry
axes are indicated by a black oval, tri-
angle and pentagon, respectively. b)
Surface rendition of the AAV2 capsid.
Icosahedral symmetry axes are labeled.
Colors of variable regions match with
a). Note the cylindrical channels at
the ﬁve-fold and the protrusions at the
three-fold axes (see text for more de-
tails).
The comparison between AAV serotype 2 and 4 capsids revealed a high variability within
these loop structures. Thus, they were named variable region (VR) I  IX [69,77]. Resulting
diﬀerences in surface topology are responsible for varying antibody interactions and receptor
bindings. For instance, the GH loop encompasses VR-IV and -VIII which build the afore-
mentioned peak structure at the three-fold axes and mainly mediate AAV2 receptor binding
(see also sections 1.1.3.2 and 1.2.2.2).
The cylindrical pores at the ﬁve-fold symmetry axes connect the inner part of the capsid with
the outside. The N-terminal regions of VP1 and VP2 which have not been accessible for
structural determination so far are potentially located at the base of these channels [66, 78].
Due to conformational changes of the capsid during intracellular traﬃcking, VP1/2 N termini
are exported through the ﬁve-fold channel and exposed on the outer capsid surface (see also
section 1.1.2). Next to the externalization of VP domains, also the encapsidation of viral
DNA occurs through the ﬁve-fold pore [63].
Of note, not only virus packaging or tissue tropism are inﬂuenced by the capsid structure but
also the interaction with the immune system. In detail, depending on their surface epitopes
AAVs can cause B-cell mediated antibody responses [80] which entails neutralization of virus.
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This is especially important for AAV vector applications in gene therapeutic approaches and
was thus a matter of intense investigation: It has been shown that the prevalence of pre-
existing antibodies in the human population reaches up to 70 % depending on the AAV
serotype [79]. Anti-AAV2 antibodies could be detected in ∼ 60  70 % of examined indi-
viduals followed by ∼ 35  70 % with anti-AAV1 antibodies, ∼ 50 % anti-AAV9, ∼ 50 %
anti-AAV6, ∼ 40 % anti-AAV8 and ∼ 40 % anti-AAV5 antibodies [81, 82]. For capsids with
high homology (e.g. AAV2 and 3) also antibody cross-reactivities could be observed [83].
1.1.3.2 AAV serotypes and their tropism
Since the discovery of AAVs ∼ 50 years ago at least 12 serotypes and more than 100 isolates
of AAVs were described. They are characterized by a diﬀerent cell tropism and/or immuno-
genicity and classiﬁed according to their similarities in VP sequences. Based on these protein
analyses, nine clades of AAVs are deﬁned (clade A  I, ﬁgure 1.4) [84, 85]. AAVs assigned to
clade A  C and F originate from humans whereas AAVs belonging to clade D or G  I were
isolated from non-human primate (NHP) or porcine tissue, respectively. An exception is clade
Figure 1.4: AAV clades
(modiﬁed from Bello, A. et
al., 2014 [84]). Phylogenetic
tree of important AAV isolates
based on the comparison of
AAV capsid protein sequences.
Designated AAV clades are in-
dicated by vertical lines next to
representative members. AAVs
marked in orange are variants
used in this study. Importantly,
AAV3, 4, 5 and 12 are not as-
signed to any clade. Serotypes
AAV3b and AAVrh10, which
are not depicted in the ﬁgure,
are closely related to AAV3 and
AAV10 (6 / 12 aa diﬀerence),
respectively. The phylogenetic
distance between the AAV
variants is indicated by the
scale bar at the lower left. hu.
= human, po. = porcine, rh. =
rhesus macaque, go. = goat.
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E that contains AAV isolates from human as well as NHP tissue. AAV serotypes 3, 4, 5 and
12 are not assigned to any clade. Out of these, especially AAV4, 5 and 12 substantially diﬀer
from the sequences of other AAV variants and show a sequence identity of only ∼ 60 % (see
also ﬁgure 3.3). In contrast, AAV1  3, 6  9 and rh10 exhibit between 78  97 % sequence
homology. However, already these small diﬀerences in the aa sequence can inﬂuence AAV cell
tropism due to variations in receptor binding. In detail, AAV2 and 3b use heparan sulfate
proteoglycan (HSPG) as main receptor for cell entry [8688] whereas AAV1, 4 and 5 bind N-
or O-linked sialic acids [89, 90]. AAV6 which is assumed to be a chimera between AAV1 and
AAV2 [91] binds both, HSPG and sialic acids [89, 92]. For AAV7, 8, 12, rh10 and po.1 the
primary cell receptor has not been identiﬁed so far. Interestingly, AAV9 is the only variant
that uses N-linked glycans with terminal galactosyl residues as binding partner [93]. Thus,
AAV9 transduction can be increased by neuraminidase treatment of the cells prior to infection
since sialic acids mask N-linked galactose on the cell surface [93, 94]. Recently, Pillay et al.
discovered a new universal receptor for diﬀerent AAV serotypes [95]. This transmembrane
protein was named AAVR and seems to be essential for cellular transduction of AAV1, 2,
3b, 5, 6, 8 and 9. Next to the binding of AAV particles, AAVR was shown to enable virus
traﬃcking from the cell membrane to the trans-Golgi network. Hence, AAVR appears to play
a critical role in the infectious life cycle of human and NHP AAVs.
Next to primary receptors, also co-receptors were identiﬁed to be necessary for eﬃcient vi-
ral cell entry. Particularly for AAV2 diﬀerent co-receptors have been described and stud-
ied in more detail, i.e. αVβ5 and α5β1 integrins [96, 97], ﬁbroblast growth factor recep-
tor 1 (FGFR1) [87], hepatocyte growth factor receptor (HGFR) [98] and laminin receptor
(LamR) [99]. In addition, AAV8 and 9 were reported to use LamR whereas AAV3 also binds
FGFR1 [99, 100]. Table 1.1 summarizes the known receptors and co-receptors for the men-
tioned AAV variants and depicts reported AAV cell speciﬁcities ranging from liver, heart and
kidney to skeletal muscle and the central nervous system. However, although many cell types
can be transduced with AAVs others like T- or B-cells are less or not permissive for AAV
transfer and thus not accessible for gene therapeutic applications. Of note, modiﬁcations of
the viral capsid can overcome these hurdles. In order to provide further insights into the
generation of new AAV variants, the next chapter will explain the options for genomic and
capsid surface engineering in more detail.
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Table 1.1: Mainly used AAV serotypes or variants and their tropism. Informations were gathered
from publications [30] and [65] as well as serveral original articles.
AAV
serotype
Origin Receptor Co-receptor Tropisma Sequence
reference
AAV1 Laboratory
isolate
(probably
human)
N-linked
sialic acid
Unknown SM, CNS, retina,
pancreas
Hoggan
et al.
(1966) [101]
AAV2 Human HSPG FGFR1,
HGFR,
LamR, CD9
tetraspanin
VSMC, SM,
CNS, liver, kid-
ney
Hoggan
et al.
(1966) [101]
AAV3b Human HSPG FGFR1,
HGFR,
LamR
SM, human liver
(x.m.m.)
Rutledge
et al.
(1998) [102]
AAV4 NHP
(African
green mon-
key)
O-linked
sialic acid
Unknown CNS, retina Parks et al.
(1967) [103]
AAV5 Human N-linked
sialic acid
PDGFR SM, CNS, lung,
retina
Bantel-
Schaal
et al.
(1984) [104]
AAV6 Laboratory
isolate
(probably
human)
N-linked
sialic acid,
HSPG
EGFR SM, heart, lung Rutledge
et al.
(1998) [102]
AAV7 NHP (rhesus
monkey)
Unknown Unknown SM, retina, CNS Gao et al.
(2002) [105]
AAV8 NHP (rhesus
monkey)
Unknown LamR Liver, SM, CNS,
retina, pancreas,
heart
Gao et al.
(2002) [105]
AAV9 Human N-linked,
terminal
galactose
LamR Liver, lung, pan-
creas, kidney,
heart (i.v), brain
(i.v.), SM (i.v.)
Gao et al.
(2004) [85]
AAVrh10 NHP (rhesus
monkey)
Unknown Unknown CNS (r) Gao et al.
(2004) [85]
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AAV
serotype
Origin Receptor Co-receptor Tropisma Sequence
reference
AAVpo.1 Porcine Unknown Unknown SM, retina Bello et al.
(2009) [106]
AAV12 NHP (Vervet
monkey)
Unknown Unknown Lung (t.c.), colon
(t.c.), nasal ep-
ithelia
Schmidt
et al.
(2008) [107]
aTissue tropism after local delivery unless indicated otherwise
Abbreviations: AAV = Adeno-associated virus, CNS = central nervous system, EGFR = epidermal growth
factor receptor, FGFR1 = ﬁbroblast growth factor receptor 1, HGFR = hepatocyte growth factor receptor;
HSPG = heparan sulfate proteoglycan, i.v. = intravenous injection, LamR = laminin receptor, NHP = non-
human primate, PDGFR = platelet-derived growth factor receptor, r = rodent model, SM = skeletal muscle,
t.c. = tissue culture, VSMC = vascular smooth muscle cell, x.m.m. = xenograft mouse model.
1.2 Recombinant AAV vectors for gene therapy
1.2.1 Genome engineering
Naturally, the AAV genome consists of a rep and a cap gene ﬂanked by two ITRs (see chapter
1.1.1 for more details). In order to use AAVs as vectors for gene therapeutic approaches a
transgene has to be encoded and packaged within the viral capsid. This can be simply achieved
by exchanging rep and cap with a transgene of interest under the control of a selected promoter
as well as a polyA signal. Rep and cap can be provided in trans during vector production and
hence ITRs are the only cis-acting elements required for eﬃcient vector generation [108]. In
addition, adenoviral genes (namely E2A, E4, VA-RNA and E1A/E1B) have to be supplied for
stimulation of productive AAV replication in the absence of infectious helper-virus [109]. The
advantage of the described system is the complete elimination of AAV genes which results
in replication-incompetent particles with an improved safety proﬁle. Moreover, it has been
shown that the absence of Rep proteins averts the directed integration of AAV vector genomes
into the AAVS1 locus [110, 111]. Instead of integrating, recombinant AAV genomes persist
preferentially episomally [110,112,113] and therefore mediate long-term expression especially
in non-dividing cells. However, AAVs were also reported to integrate randomly to a small
extent (< 1 %) into the host cell genome [1, 112, 114]. Of note, neither integration hotspots
could be detected in AAV treated patient samples [113] nor a correlation between integration
sites and oncogenesis could be observed in mice [115]. The latter was recently questioned by
a publication which postulated an oncogenic role of wild-type AAV2 in human hepatocellular
carcinomas [116]. Yet, this presumption was critically discussed and disproved by leading
AAV researchers who again emphasized the safety of AAV as a therapeutic tool [117,118].
Since AAV expression is not only inﬂuenced by eﬃcient gene transfer or intracellular traﬃcking
but also by the eﬀective conversion of ss to ds DNA [119,120], researchers have improved the
AAV vector design towards enhanced gene expression. Therefore, self-complementary AAV
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Figure 1.5: AAV genome
conformations (modiﬁed
from Le Bec, C. & Douar,
A., 2006 [128]). Schematic
depiction of single-strand
(ss - left side) and self-
complementary (sc - right
side) AAV vector genomes.
Note that the sc genome is
half the size of the ssAAV.
After uncoating in the nu-
cleus, ss genomes have to
be converted into ds DNA
by nuclear factors for later
transcription and replication.
In contrast, sc genomes
re-fold and directly serve as
transcription template.
vectors (scAAV) were developed which carry ds instead of ss transgene expression cassettes
(ﬁgure 1.5) [121]. For this purpose, one ITR of the AAV genome was mutated at the trs
resulting in a failure of DNA nicking mediated by Rep (see also ﬁgure 1.2) [52, 53]. As a
consequence, dimeric AAV genomes are created which can re-anneal after AAV uncoating in
the nucleus and directly serve as transcription template independent of the hosts replication
machinery. It is important to note that due to this modiﬁcation the packaging capacity of
scAAVs is reduced from ∼ 4.4 kb to ∼ 2.2 kb (without ITRs) in comparison to ssAAVs.
However, 2.2 kb are still suﬃcient to encode small proteins or RNA-based therapeutics such
as microRNAs (miRNA) or short-hairpin RNAs (shRNA).
In order to increase AAV packaging capabilities (mainly for ss vectors), dual AAV vectors have
been developed. Therefore, oversized transgenic cDNA is split into two parts and packaged
into separate vectors. Under these conditions the virus with the 5' part of the transgene
also encodes a promoter whereas the vector with the 3' fragment encodes the polyA signal.
Subsequent expression of the full-length protein can be achieved by homologous recombination
in the cell due to overlapping regions in the cDNA [122124]. Moreover, splice donor and
acceptor sites can be added to the ends of the cDNA to allow for eﬃcient recombination
on the RNA level [124, 125]. Both methods were also combined and have yielded increased
transgenic expression [126,127].
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1.2.2 Capsid engineering
1.2.2.1 DNA family shuing
To overcome AAV gene therapy limitations caused by pre-existing immunity or a lack of
suitable serotypes for speciﬁc tissues, the AAV capsid can be modiﬁed to obtain new variants
with desired characteristics. One possibility to generate new particles is DNA family shuing.
The general method was ﬁrst described in 1994 [129] and has the potential to create a large
library of diﬀerent DNA variants originating from a few parental sequences. In detail, DNA
family shuing is based on the fragmentation of input parental DNA and its re-assembly
to full-length genes in a primer-less PCR reaction. A prerequisite for recombination during
PCR is an initial DNA homology of at least 50 % of the parental sequences in order to allow
smaller fragments to act as primers in the ampliﬁcation reaction. During these priming events
fragments of diﬀerent parents bind each other and thereby generate crossovers which lead to
highly diverse shued DNA variants.
In 2000 researchers started to apply the method to viruses and generated viral capsids
with new tropisms [131, 132]. In 2008 AAV cap genes were successfully modiﬁed for the ﬁrst
time by Grimm and colleagues [133] followed by several other reports [134136]. Each of
the published studies used between 7 and 10 diﬀerent AAV capsids as input material for
library generation. In this respect it is advantageous that all AAV capsids exhibit a homology
of more than 50 % (see section 1.1.3.2) which allows to include any existing capsid in the
library design. The genes are then further fragmented by using DNaseI enzyme followed
by a ﬁrst re-assembly PCR and a second PCR with ﬂanking primers to speciﬁcally amplify
the full-length cap gene (ﬁgure 1.6). After puriﬁcation of the speciﬁc product, the library
is cloned into a wild-type AAV construct containing the rep gene and two ﬂanking ITRs.
Randomly picked chimeras of the generated library are sequenced in order to validate shuing
eﬃciency and library diversity. The latter typically ranges between 7x105 and 107 diﬀerent cap
sequences per approach [133135] which is normally determined by counting bacterial colony
numbers. Finally, virus particles are produced by transfection of cells with the generated rep-
cap library constructs and a plasmid providing all necessary adenoviral genes for replication,
followed by selection of the shued AAV capsids in diﬀerent cell lines or mouse models. The
selection process is characterized by several rounds of transduction in the presence or absence
of helpervirus infection and ideally enriches one or several functional AAV cap variants (see
section 1.2.3 for more details). Two of the most promising selected and evaluated shued
AAVs so far are AAV-DJ [133] and AAV-LK03 [136]. The ﬁrst one is a chimera of AAV2, 8
and 9 cap sequences which outperformed eight naturally existing AAV serotypes in various cell
lines as well as primary cells. Additional studies further validated the potential of AAV-DJ as
gene therapeutic vector in various tissues [137,138] and in 2012 also the capsid structure could
be resolved via cryo-EM [139]. The second AAV chimera, LK03, was selected in vivo in mouse
livers which were partially repopulated with primary human hepatocytes. It mainly consists of
AAV3b but also contains parts of AAV cap 1, 2, 4, 6, 8 and 9. LK03 was reported to speciﬁcally
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Figure 1.6: Schematic representation of AAV capsid DNA family shuing. At the beginning
(1) several AAV cap genes are selected and PCR-ampliﬁed from a plasmid construct. Cap genes are
further puriﬁed and (2) fragmented e.g. with DNase enzyme. DNA fragments serve as input for a
(3) primer-less re-assembly PCR followed by a (4) second PCR with ﬂanking primers. Full-length
shued cap genes are (5) puriﬁed and (6) re-cloned (in this study via PacI/AscI restriction sites)
into an AAV wild-type plasmid containing AAV rep and ITRs. In order to validate the generated
AAV library, (7) random clones are sequenced and analyzed. Successful validation is followed by (8)
virus production and (9) several selection rounds in vitro or in vivo. pBS = Bluescript plasmid with
AAV cap gene, pSSV9 = ss AAV plasmid carrying rep and cap ﬂanked by two ITRs of AAV2 [130].
transduce human but not mouse hepatocytes in vitro and in vivo and thereby represents a
leading candidate for human gene therapeutic approaches in the liver. In summary, AAV-
DJ and LK03 exemplify the great potential of DNA family shuing in the context of AAV
capsids. Thus, shuing is a promising tool for the generation of more AAV variants with
speciﬁc features and expanded tropism.
1.2.2.2 Peptide display
Apart from DNA family shuing the insertion of small peptides oﬀers another option for the
modiﬁcation of AAV capsids. Typically, these peptides are inserted into exposed regions of
the capsid surface and thereby (I) destroy the natural tropism and (II) mediate new recep-
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tor binding. In contrast to DNA family shuing, the capsid backbone comprises only one
serotype. First attempts of ligand introduction into AAV were made in 1999 by Girod and
colleagues [140]. They inserted a 14 aa peptide into several regions of the AAV2 capsid based
on a hypothetical model of the virus. Of note, one of the generated capsid variants could
eﬃciently transduce B16F10 cells which are normally not susceptible to AAV2 infection. Sev-
eral subsequent studies modiﬁed the AAV2 particle in similar ways which resulted in altered
vector tropism but also revealed more insights into structure-function relationships [141144].
The fact that (random) aa insertions into the capsid can also inﬂuence viral assembly, DNA
packaging or intracellular traﬃcking underlined the importance of basic knowledge of virus
biology. Hence, capsid modiﬁcations were facilitated in 2002 when the atomic structure of
AAV2 was elucidated [67] which enabled site-directed mutagenesis or rational design of in-
sertion sites into speciﬁc positions of the viral surface. Interestingly, already the 1999 study
determined a region (aa pos. 587) important for receptor binding which was later identiﬁed to
be located in close proximity to the heparin binding motif in VR-VIII of AAV2 (aa R585 and
R588) [145,146]. Therefore, further eﬀorts often inserted peptides between aa 587 and 589 in
order to destroy the HSPG binding pattern of AAV2 and re-direct receptor binding to natu-
rally non-target cells [147149]. To moreover allow for a high-throughput analysis of diﬀerent
aa sequences, a library of randomly generated peptides is inserted into capsid positions of
interest (named peptide display) and screened for lead candidates [150,151]. Interesting pep-
tide sequences that were identiﬁed by this method and lead to re-direction of AAV2 capsids
are NDVRAVS and NSSRDLG in primary human endothelial cells [151], LATQVGQKTA
(with an additional V719M mutation) in neural stem cells [152] or PSVSPRP in mouse heart
cells [153], amongst others. However, although peptide display is an eﬃcient method to re-
direct AAV capsids it is limited by the restricted knowledge of receptor binding motifs and
3D structures of other AAV serotypes. Thus, it is diﬃcult to transfer lead peptide candidates
into other capsids without the need for a new selection [154156]. Moreover, the modiﬁcations
achieved by peptide display are limited to less than 1 % of the capsid surface [157] and are
rarely applicable for alterations of complex multi-domain interactions.
1.2.2.3 Other methods
Instead of DNA family shuing or peptide display also other methods can be exploited for
the modiﬁcation of the AAV capsid surface. For example, with error-prone PCR random
mutations are inserted into the cap gene during DNA ampliﬁcation [158, 159]. Of note, the
used polymerase misses proof-reading ability which favors point mutations. As a result, gen-
erated cap libraries carry single aa substitutions at random positions. In contrast to the
already described methods, the diversity of achieved mutations per capsid is rather low [158]
and thereby also limited in terms of complexity. Improvements of the method can be accom-
plished by restriction of mutagenesis to speciﬁc regions of the capsid like surface receptors or
antibody binding sites [160,161].
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Next to error-prone PCR also site-directed mutagenesis can modify the capsid surface eﬃ-
ciently. This method resulted in e.g. the identiﬁcation of the HSPG receptor of AAV2 before
the 3D structure was solved [145,146] or immune escape cap variants with reduced binding of
neutralizing antibodies [160, 162]. Additionally, deliberated deletions of tyrosine residues at
the capsid surface led to an improved transduction eﬃciency of several AAV serotypes due to
an increased cellular traﬃcking of viral particles from the cell surface to the nucleus [163167].
The latter is related to a decrease in virus capsid phosphorylation and subsequent ubiquitina-
tion, which in turn circumvents proteasomal degradation. Despite the eﬃcient modiﬁcation of
several AAV capsids in the described studies, site-directed mutagenesis still requires detailed
knowledge of the 3D particle structure. Since only a few AAV isolated have been characterized
suﬃciently so far, also this method is limited regarding diversity generation.
Another diﬀerent approach for capsid modiﬁcation is the incorporation of exogenous molecules
into one of the viral proteins. It has been reported that VP2 tolerates a fusion of at least 238 aa
(GFP) which is successfully integrated into the capsid and displayed at the surface [168,169].
Others used this ability to expose e.g. designed ankyrin repeat proteins (DARPins) on the
AAV surface. DARPins are small, highly speciﬁc binders which are pre-selected on molecules
of interest [170172]. By integration of DARPins binding speciﬁcally to the CD4 receptor,
eﬃcient re-direction of AAV capsids to CD4-positive cells could be observed [173]. Another
report introduced the variable region of an anti-CD34 antibody into the viral capsid and
achieved an improved transduction of a CD34+ human myoleukemia cell line [174]. However,
although VP2 fusions can induce successful re-direction of vector tropism, the production of
these modiﬁed AAVs is highly ineﬃcient and needs additional puriﬁcation steps.
Recently, an innovative strategy for the generation of new AAV capsids called ancestral se-
quence reconstruction was published [175,176]. Here the authors ﬁrst analyzed isolated AAV
variants and calculated their phylogenic relation. Second, they identiﬁed common nodes and
reconstructed a library of ancestor sequences based on computational analysis. Impressively,
one of the identiﬁed ancestral capsids (Anc80L65) yielded higher transduction rates than
AAV8 in the liver and retina of injected mice and also outperformed this AAV in the liver
of rhesus macaques [175]. Thus, ancestral reconstruction represents a powerful method for
AAV capsid modiﬁcation which can result in promising vector candidates for gene therapeutic
applications.
1.2.3 Selection strategies
After AAV cap library generation with one of the aforementioned methods (see chapter 1.2.2),
lead candidates have to be selected in order to obtain eﬃciently transducing vector particles.
Therefore, two diﬀerent selection strategies depending on the intended outcome can be applied.
(I) AAV libraries can be selected in vitro on cells of interest that best match the future
application. In case the chosen cell line is susceptible for adenovirus, a helpervirus co-infection
can accelerate the selection process due to the induction of active AAV replication [133, 150,
177]. If not applicable, PCR rescue has to be performed to recover potent AAV sequences
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followed by new virus productions. Ideally, after 3  5 screening rounds at least one lead
AAV candidate can be characterized. In order to obtain AAV variants that are resistant to
antibody neutralization, an additional selection pressure by adding e.g. IVIGs (pooled human
immunoglobulins) can be applied [133]. Therefore, IVIGs have to be pre-incubated with the
library followed by cell transduction. Despite the simplicity and speed of in vitro selection,
some drawbacks diminish the potential of the strategy. On the one hand it is not sure whether
the evolved capsids target the same cell types under in vivo conditions [133,178]. On the other
hand, eﬃcient vectors often transduce more cell types apart from their selection tissue and thus
cause unintended oﬀ-target eﬀects [133]. To overcome these problems, (II) AAV libraries can
be selected directly in vivo and interesting AAV sequences can be PCR-rescued from organs
of interest. This strategy outperforms the in vitro system especially regarding the complexity
of cellular interactions and the presence of the immune system which cannot be mimicked
with a cell line. Normally, mice or rats serve as model system for in vivo selections [179181].
However, since rodents are not necessarily predictive for the future application in human gene
therapy [182, 183] also screenings in NHP can be considered [184, 185]. It is important to
note that the latter is more cost-intensive and has to cope extensive administration processes,
logistics as well as ethical barriers. Moreover, in vivo selections generally require AAV libraries
with high virus titers and can last several months before a lead capsid candidate is enriched.
Thus, one has to weigh the costs versus beneﬁts before decisions about the selection system
can be made.
1.3 Aim of thesis
Due to the need for AAV capsids that eﬃciently transduce speciﬁc tissues in gene therapeutic
approaches, this thesis focused on the technique of DNA family shuing for the generation of
new AAV cap variants. We especially wanted to optimize the currently used protocol for DNA
family shuing and aimed to standardize speciﬁc steps (i.e. DNA fragmentation) which are
highly susceptible to external inﬂuences. Moreover, our goal was to improve the incorporation
of AAV cap 4 and 5 into shued libraries since several reports exempliﬁed the challenges in
integrating these distinct capsids. Towards this aim we planned to sequence-optimize these
cap sequences and to compare their incorporation into diﬀerent shued AAV libraries with
varying complexities. In this context, we also wanted to determine the role of AAP in the
shuing procedure. Because of the limited knowledge of AAP biology it seemed plausible that
AAP shuing aﬀects the outcome of the method and the formation of particles. Therefore,
we planned to ﬁrst develop a model system in order to be able to test functionalities of AAPs
derived from diﬀerent AAV serotypes. Second, we wanted to clone a number of shued AAPs
from various AAV libraries which should be validated in this system. Based on the developed
model we also intended to investigate AAP biology in more detail. Thus, we aimed to examine
the eﬀect of AAP knock-out on AAV RNA and protein levels. Moreover, we planned to obtain
a polyclonal antibody against AAP2 which would allow us to perform detailed microscopy
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analyses to gain more insights into AAP localization and expression. Apart from AAP2, also
the localization of AAPs from other serotypes should be determined. In summary, this thesis
wanted to optimize DNA family shuing in order to allow improved AAV capsid modiﬁcations
and wished to contribute to the elucidation of AAP functions.
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Materials and methods
2.1 Materials
Table 2.1: Oligonucleotides
Internal
number
Name Sequence
#36 Mid  Cap 1-3/6-9,
rh10, po.1, 12
GAAATTGGCATTGCGATTCC
#37 Mid  Cap 4/5 GATTGGCATTGCGATTCCAC
#178 DJRev GTCGCAAAACACTCACGTGACCTC
#459 SAFor GACTACAAGGACGACGATGACAAG
#460 SARev CACTGAATTCTCATCAGGCGAAG
#641 Fw_SSV9_rep2_
HindIII
ACGCGGAAGCTTCGATCAAC
#642 Rev_SSV9_Spe/Xba gatactctagaGTTCGACCGCAGCCTTTCGAATGTC
CGGTTTATTactagtGGCGCGCCCTGGACTC
#780 mCherry-For BamHI ctggcaggatccattgctcATGGTGAGCAAGGGCGAGG
AGGATAACATG
#781 mCherry-Rev
NotI/XhoI/SalI
ccgacgtcgacggttagcggccgcattctccgctcgagcggattaCTT
GTACAGCTCGTC
#792 pEGFP _C2_FP GATCACATGGTCCTGCTG
#822 LSeqFor GATCTGGTCAATGTGGATTTG
#823 LSeqRev GACCGCAGCCTTTCGAATGTC
#827 M13For GTAAAACGACGGCCAGTGAG
#828 M13Rev GGAAACAGCTATGACCATG
#833 Rep2For AGACGCGGAAGCTTCGATCAA
#835 CMV for CGCAAATGGGCGGTAGGCGTG
#964 SwaI_4GA For ctgatttaaatCAGGTATGACCGATGGTTATCTTC
#965 SwaI_5GA For ctgatttaaatCAGGTATGTCTTTCGTTGATCATC
#966 AAV4GA_PacI For ccttaattaaCAGGTATGACCGATGGTTATCTTC
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number
Name Sequence
#967 AAV4GA_AscI_SpeI
Rev
ggactagtggcgcgccTTACAGATGATGAGTCAGGTA
TC
#968 Start-Leu repair
AAP4GA For
GTTTTTGAGGACGAGACTGGCGCAGGCGACG
GACC
#969 Start-Leu repair
AAP4GA Rev
GGTCCGTCGCCTGCGCCAGTCTCGTCCTCAA
AAAC
#970 1st STOP remove
AAP4GA For
CTGGCGGAGCAGCGGTCGAGGGTGGCCAGGG
#971 1st STOP remove
AAP4GA Rev
CCCTGGCCACCCTCGACCGCTGCTCCGCCAG
#972 2nd STOP remove
AAP4GA For
GGGAATGCGACCCAAGGCAATGCGGGTCAAG
ATCTTTAACATTCAAG
#973 2nd STOP remove
AAP4GA Rev
CTTGAATGTTAAAGATCTTGACCCGCATTGCC
TTGGGTCGCATTCCC
#974 STOP repair
AAP4GA For
GTACGAGCTCCCGTACGTGATGGACGCGGGG
CAGG
#975 STOP repair
AAP4GA Rev
CCTGCCCCGCGTCCATCACGTACGGGAGCTC
GTAC
#976 TGA_repair
5GA_PacI For
ccttaattaaCAGGTATGTCTTTCGTTGATCATCCT
CCAGATTGGCTCGAGGAGGTTGGTGAAGGA
CTAAGAGAGTTC
#977 AAV5GA short_PacI
For
ccttaattaaCAGGTATGTCTTTCGTTGATCATC
#978 AAV5GA AscI_SpeI
Rev
ggactagtggcgcgccTTACAGAGGACGAGTCAGG
#979 Start-Leu repair
AAP5GA For
CTAGCGACGCAGAGGCTGGACCTAGCGGATC
CCAG
#980 Start-Leu repair
AAP5GA Rev
CTGGGATCCGCTAGGTCCAGCCTCTGCGTCG
CTAG
#981 STOP remove
AAP5GA For
GAAATTAAGAGCGGATCAGTCGACGGCTCGA
ACGCCAATG
#982 STOP remove
AAP5GA Rev
CATTGGCGTTCGAGCCGTCGACTGATCCGCT
CTTAATTTC
#983 AAP2 NotI For ataagaatgcggccgcATGGAGACGCAGACTCAGTAC
#984 AAP2 / 3b EcoRI
Rev
ccggaattcTCAGGGTGAGGTATCCATAC
#985 AAP4 NotI For ataagaatgcggccgcATGGAGCAGGCGACGGACCC
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Internal
number
Name Sequence
#986 AAP4 EcoRI Rev ccggaattcTCACGTACGGCAGTTCGTAC
#987 AAP5 NotI For ataagaatgcggccgcATGGACCCAGCGGATCCCAGC
#988 AAP5 EcoRI Rev ccggaattcTCAGCGTCGCGTAACCGTAC
#989 AAP8 NotI For ataagaatgcggccgcATGGCGACTCAGAGTCAGTTC
#990 AAP8 / 1 / 6 EcoRI
Rev
ccggaattcTCATGAACACGTCCGCCGGG
#991 AAP9 NotI For ataagaatgcggccgcATGGCGACACAGAGTCAGTCC
#992 AAP9 EcoRI Rev ccggaattcTCATGAAAACGTCCGCTGG
#993 AAV2 mut Fw Rev GGCTGTCCGAGAGGCTGGGGGTCAGGTACT
GAGTCTGCGTCTCCGGTCTGACCAAAATTC
#994 AAV2 mut Rev Fw CCAGCCTCTCGGACAGCCACCAGCAGCCCCC
TCTGGTCTAGGAACTAATACGATGGCTAC
#1014 AAV8 mut Fw TCAACCTCTCGGAGAACCTCCAGCAGCGCCC
TCTGGTGTAGGACCTAATACAATGGCTGC
#1015 AAV8 mut Rev GGTTCTCCGAGAGGTTGAGGGTCTGGAACT
GACTCTGAGTCGCCGGTCTGACCAAAATTG
#1016 AAV9 mut Fw TCAACCAATCGGAGAACCTCCCGCAGCCCCC
TCAGGTGTAGGATCTCTTACAATGGCTTC
#1017 AAV9 mut Rev GGTTCTCCGATTGGTTGAGGGTCTGGGACT
GACTCTGTGTCGCCGGTCTGACCGAAATTG
#1038 SwaI_Cap289 Fw ctgatttaaatCAGGTATGGCTGCCGATGGTTATC
#1039 Swa_Cap4 Fw ctgatttaaatCAGGTATGACTGACGGTTACCTTC
#1040 SwaI_Cap5 Fw ctgatttaaatCAGGTATGTCTTTTGTTGATCACC
#1041 SwaI_Cap4SO Fw ctgatttaaatCAGGTATGACCGATGGTTATCTTC
#1042 SwaI_Cap5SO Fw ctgatttaaatCAGGTATGTCTTTCGTTGATCATC
#1107 qPCR Cap2 rep78/68
For
GAGGCCCTTTTCTTTGTGCA
#1108 qPCR Cap2 rep78/68
Rev
CGATCCCGCGGTAAATTCTC
#1109 qPCR Cap2 rep52/40
For
CCTTCTACGGGTGCGTAAAC
#1110 qPCR Cap2 rep52/40
Rev
CCGAGGACTTGCATTTCTGG
#1111 qPCR Cap2 VP1 For GCTGCCGATGGTTATCTTCC
#1112 qPCR Cap2 VP1 Rev ACTTGTACCCAGGAAGCACA
#1113 qPCR Cap2
VP2/3+AAP For
AGGAACCTGTTAAGACGGCT
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number
Name Sequence
#1114 qPCR Cap2
VP2/3+AAP Rev
GGTACTGAGTCTGCGTCTCC
#1117 GAPDH human
qPCR Fw
ACCCACTCCTCCACCTTTGAC
#1118 GAPDH human
qPCR Rev
TGTTGCTGTAGCCAAATTCGTT
#1161 GFP-AAP2 Rev CAGCTCCTCGCCCTTGCTCACGGGTGAGGTA
TCCATAC
#1162 AAP2-GFP Fw GTATGGATACCTCACCCGTGAGCAAGGGCGA
GGAGCTG
#1163 GFP EcoRI Rev ccggaattcTTACTTGTACAGCTCGTCCATG
#1242 AAP4SO NotI For ataagaatgcggccgcATGGCGCAGGCGACGGACCTC
#1243 AAP4SO EcoRI Rev ccggaattcTCACGTACGGGAGCTCGTAC
#1244 AAP5SO NotI For ataagaatgcggccgcATGGACCTAGCGGATCCCAG
#1245 AAP5SO EcoRI Rev ccggaattcTCAGGGTGGCGTATCCATAC
#1282 AAV1 mut Fw ACAACCTCTCGGAGAACCTCCAGCAACCCCC
GCTGCTGTAGGACCTACTACAATGGCTTC
#1283 AAV1 mut Rev GGTTCTCCGAGAGGTTGTGGATCGGGGACT
GACTCTGAGTCGCCGGTCTGACCAAAATTG
#1284 AAV3b mut Fw TCAACCTCTCGGAGAACCACCAGCAGCCCCC
ACAAGTTTAGGATCTAATACAATGGCTTC
#1285 AAV3b mut Rev TTCTCCGAGAGGTTGAGGGTCTGGGACTGAC
TCTGAGTCGCCGGTCTGACCGAAATTTAG
#1286 AAV6 mut Fw ACAACCTCTCGGAGAACCTCCAGCAACCCCC
GCTGCTGTAGGACCTACTACAATGGCTTC
#1287 AAV6 mut Rev GGTTCTCCGAGAGGTTGTGGGTCGGGGACT
GACTCTGAGTCGCCGGTCTGACCAAAATTG
#1288 AAV7 mut Fw TCAACCTCTCGGAGAACCTCCAGCAGCGCCC
TCTAGTGTAGGATCTGGTACAGTGGCTGC
#1289 AAV7 mut Rev GGTTCTCCGAGAGGTTGAGGGTCGGGGACT
GACTCTGAGTCGCCGGTCTGACCGAAATTG
#1290 AAVrh10 mut Fw CTCAACCAATCGGAGAACCCCC CGCAGGCCC-
CTCTGGTCTAGGATCTGGTACAATGGCTG
#1291 AAVrh10 mut Rev GGTTCTCCGATTGGTTGAGGGTCGGGCACT
GACTCTGAGTCGCCGGTCTGCCCAAAGTTG
#1292 AAP1/3/6/7 NotI
For
ataagaatgcggccgcATGGCGACTCAGAGTCAGTCC
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Internal
number
Name Sequence
#1293 AAPrh10 NotI For ataagaatgcggccgcATGGCGACTCAGAGTCAGTGC
#1294 AAP7/rh10 EcoRI
Rev
ccggaattcTCATGAAGACGTCCGCCGGG
#1318 Rep2 rev, pos. 1827 TCATCCAAATCCACATTGAC
#1319 Rep2 rev, pos. 944 CGTGGCCCATCCCAGAAAG
Oligonucleotides used in this work were synthetized by the companies IDT and Sigma
Overhangs are written in small letters
Enzyme restriction sites are underlined
Introduced mutations are marked in red
Table 2.2: Plasmids
Internal
number
Name Description Reference / origin
#68 pIRES(blast)
FLAG/HA-hAgo2-
GA
CMV-hAgo2 (codon-
optimized), HA-tag, IRES,
blasticidin
Cloned by N.
Schürmann
#182 WHc1(SpeI) helper plasmid with AAV2
rep, AAV1 cap, SpeI site
Cloned by E. Kienle
#183 WHc2(SpeI) helper plasmid with AAV2
rep, AAV2 cap, SpeI site
Cloned by E. Kienle
#184 WHc4(SpeI) helper plasmid with AAV2
rep, AAV4 cap, SpeI site
Cloned by E. Kienle
#185 WHc5(SpeI) helper plasmid with AAV2
rep, AAV5 cap, SpeI site
Cloned by E. Kienle
#186 WHc6(SpeI) helper plasmid with AAV2
rep, AAV6 cap, SpeI site
Cloned by E. Kienle
#187 WHc7(SpeI) helper plasmid with AAV2
rep, AAV7 cap, SpeI site
Cloned by E. Kienle
#188 WHc8(SpeI) helper plasmid with AAV2
rep, AAV8 cap, SpeI site
Cloned by E. Kienle
#189 WHc9(SpeI) helper plasmid with AAV2
rep, AAV9 cap, SpeI site
Cloned by E. Kienle
#190 WHcrh10(SpeI) helper plasmid with AAV2
rep, AAVrh10 cap, SpeI site
Cloned by E. Kienle
#545 pBS-sds-decoy-
empty
AAV expression vector with
ITR2, CMV-GFP, ITR4
Cloned by S.
Mockenhaupt
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#714 pSSV9_pSi AAV expression vector with
ITR2, hRluc, hluc+, ITR2
Cloned by D. Niopek
#778 pSSV9_Pac_Asc AAV expression vector with
ITR2, AAV2 rep, PacI site,
AscI site, ITR2
Cloned during this
study
#1079 pBS-sds-CMV-
mCherry
AAV expression vector with
ITR2, CMV-mCherry, ITR4
Cloned during this
study
#1080 pIRES(blast)
FLAG-AAP2
CMV-AAP2 expression vec-
tor with FLAG / HA tag
Cloned during this
study
#1081 pIRES(blast)
FLAG-AAP4
CMV-AAP4 expression vec-
tor with FLAG / HA tag
Cloned during this
study
#1082 pIRES(blast)
FLAG-AAP5
CMV-AAP5 expression vec-
tor with FLAG / HA tag
Cloned during this
study
#1109 pIRES(blast)
FLAG-AAP8
CMV-AAP8 expression vec-
tor with FLAG / HA tag
Cloned during this
study
#1110 pIRES(blast)
FLAG-AAP9
CMV-AAP9 expression vec-
tor with FLAG / HA tag
Cloned during this
study
#1111 Adeno helper plas-
mid
helper plasmid with Ad5
genes E2A, E4, VA RNA
Matsushita et al.
(1998) [109]
#1134 WHC2mutAAP helper plasmid with AAV2
rep, AAV2 cap with mu-
tated AAP2
Cloned during this
study
#1189 WHC4GA (4O) helper plasmid with AAV2
rep, AAV4 cap (sequence
optimized)
Cloned during this
study
#1190 WHC5GA (5O) helper plasmid with AAV2
rep, AAV5 cap (sequence
optimized)
Cloned during this
study
#1194 WHc3(SpeI) helper plasmid with AAV2
rep, AAV3 cap, SpeI site
Cloned by E. Kienle
#1290 WHC4GA_w/o
PacI
helper plasmid with AAV2
rep, AAV4 cap (sequence
optimized), no PacI site be-
tween rep and cap
Cloned during this
study
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Internal
number
Name Description Reference / origin
#1291 WHC4GA repaired
(4O repaired)
helper plasmid with AAV2
rep, AAV4 cap (sequence
optimized), mutations in
AAP frame repaired, no
PacI site
Cloned during this
study
#1292 WHC5GA repaired
(5O repaired)
helper plasmid with AAV2
rep, AAV5 cap (sequence
optimized), mutations in
AAP frame and rep stop
repaired, no PacI site
Cloned during this
study
#1293 WHC5GA only
repSTOP (5O_rep)
helper plasmid with AAV2
rep, AAV5 cap (sequence
optimized), mutation of
rep stop codon repaired,
no PacI site
Cloned during this
study
#1326 WHC8mutAAP helper plasmid with AAV2
rep, AAV8 cap with mu-
tated AAP8, no PacI site
Cloned during this
study
#1327 WHC9mutAAP helper plasmid with AAV2
rep, AAV9 cap with mu-
tated AAP9, no PacI site
Cloned during this
study
#1452 pBSc1 AAV1 cap Cloned by E. Kienle
#1453 pBSc2 AAV2 cap Cloned by E. Kienle
#1454 pBSc3 AAV3 cap Cloned by E. Kienle
#1455 pBSc4 AAV4 cap Cloned by E. Kienle
#1456 pBSc5 AAV5 cap Cloned by E. Kienle
#1457 pBSc6 AAV6 cap Cloned by E. Kienle
#1458 pBSc7 AAV7 cap Cloned by E. Kienle
#1459 pBSc8 AAV8 cap Cloned by E. Kienle
#1460 pBSc9 AAV9 cap Cloned by E. Kienle
#1461 pBScrh10 AAVrh10 cap Cloned by E. Kienle
#1462 pBScpo1 AAVpo.1 cap Cloned by E. Kienle
#1463 pBSc12 AAV12 cap Cloned by E. Kienle
#1483 pIRES(blast)_
AAP2_GFP
CMV-AAP2-GFP fusion ex-
pression vector with FLAG
/ HA
Cloned during this
study
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Internal
number
Name Description Reference / origin
#1492 pBSc4SO (4O) AAV4 cap (sequence opti-
mized)
Cloned by E. Kienle
#1493 pBSc5SO (5O) AAV5 cap (sequence opti-
mized)
Cloned by E. Kienle
#1494 pBSc4SO repaired
(4O repaired)
AAV4 cap (sequence opti-
mized), mutations in AAP
frame repaired
Cloned during this
study
#1495 pBSc5SO repaired
(5O repaired)
AAV5 cap (sequence opti-
mized), mutations in AAP
frame and rep stop repaired
Cloned during this
study
#1500 WH_empty_Hind/
Spe
helper plasmid with AAV2
rep until HindIII site, SpeI
site
Cloned during this
study
#1544 WHC_ccdb_PacI_
AscI
helper plasmid with AAV2
rep, PacI site, ccdB, AscI
site
Cloned by A-K.
Herrmann
#1608 pSSV9_Pac_Asc_
ccdB
AAV expression vector with
ITR2, AAV2 rep, PacI site,
ccdB, AscI site, ITR2
Cloned by A-K.
Herrmann
#1661 WHC1mutAAP helper plasmid with AAV2
rep, AAV1 cap with mu-
tated AAP1, no PacI site
Cloned during this
study
#1662 WHC3mutAAP helper plasmid with AAV2
rep, AAV3 cap with mu-
tated AAP3, no PacI site
Cloned during this
study
#1663 WHC6mutAAP helper plasmid with AAV2
rep, AAV6 cap with mu-
tated AAP6, no PacI site
Cloned during this
study
#1664 WHC7mutAAP helper plasmid with AAV2
rep, AAV7 cap with mu-
tated AAP7, no PacI site
Cloned during this
study
#1665 WHCrh10mutAAP helper plasmid with AAV2
rep, AAVrh10 cap with mu-
tated AAPrh10, no PacI site
Cloned during this
study
#1666 pIRES(blast)
FLAG-AAP1
CMV-AAP1 expression vec-
tor with FLAG / HA tag
Cloned during this
study
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Internal
number
Name Description Reference / origin
#1667 pIRES(blast)
FLAG-AAP3
CMV-AAP3 expression vec-
tor with FLAG / HA tag
Cloned during this
study
#1668 pIRES(blast)
FLAG-AAP6
CMV-AAP6 expression vec-
tor with FLAG / HA tag
Cloned during this
study
#1669 pIRES(blast)
FLAG-AAP7
CMV-AAP7 expression vec-
tor with FLAG / HA tag
Cloned during this
study
#1670 pIRES(blast)
FLAG-AAPrh10
CMV-AAPrh10 expression
vector with FLAG / HA tag
Cloned during this
study
Table 2.3: Chemicals and reagents
Product Company
Acetic acid VWR (Radnor, USA)
Agarose Biozym Scientiﬁc GmbH
(Hessisch Oldendorf, Germany)
Albumin fraction V (BSA) Roth (Karlsruhe, Germany)
Ampicillin Roth (Karlsruhe, Germany)
Ammonium persulfate (APS) Grüssing (Filsum, Germany)
BactoTM agar BD (Franklin Lakes, USA)
BactoTM tryptone BD (Franklin Lakes, USA)
BactoTM yeast extract BD (Franklin Lakes, USA)
Bromophenol blue Waldeck GmbH (Münster, Germany)
Calcium chloride (CaCl2) Roth (Karlsruhe, Germany)
Cesium chloride (CsCl) Roth (Karlsruhe, Germany)
Disodium phosphate (Na2HPO4 x 2H2O) AppliChem (Darmstadt, Germany)
Dimethyl sulfoxide (DMSO) Merck (Darmstadt, Germany)
Dodecylsulfate-Na-salt pellets (SDS) SERVA Electrophoresis GmbH
(Heidelberg, Germany)
Ethylenediaminetetraacetic acid (EDTA)
disodium salt
Sigma-Aldrich (St. Louis, USA)
Ethanol Sigma-Aldrich (St. Louis, USA)
Ethidium bromide Roth (Karlsruhe, Germany)
Ficoll type 400 Sigma-Aldrich (St. Louis, USA)
Gelatin Sigma-Aldrich (St. Louis, USA)
Glucose Merck (Darmstadt, Germany)
Glycerol VWR (Radnor, USA)
HEPES Roth (Karlsruhe, Germany)
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Product Company
Höchst 33258 Invitrogen / Life Technologies
(Paisley, UK)
Hydrochloric acid (HCl) Sigma-Aldrich (St. Louis, USA)
Immunoselect Antifading Mounting Media Dianova (Hamburg, Germany)
Iodixanol (OptiprepTM) Axis-Shield (Oslo, Norway)
Isopropanol Sigma-Aldrich (St. Louis, USA)
b-mercaptoethanol Roth (Karlsruhe, Germany)
Methanol Sigma-Aldrich (St. Louis, USA)
Milk powder Roth (Karlsruhe, Germany)
Magnesium chloride (MgCl2) AppliChem (Darmstadt, Germany)
Magnesium sulfate (MgSO4) Merck (Darmstadt, Germany)
N-Ethylmaleimide (NEM) Sigma-Aldrich (St. Louis, USA)
Nuclease-free water QIAGEN (Hilden, Germany)
Orange G Waldeck GmbH (Münster, Germany)
PEG8000 Promega (Madison, USA)
Phenol red Merck (Darmstadt, Germany)
Ponceau S solution Sigma-Aldrich (St. Louis, USA)
Potassium acetate (KAc) AppliChem (Darmstadt, Germany)
Potassium chloride (KCl) AppliChem (Darmstadt, Germany)
Potassium dihydrogen phosphate
(KH2PO4)
AppliChem (Darmstadt, Germany)
Protease inhibitor cocktail
(cOmpleteTM, EDTA-free)
Roche (Penzberg, Germany)
Protein A/G PLUS-Agarose Santa Cruz Biotechnology (Heidelberg,
Germany)
QIAzol lysis reagent QIAGEN (Hilden, Germany)
Rotiphorese® Gel 40 (19:1) Roth (Karlsruhe, Germany)
Sodium bicarbonate (NaHCO3) Merck (Darmstadt, Germany)
Sodium acetate (NAc) Grüssing (Filsum, Germany)
Sodium carbonate (Na2CO3) Merck (Darmstadt, Germany)
Sodium chloride (NaCl) Sigma-Aldrich (St. Louis, USA)
Sodium hydroxide (NaOH) Sigma-Aldrich (St. Louis, USA)
Sulfuric acid (H2SO4) J.T.Baker / Avantor Performance Materi-
als (Center Valley, USA)
TE buﬀer Invitrogen / Life Technologies
(Paisley, UK)
TEMED (Ultra PureTM) Invitrogen / Life Technologies
(Paisley, UK)
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Product Company
TGS (Tris/Glycine/SDS) buﬀer (10x) BioRad (Hercules, USA)
Tris Roth (Karlsruhe, Germany)
Tris-HCl Roth (Karlsruhe, Germany)
TweenTM20 Roth (Karslruhe, Germany)
Table 2.4: Buﬀers and reagents
Buﬀer / Solution Composition
Ampicillin stock solution 5 % (w/v) Ampicillin (50 mg/ml)
Benzonase buﬀer (pH 8.5)
50 mM Tris-HCl (pH 8.5)
150 mM NaCl
2 mM MgCl2
Blocking buﬀer (Western blot)
5 % (w/v) milk powder
(or 1 % [w/v]) Albumin fraction V)
solvent 1x TBS-T
CaCl2 solution 1 M CaCl2
Coating buﬀer (pH 9.6, ELISA)
13 mM Na2CO3
35 mM NaHCO3
DNA loading dye (6x, orange)
0.25 % (w/v) Orange G
15 % (w/v) Ficoll type 400
DNA loading dye (10x, blue)
0.25 % (w/v) bromophenol blue
49.5 mM Tris-HCl (pH 7.6)
60 % (v/v) glycerol
Freezing media
10 % (v/v) DMSO
90 % (v/v) FBS
IF blocking buﬀer
1 % (w/v) Albumin fraction V
49.2 µM MgCl2
90.1 µM CaCl2
solvent 1x PBS
Iodixanol (15 %)
25 % (v/v) Iodixanol (Optiprep)
75 % (v/v) PBS-MK-NaCl
Iodixanol (25 %, red color)
41.56 % (v/v) Iodixanol (Optiprep)
58.19 % (v/v) PBS-MK
0.25 % (v/v) phenol red solution
Iodixanol (40 %)
66.67 % (v/v) Iodixanol (Optiprep)
33.33 % (v/v) PBS-MK
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Buﬀer / Solution Composition
Iodixanol (60 %, yellow color)
99.75 % (v/v) Iodixanol (Optiprep)
0.25 % (v/v) phenol red solution
Lysogeny broth (LB) media1
1 % (w/v) tryptone
0.5 % (w/v) yeast extract
1 % (w/v) NaCl
Lysogeny broth (LB) agar2
1 % (w/v) tryptone
0.5 % (w/v) yeast extract
1 % (w/v) NaCl
1.5 % (w/v) agar
NaHEPES resuspension buﬀer
50 mM HEPES
150 mM NaCl
25 mM EDTA
PBS (1x)
137 mM NaCl
3 mM KCl
10 mM Na2HPO4
2 mM KH2PO4
PBS-MK
solvent 1 x PBS
1 mM MgCl2
2.5 mM KCl
PBS-MK-NaCl
solvent 1 x PBS
1 mM MgCl2
2.5 mM KCl
1 M NaCl
P1 resuspension buﬀer (pH 8)
50 mM Tris-HCl
10 mM EDTA
100 µg/ml RNase
P2 lysis buﬀer
200 mM NaOH
1 % (w/v) SDS
P3 neutralization buﬀer (pH 5.1) 2.8 M KAc
40 % PEG / NaCl solution
40 % (w/v) PEG8000
1.915 M NaCl
Phenolred solution 0.5 % phenol red
Running gel buﬀer (pH 8.8)
1.5 M Tris
0.4 % SDS
1supplemented with 50 µg/ml ampicillin before use
2supplemented with 100 µg/ml ampicillin before use
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Buﬀer / Solution Composition
SDS sample buﬀer (2x)
2 mM EDTA
100 mM Tris-HCl pH 7.5
4 % SDS
20 % (v/v) glycerol
10 % b-mercaptoethanol
0.02 % bromophenol blue
SOB media
2 % (w/v) tryptone
0.5 % (w/v) yeast extract
0.05 % (w/v) NaCl
2.5 mM KCl
10 mM MgCl21
10 mM MgSO41
SOC media
20 mM glucose2
solvent SOB media
Stacking gel buﬀer (pH 6.8)
500 mM Tris
0.4 % (w/v) SDS
TAE buﬀer (50x, pH 8.3)
2 M Tris
50 mM EDTA
5.71 % (v/v) acetic acid
TBS (10x, pH 7.5)
250 mM Tris
1.25 M NaCl
TBS-T (1x)
solvent 1x TBS
0.05 % Tween
TFBI (pH 5.8)
30.6 mM KAc
80 mM MgCl2
100 mM KCl
16 mM CaCl2
13.2 % (v/v) glycerol
TFBII (pH 8.0)
4.8 mM MOPS
76 mM CaCl2
10 mM KCl
13.2 % (v/v) glycerol
Topping solution (RI = 1.3710)
3.27 M CsCl (0.55 g/ml)
solvent NaHEPES resuspension buﬀer
1addition after autoclaving
2sterile-ﬁltered
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Buﬀer / Solution Composition
Transfer buﬀer
20 % methanol
solvent 1x TGS
Table 2.5: Cell culture media, additives and transfection reagents
Component Company
Dulbecco's Modiﬁed Eagle Medium (DMEM) Gibco / Life Technologies (Paisley, UK)
Dulbecco's phosphate-buﬀered saline
(DPBS, 1x)
Gibco / Life Technologies (Paisley, UK)
Fetal bovine serum (FBS) Sigma-Aldrich (St. Louis, USA)
MG-132 proteasome inhibitor Santa Cruz Biotechnology (Heidelberg,
Germany)
Minimum Essential Medium Non-Essential
Amino Acids (MEM-NEAA, 100x)
Gibco / Life Technologies (Paisley, UK)
Polyethylenimine (PEI, linear, MW ∼25 000) Polyscience (Warrington, USA)
Penicillin-Streptomycin (10,000 U/mL) Gibco / Life Technologies (Paisley, UK)
Table 2.6: Cell lines
Cell line Origin Tissue type Reference
HEK293T H. sapiens Embryonic kidney DuBridge et al. (1987) [186]
Huh7 H. sapiens Hepatocellular carcinoma Nakabayashi et al.
(1982) [187]
MCF-7 H. sapiens Mammary carcinoma Soule et al. (1973) [188]
SF-539 H. sapiens Gliosarcoma Rutka et al. (1986) [189]
Table 2.7: Bacterial strains
Bacterial strain Description Source
E. coli ccdB SurvivalTM T1R chemically competent Life Technologies GmbH
(Paisley, UK)
E. coli MAX Eﬃciency DH5aTM chemically competent Life Technologies GmbH
(Paisley, UK)
E. coli MegaX DH10BTM T1R electro-competent Life Technologies GmbH
(Paisley, UK)
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Table 2.8: Enzymes
Enzyme Company
Antarctic phosphatase NEB (Frankfurt am Main, Germany)
Benzonase Merck (Darmstadt, Germany)
DNaseI Life Technologies (Paisley, UK)
HotStar HiFidelity Polymerase Qiagen (Hilden, Germany)
Phusion Hot Start II DNA polymerase Thermo Fisher Scientiﬁc (Waltham, USA)
Restriction enzymes NEB (Frankfurt am Main, Germany)
RNase (100 mg/ml) Qiagen (Hilden, Germany)
T4 DNA ligase NEB (Frankfurt am Main, Germany)
Table 2.9: Primary antibodies
Name Antigen Source Purity Appli-
cation
Dilu-
tion
Reference /
Company
A1 AAV VP1 Mouse,
mono-
clonal
hybridoma
cell culture
supernatant
WB 1:10 Kind gift from
J. Kleinschmidt
lab (DKFZ),
published
1997 [57]
A20 Assembled
AAV2 cap-
sids
Mouse,
mono-
clonal
hybridoma
cell culture
supernatant
IF undil. Kind gift from
J. Kleinschmidt
lab (DKFZ),
published
1995 [190]
AAP1 AAP2 Rabbit,
poly-
clonal
puriﬁed IF
WB
1:250
1:500
Perbio /
Thermo Fisher
Scientiﬁc
(Waltham,
USA)
B1 AAV VP1,
VP2, VP3
Mouse,
mono-
clonal
hybridoma
cell culture
supernatant
IF
IP
WB
undil.
1:11
1:20-30
Kind gift from
J. Kleinschmidt
lab (DKFZ),
published
1995 [190]
1This antibody was ordered and produced during this work
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Name Antigen Source Purity Appli-
cation
Dilu-
tion
Reference /
Company
b-actin
(C4)
mouse,
rat, hu-
man, avian,
bovine,
canine,
porcine and
rabbit b-
actin
Mouse,
mono-
clonal
puriﬁed WB 1:1000 Santa Cruz
Biotechnology
(Heidelberg,
Germany)
FK2 mono-
and poly-
ubiquitiny-
lated pro-
teins
Mouse,
mono-
clonal
puriﬁed IP
WB
1:3125
1:800
Enzo Life Sci-
ence (Lörrach,
Germany)
HA HA tag Mouse,
mono-
clonal
puriﬁed IF
IP
WB
1:300-
1:400
1:1250
1:200-
300
Santa Cruz
Biotechnology
(Heidelberg,
Germany)
Oct-
3/4
(N-19)
Human,
mouse and
rat Oct-3/4
Goat,
poly-
clonal
(IgG)
puriﬁed IP 1:1250 Santa Cruz
Biotechnology
(Heidelberg,
Germany)
SSEA-
1 (480)
Human,
mouse and
rat SSEA-1
Mouse
mono-
clonal
(IgM)
puriﬁed IP 1:1250 Santa Cruz
Biotechnology
(Heidelberg,
Germany)
303.9 AAV Rep
proteins
Mouse,
mono-
clonal
hybridoma
cell culture
supernatant
IF
WB
undil.
1:10
Kind gift from
J. Kleinschmidt
lab (DKFZ)),
published
1995 [190]
Abbreviations: IF = Immunoﬂuorescence, IP = Immunoprecipitation, WB = Western blot.
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Table 2.10: Secondary antibodies
Name / Antigen Source Appli-
cation
Dilution Company
Alexa Fluor® 488 anti-
mouse IgG (H+L)
Goat IF 1:500 Life Technologies
(Paisley, UK)
Alexa Fluor® 568 anti-
rabbit IgG (H+L)
Goat IF 1:1000 Life Technologies
(Paisley, UK)
Alexa Fluor® 647 anti-
mouse IgG (H+L)
Goat IF 1:750-
1500
Life Technologies
(Paisley, UK)
Anti-mouse IgG + IgM,
HRP-conjugated
Goat WB 1:10000 Jackson ImmunoRe-
search Laboratories
(West Grove, USA)
Anti-rabbit IgG, HRP-
conjugated
Donkey WB 1:10000 GE Healthcare
(Chalfont St. Giles,
UK)
Abbreviations: HRP = Horseradish peroxidase, IF = Immunoﬂuorescence, WB = Western blot.
Table 2.11: Kits
Kit Company
AAV2 Titration ELISA PROGEN Biotechnik (Heidelberg,
Germany)
Agilent DNA 1000 Kit Agilent Technologies (Santa Clara, USA)
NucleoBond® Xtra Maxi Macherey-Nagel (Düren, Germany)
PureYieldTM Plasmid Midiprep System Promega (Madison, USA)
Qubit® dsDNA BR Assay Kit Invitrogen / Life Technologies (Paisley,
UK)
RNeasy Mini Kit QIAGEN (Hilden, Germany)
SensiMixTM II Probe No-ROX Kit Bioline (London, UK)
SensiMixTM SYBR No-ROX Kit Bioline (London, UK)
QIAquick Gel Extraction Kit QIAGEN (Hilden, Germany)
Tetro cDNA Synthesis Kit Bioline (London, UK)
Western Lightning® Plus-ECL PerkinElmer (Waltham, USA)
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Table 2.12: Standard markers
Marker Company
100 bp DNA ladder Life Technologies GmbH (Paisley, UK)
1 kb DNA ladder Life Technologies GmbH (Paisley, UK)
PageRulerTM plus prestained protein ladder Thermo Fisher Scientiﬁc (Waltham, USA)
Table 2.13: Materials
Material Company
Amersham Hyperﬁlm ECL (X-ray ﬁlm, 18
Ö 24 cm)
GE Healthcare (Buckinghamshire, UK)
Amicon® Ultra Centrifugal Filter Units,
15ml, 100000 NMWL
Millipore / Merck (Darmstadt, Germany)
Blotting paper (3 mm, 46 Ö 57 cm) neoLab (Heidelberg, Germany)
Cell culture dishes (Ø 6 cm / 15 cm) Greiner Bio-One (Frickenhausen,
Germany), Nunc / Thermo Fisher
Scientiﬁc (Waltham, USA)
Cell culture ﬂasks (Ø 75 cm2 / 175 cm2) Greiner Bio-One (Frickenhausen,
Germany)
Cell culture plates (6-well / 96-well) Greiner Bio-One (Frickenhausen,
Germany)
Cell lifter (18 cm) Corning (New York, USA)
Centrifuge tubes (15 ml / 50 ml / 500 ml) BD (Franklin Lakes, USA), Corning
(New York, USA), Greiner Bio-One
(Frickenhausen, Germany)
Combitips Eppendorf (Hamburg, Germany)
Covaris reaction tubes (microTUBE AFA
Fiber Snap-Cap 6x16mm)
Covaris (Woburn, USA)
Counting chambers Invitrogen / Life Technologies (Paisley,
UK)
Cuvettes (Polystyrene, 10 x 4 x 45 mm) Sarstedt (Nümbrecht, Germany)
Dialysis tubing visking (Typ 20/32 inch,
wall thickness 0.020 mm, MWCO 14 000)
Roth (Karlsruhe, Germany)
Electroporation cuvettes (1 mm gap) Peqlab (Erlangen, Germany)
Erlenmeyer ﬂasks Fisher Scientiﬁc (Schwerte, Germany)
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Material Company
Filter tips Biozym Scientiﬁc GmbH (Hessisch
Oldendorf, Germany), Greiner Bio-One
(Frickenhausen, Germany), Sarstedt
(Nümbrecht, Germany)
Glass bottles DURAN Group (Wertheim/Main,
Germany)
Glass culture tubes (16 x 160 mm) DURAN Group (Wertheim/Main,
Germany)
LabTek® II Chamber SlideTM System Nunc / Thermo Fisher Scientiﬁc
(Waltham, USA)
Needles (0.8 x 40 mm / 0.9 x 40 mm) BD (Franklin Lakes, USA)
Nitrocellulose blotting membrane neoLab (Heidelberg, Germany)
Microscopy well plates (µ-Plate ibiTreat) ibidi (Planegg / Martinsried, Germany)
OptiSealTM Ultracentrifuge tubes  cesium
chloride puriﬁcation (26x77 mm)
Beckman Coulter (Brea, USA)
Pasteur capillary pipettes (230 mm) neoLab (Heidelberg, Germany)
PCR tubes STARLAB (Hamburg, Germany)
Petri dishes Greiner Bio-One (Frickenhausen,
Germany)
Pipette tips Greiner Bio-One (Frickenhausen,
Germany), Kisker (Steinfurt, Germany)
qPCR tubes and lids QIAGEN (Hilden, Germany)
Qubit reaction tubes Invitrogen / Life Technologies (Paisley,
UK)
Reaction tubes (0.5 / 1.5 / 2 / 5 ml) Eppendorf (Hamburg, Germany), Sarstedt
(Nümbrecht, Germany)
Rotor discTM 100 QIAGEN (Hilden, Germany)
Rotor discTM heat sealing ﬁlm QIAGEN (Hilden, Germany)
Serological pipettes Greiner Bio-One (Frickenhausen,
Germany)
Slide-A-Lyzer dialysis cassette (MWCO
20000)
Thermo Fisher Scientiﬁc (Waltham, USA)
Steritop ﬁlter (0.22µm) Millipore / Merck (Darmstadt, Germany)
Syringes (3 ml / 50 ml) BD (Franklin Lakes, USA)
Syringe ﬁlter units (0.2 / 0.45 µm pore size) Whatman / GE Healthcare (Bucking-
hamshire, UK)
Ultracentrifuge tubes - iodixanol puriﬁca-
tion (16x76 mm)
Seton Scientiﬁc (Petaluma, USA)
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Material Company
VacConnectors QIAGEN (Hilden, Germany)
Table 2.14: Equipment
Material Company
Bacterial incubator Heraeus Function Line Thermo Fisher Scientiﬁc (Waltham, USA)
2100 Bioanalyzer Agilent Technologies (Santa Clara, USA)
Biophotometer Plus Eppendorf (Hamburg, Germany)
CaptairBio PCR workstation Erlab (Köln, Germany)
Centrifuge 5415 R Eppendorf (Hamburg, Germany)
Centrifuge Avanti J-26 XP Beckman Coulter (Brea, USA)
Confocal microscope TCS SP5 Leica (Wetzlar, Germany)
CountessTM Automated Cell Counter Invitrogen / Life Technologies (Paisley,
UK)
Covaris focused-ultrasonicator S2 Covaris (Woburn, USA)
HERAcell 150 CO2 Incubator Heraeus / Thermo Fisher Scientiﬁc
(Waltham, USA)
HERAsafe® sterile workbench Thermo Fisher Scientiﬁc (Waltham, USA)
Fixed angle type 70 Ti rotor Beckman Coulter (Brea, USA)
Fixed angle type 70.1 Ti rotor Beckman Coulter (Brea, USA)
Fixed angle JA-10 rotor Beckman Coulter (Brea, USA)
FlexCycler (PCR thermocycler) Analytik Jena (Jena, Germany)
Flow cytometer FC500 MPL Beckman Coulter (Brea, USA)
Gas cartridge CV470 plus Camping Gaz (Hattersheim, Germany)
Gene-Disc Heat Sealer Corbett Life Science (Sydney, Australia) /
QIAGEN (Hilden, Germany)
Gel caster (DNA electrophoresis) BioRad (Hercules, USA)
Gel DocTM XR BioRad (Hercules, USA)
Gene Pulser XcellTM Electroporation Sys-
tem
BioRad (Hercules, USA)
Hamilton syringe, model #705 (50 µl) Hamilton (Reno, USA)
Inverted microscope CKX-41 Olympus (Hamburg, Germany)
Inverted ﬂuorescence microscope IX-81 Olympus (Hamburg, Germany)
Mastercycler® pro Eppendorf (Hamburg, Germany)
Microwave Sharp Electronics GmbH (Hamburg,
Germany)
Mini-PROTEAN® comb 10-well (30 µl) /
15-well (15 µl)
BioRad (Hercules, USA)
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Material Company
Mini-PROTEAN® spacer plates (1 mm) BioRad (Hercules, USA)
Mini-PROTEAN® short plates BioRad (Hercules, USA)
Mini-PROTEAN® tetra cell casting module BioRad (Hercules, USA)
Mini-PROTEAN® tetra vertical elec-
trophoresis cell
BioRad (Hercules, USA)
Mini-Sub® cell GT / Sub-Cell® GT combs
(1-/2-/8-/10-/15-/20-/30-well)
BioRad (Hercules, USA)
Mini-Sub® cell GT / Sub-Cell® GT DNA
electrophoresis system
BioRad (Hercules, USA)
Mini-Sub® cell GT / Sub-Cell® GT UV
transparent gel trays
BioRad (Hercules, USA)
MultiskanTM FC Microplate Spectropho-
tometer
Thermo Fisher Scientiﬁc (Waltham, USA)
NanoDrop 2000 UV-Vis Spectrophotometer Thermo Fisher Scientiﬁc (Waltham, USA)
NanoVue Spectrophotometer GE Healthcare (Buckinghamshire, UK)
pH meter PB-11 Sartorius (Göttingen, Germany)
Pipettes Eppendorf (Hamburg, Germany), Gilson
(Middleton, USA)
PowerPacTM Basic / HC / HV Power Sup-
ply
BioRad (Hercules, USA)
Qubit® ﬂuorometer Invitrogen / Life Technologies (Paisley,
UK)
Refractometer Exacta Optech (San Prospero, Italy)
Rotor-Gene 6000 Corbett Life Science (Sydney, Australia) /
QIAGEN (Hilden, Germany)
Shaker DOS-10L neoLab (Heidelberg, Germany)
Shaker DRS-12 neoLab (Heidelberg, Germany)
Shaking Incubator Multitron INFORS HT (Basel, Switzerland)
ThermoCell Mixing Block MB-102 Bioer (Hangzhou, China)
Trans-Blot® SD Semi-Dry Transfer Cell BioRad (Hercules, USA)
Triangular support with rod and burette
clamp
Roth (Karlsruhe, Germany)
Tube rotator VWR (Radnor, USA)
Tube sealer Beckman Coulter (Brea, USA)
Ultracentrifuge Optima L-90K Beckman Coulter (Brea, USA)
Ultrasonic bath BANDELIN (Berlin, Germany)
UV transilluminator UST-30M-8E biostep GmbH (Burkhardtsdorf, Germany)
Vortex Genie 2 Scientiﬁc Industries (Bohemia, USA)
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Material Company
Water bath TW12 Julabo (Seelbach, Germany)
X-OMAT 2000 processor KODAK (Rochester, NY, USA)
Table 2.15: Software
Software Application Company / Reference
2100 Expert Software Agilent software Agilent Technologies (Santa
Clara, USA)
CellProﬁler Fluorescence picture quan-
tiﬁcation
Carpenter et al. (2006) [191],
Kamentsky et al.
(2011) [192]
Clustal W / Clustal X DNA / protein alignments Larkin et al. (2007) [193]
Fiji Fluorescence picture pro-
cessing
Schindelin et al. (2012) [194]
GraphPad Prism Graphical and statistical
analysis
GraphPad Software, Inc.
(La Jolla, USA)
Microsoft Excel Coloring and analysis of
Salanto-derived ﬁles
Microsoft Corporation
(Redmond, USA)
MXP software Flow cytometry software Beckman Coulter (Brea,
USA)
Quantity One 1-D Analy-
sis Software 4.6.9
Gel documentation software BioRad (Hercules, USA)
Rotor Gene 6000 Series
Software 1.7
qPCR analysis QIAGEN (Hilden,
Germany)
Salanto1 Shuing alignment analysis Schürmann et al.
(2013) [195]
Vector NTI Plasmid maps visualization
/ editing and DNA / pro-
tein alignments
Life Technologies GmbH
(Paisley, UK)
1This program was further developed in cooperation with C. Bender during this study
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2.2 Methods
2.2.1 Cloning procedures
2.2.1.1 Cloning of the pSSV9_PacI_AscI construct
A pSSV9 vector (pSub201 [130]) with PacI, AscI and SpeI sites was generated in order to al-
low cloning of created shued AAV cap sequences (see section 2.2.3.7) downstream of the rep
sequence. For construction of the pSSV9_PacI_AscI vector, a PacI site containing fragment
was ampliﬁed with the primers #641 and #642 from the pTRUF3 cap plasmid which was
generated by Grimm et al. [133]. In addition, a SpeI and an AscI restriction site were intro-
duced with primer #642. Subsequently, the puriﬁed and digested PCR product was cloned
via HindIII / XbaI into a pSSV9 backbone available in the lab. Figure 2.1 depicts the ﬁnal
construct after insertion of a cap gene. After transfection into HEK293T cells together with
an adeno-viral helper construct (#1111), plasmids will produce replication competent AAVs
which package the encoded viral genome. The inserted SpeI site allowed an easy cloning of
cap from _pSSV9_PacI_AscI into an ITR-less rep-cap helper which permits the packaging
of a reporter gene and the control of capsid infectivity (see also next section).
Figure 2.1: Plasmid map of construct
no. 778_pSSV9_PacI_AscI. The depicted
pSSV9 vector contains the AAV2 rep gene (dark
red) driven by the AAV2 p5 promoter (white)
and followed by a cap gene (light red) inserted via
PacI and AscI site. Both are ﬂanked by AAV2
ITRs which enable viral genome packaging into
the encoded capsid. The plasmid map was gen-
erated with the program SnapGene.
2.2.1.2 Subcloning of shued AAV cap sequences into a helper construct
Shued AAV cap sequences were cloned from the single-stranded pSSV9 construct (see section
2.2.1.1) into a rep-cap helper plasmid without ITRs (generated by E. Kienle [196]) in order to
package a gfp reporter into the capsids and assess the functionality of single clones. Therefore,
cap genes were ampliﬁed from picked and analyzed shued AAV clones (see 2.2.3.7 for details)
with the primers #823 and #1038  #1042 (see table 2.16 for conditions). The latter were
selected based on the AAV serotype at the 5' end of the shued sequence and introduced
a SwaI site in front of the cap gene. Next, PCR fragments were puriﬁed and sequentially
digested. First, SpeI digestion was performed over night at 37°C with NEB buﬀer 1.1. Second,
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the DNA was incubated with SwaI enzyme at 25°C for at least 3 hours after addition of NEB
buﬀer 3.1. No intermediate puriﬁcation step was needed. Digested PCR products were
puriﬁed and ligated into SpeI / SwaI digested plasmid #188. In case SwaI cloning did not
work, cap sequences were ampliﬁed with primers #833 and #823 and cloned into the rep-cap
helper plasmid via HindIII / SpeI or HindIII / AscI digestion.
Table 2.16: PCR mix and PCR program for shued AAV cap ampliﬁcation
PCR reaction PCR program
Components Amount Temperature Time
DNA template 0.5 µl
Forward primer 15 pmol 98°C 30 sec
Reverse primer 15 pmol 98°C 10 sec
DMSO 1.5 µl 58°C 15 sec 35 cycles
2.5 mM dNTPs 1 µl 72°C 70 sec
5x polymerase buﬀer HF 10 µl 72°C 10 min
Phusion Hot Start II DNA Polymerase 0.5 µl 4°C ∞
H2O 33.5 µl
2.2.1.3 Sequence optimization of AAV cap 4 / cap 5 and repair of the AAP frame
Cap sequences of AAV4 and AAV5 were modiﬁed by the company GeneArt in order to increase
their homology to AAV cap 2. Therefore, single nucleotides were mutated without changing
the viral protein sequence (see also ﬁgure 3.4). The resulting capsids were named 4O and 5O,
respectively. Since the assembly-activating protein (AAP) was not discovered at the time of
sequence generation, several mutations were inadvertently introduced into the AAP frame.
In detail, AAP4O lost its start and stop codon. Moreover, two stop codons were generated
within AAP4O. AAP5O lost its start codon and contained one additional stop codon after
modiﬁcation. Unintentionally, it also lost the stop codon of the viral proteins Rep68 and
Rep40 which is located in the VP frame. In order to repair the created mutations, overlap
extension PCR was used (see section 2.2.3.1 for details). First, ﬁve or three cap gene fragments
were ampliﬁed from AAV4O or AAV5O, respectively, using the primers #966  #982 which
carried the correct nucleotides to repair the generated mutations. Second, primers #964 and
#967, or #965 and #978, were used to amplify the full-length AAV cap gene of 4O and
5O, respectively. The cap fragments generated in the ﬁrst PCR served as input. The ﬁnal
corrected cap sequence was cloned via SwaI / SpeI into a rep-cap helper construct (e.g. #189,
table 2.1).
2.2.1.4 Construction of AAP expression vectors
For generation of AAP expression vectors, AAP sequences were ampliﬁed from AAV cap genes
with primers #983  #992, #1242  #1245 and #1292  #1294 depending on the serotype.
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The used primers introduced a NotI restriction site in front and an EcoRI restriction site
behind AAP, and allowed cloning into a pre-existing backbone (#68, elimination of hAgo2
was achieved by NotI / EcoRI digestion). The latter already contained a CMV promoter
followed by a FLAG-tag, an HA-tag and the two restriction sites. In addition the plasmid
carried an IRES followed by a blasticidin gene.
An AAP-GFP expression vector was generated by overlap extension PCR (see section 2.2.3.1
for details) with the primers #1161 and #1162. Thus, the AAP stop codon as well as the GFP
start codon were removed and GFP was fused C-terminally to AAP. The obtained sequence
was cloned via NotI / EcoRI into the same backbone mentioned above.
2.2.1.5 Cloning of AAVmut constructs
AAP knock-out AAV cap genes were generated through overlap extension PCR (section
2.2.3.1). The used primers (#993  #994, #1014  #1017, #1283  #1291) introduced
mutations that led to an exchange of the AAP start codon from CTG to CCG and introduced
a stop codon within the AAP frame 66 bp downstream of the start codon (TGG → TAG).
Both modiﬁcations did not change the AAV-VP amino acid sequences. In total, eight AAV
serotypes were mutated (AAV1, 2, 3b, 6, 7, 8, 9, rh10). Primers #178 and #833 served as
ﬂanking primers during the second PCR and allowed for cloning of the cap gene into a rep-cap
helper plasmid (e.g. #188, table 2.1) via HindIII / SpeI.
2.2.2 Microbiological methods
2.2.2.1 Production of chemo-competent bacteria
DH5α E. coli were streaked on an antibiotic-free agar plate and grown over night at 37°C.
The following day, 10 ml antibiotic-free LB media were inoculated with one single colony
picked from the plate and again grown overnight at 37°C. Two hundred ml SOC media were
inoculated with 1 ml of this culture and incubated until the OD600 value reached 0.5. Bacteria
were then centrifuged for 15 min at 1800 x g and 4°C, resuspended in 40 ml TFBI buﬀer and
incubated on ice for 10 min. Centrifugation was repeated, and bacteria were resuspended in
10 ml TFBII buﬀer and again incubated on ice for 10 min. Finally, bacteria were frozen in
50 µl aliquots in liquid nitrogen and stored at -80°C.
2.2.2.2 Heat-shock transformation
Fifty µl of chemo-competent bacteria were mixed with 10 µl ligation mix and incubated for
30 min on ice. After 45 sec at 42°C, bacteria were again incubated for 2 min on ice and
agitated for 1 hour at 37°C with 1 ml antibiotic-free LB media. Afterwards, the reaction was
centrifuged for 5 min at 400 x g, and the bacterial pellet was resuspended in 100 µl LB media
and plated on antibiotic-containing LB agar plates. For ampicillin containing plasmids, the
transformation reaction was directly plated after 2 min incubation on ice. In case of plasmid
re-transformations, 2 µl of DNA were incubated for 1  5 min with 50 µl bacteria on ice.
Plates were incubated over night at 37°C and single colonies picked for DNA preparations.
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2.2.2.3 Production of electro-competent bacteria
For production of electro-competent bacteria, 30 ml of antibiotic-free LB media were inocu-
lated under sterile conditions from a glycerol stock of commercial Mega X DH10B bacteria
and agitated at 180 rpm over night at 37°C. The next day, four ﬂasks with 400 ml antibiotic-
free LB media were inoculated with 5 ml of the pre-culture and incubated for 2  3 hours
until the OD600 value reached 0.5  0.55. Bacterial growth was stopped by 15  20 min in-
cubation on ice, and cultures were subsequently centrifuged for 15 min at 4°C and 4424 x g.
The bacterial pellets were resuspended in a total volume of 60 ml cold ddH2O, transferred
to four pre-cooked dialysis tubings (Typ 20/32 inch, wall thickness 0.020mm) and dialyzed
against 4  8 liters of sterile ddH2O over night at 4°C. The next day, bacteria were centrifuged
for 15 min at 4°C and 4424 x g, pellets were resuspended in 10 % glycerin and OD600 set up
to 1 (which corresponds to 2.5x1010 cells) by addition of 10 % glycerin. Aliquots of 40, 100
and 300 µl bacteria were frozen for electroporation experiments. Eﬃciency of bacteria was
assessed by electroporation of 15 pg pUC19 control plasmid into 30 µl bacteria (see section
2.2.2.4 for details). The next day, colonies on the plates with the 1:10 and 1:100 dilution
were counted and eﬃciency (Colony forming units [CFU] / µg) calculated with the following
formula:
CFU
µg
=
number of colonies
15 pg pUC DNA
x
1x106pg
µg
x
volume of transformants
plated volume
x dilution factor
Eﬃciency had to reach at least 5x108 CFU/µg to be suﬃcient for transformation experiments.
2.2.2.4 Electroporation
Electro-competent bacteria were thawed on ice. Then, 30 µl of bacteria were mixed with
0.5  2 µl of ligation mix and transferred to a pre-cooled electroporation cuvette (1 mm gap).
It was made sure that all bubbles in the cuvette were removed by gentle tapping and that
metal contacts were dry. Subsequently, the cuvette was placed into a Gene Pulser Xcell
Electroporation System machine and pulsed with 1800 V, 25 µF and 200 W. One ml pre-
warmed SOC media was used to resuspend the bacteria and to transfer them to a 1.5 ml
reaction tube. Electroporated bacteria were agitated for 1 hour at 37°C and 450 rpm in a
mixing block. Afterwards, 100 µl bacteria suspension were plated on antibiotic-containing LB
agar plates and the rest of the reaction was centrifuged for 5 min at 400 xg. The pellet was
resuspended in 100 µl LB media and also plated. Plates were incubated over night at 37°C
and single colonies picked for DNA preparations. In this thesis, electroporation was mainly
used for generation of shued AAV cap libraries (see also chapter 2.2.3.7 for more details)
during this work.
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2.2.3 Molecular biology methods
2.2.3.1 Polymerase chain reaction (PCR)
Typically, 50 µl PCR reactions were prepared to amplify speciﬁc DNA fragments from plas-
mids or genomic DNA. Therefore (unless mentioned otherwise), 10 µl 5 x HF reaction buﬀer,
1 µl 2.5 mM dNTPs, 1.5 µl DMSO, 15  25 pmol forward primer, 15  25 pmol reverse primer,
0.5 µl Phusion Hot Start II DNA polymerase and 0.5  2 µl template DNA were mixed and
ﬁlled up with water to the ﬁnal volume. In the following reaction, DNA was initially denatu-
rated for 30 sec at 98°C followed by 30  35 cycles with the conditions 10 sec at 98°C; 15 sec
at 50°C  68°C (depending on the primer annealing temperatures); 30 sec / kb at 72°C and
a ﬁnal annealing step for 5  10 min at 72°C. Subsequently, DNA was run on an agarose gel
and puriﬁed with the QIAquick Gel Extraction Kit according to the manufacturer's protocol.
Overlap extension PCR was used to introduce mutations into DNA fragments. For this pur-
pose, one primer carrying the intended mutation was designed and another primer with either
the same sequence but reverse complement or at least 15 overlapping nucleotides was cre-
ated. These primers acted as forward and reverse primer in two separate ﬁrst PCR reactions
together with another forward and reverse primer ﬂanking the gene of interest. PCR compo-
nents others than the primers are listed above. DNA fragments were subsequently puriﬁed
and used as templates (0.5  2 µl per reaction) for a second (overlap extension) PCR in which
the same ﬂanking primer pair was used for ampliﬁcation. In order to allow the single frag-
ments to anneal properly, a two-step PCR program was programmed in which primers were
added only after 15 cycles (see table 2.17). Finally, full-length PCR products were puriﬁed,
cloned into a target vector and sequenced to validate correct alteration of the sequence.
Table 2.17: PCR program for overlap extension PCR
Temperature Time
98°C 30 sec
98°C 10 sec
72°C 30 sec / kb 15 cycles
Addition of primers
98°C 10 sec
50°C  68°C1 25 sec 20 cycles
72°C 30 sec / kb
72°C 5  10 min
4°C ∞
1depending on the primer annealing temperatures
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2.2.3.2 Plasmid DNA preparation
Plasmid DNA was isolated from bacterial cultures for characterization of newly generated
constructs and/or transfections. Therefore, diﬀerent volumes of antibiotic-containing media
were inoculated with single colonies of transformed bacteria (sections 2.2.2.2 and 2.2.2.4),
depending on the amount of DNA that was required, and agitated for 14  16 hours at 37°C.
Plasmid DNA was then puriﬁed with the commercial kits NucleoBond® Xtra Maxi (200 
400 ml culture), PureYield Plasmid Midiprep System (80  100 ml culture) or with self-
made buﬀers according to the alkaline lysis method [197] (3  5 ml culture). The latter was
performed as follows: 2 ml of bacterial suspension were pelleted and resuspended in 300 µl P1
Resuspension buﬀer. Three hundred µl P2 Lysis buﬀer were added and incubated for 5 min
at room temperature. After addition of 300 µl P3 Neutralization buﬀer and 5 min incubation
at room temperature, samples were centrifuged for 10 min at 16100 x g. Supernatant was
transferred into a new tube containing 600 µl isopropanol, carefully mixed and centrifuged
for 20 min at 16100 x g. Supernatant was discarded and the DNA pellet washed with 500 µl
ethanol. After 5 min of centrifugation at 16100 x g, supernatant was discarded, and the DNA
pellet was air-dried and resuspended in 50 µl nuclease-free water. DNA concentrations were
determined with a NanoVue or NanoDrop 2000 UV-Vis spectrophotometer.
2.2.3.3 Ethanol precipitation
In some cases it was necessary to further purify isolated DNA due to impurities (i.e., ethanol
contamination) after medium scale DNA preparations. Therefore, 400 µl DNA were diluted
with 200 µl 3 M sodium acetate and 1400 µl 100 % ethanol. After 25 min centrifugation at
full speed and 4°C, DNA pellets were washed with 500 µl 70 % ethanol and again centrifuged
for 5 min. DNA pellets were air-dried and resuspended in 300  500 µl nuclease-free water.
2.2.3.4 Enzymatic digests
DNA was control digested to verify plasmid identities, successful construct generation or ITR
integrity of AAV constructs. The latter were digested with XmaI to test ITR2 integrity, or PstI
for ITR4, respectively. Moreover, DNA was digested in quantitative amounts (puriﬁed PCR
products or 6  15 µg plasmid DNA) for further cloning procedures. In all cases, NEB enzymes
(2  20 U per reaction) and their corresponding buﬀers were used. Digests were performed
between 3  5 hours or over night at the recommended temperature. For combinatorial digests
either compatible buﬀers were used or sequential digests were performed.
2.2.3.5 Agarose gel electrophoresis
For separation of DNA fragments according to their size, agarose gel electrophoresis was
performed. Either PCR or restriction digest products were separated through 1  2 % agarose
gels in 1 x TAE buﬀer. Gels were prepared ahead of the run with the Sub-Cell® DNA
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electrophoresis system and supplemented with 1 µg / ml ethidiumbromide. Samples were
mixed with orange or blue loading dye, depending on the expected size of the DNA fragments,
and loaded on the gel together with a standard marker for size determination. Electrophoresis
was performed at 80  150 V for 30  60 min, and DNA was visualized on a Gel Doc XR
system or a UV transilluminator. If necessary, DNA was cut out and puriﬁed with the
QIAquick Gel Extraction Kit according to the manufacturer's protocol.
2.2.3.6 Ligation
For ligations of digested DNA fragments, normally 5  7.5 µl puriﬁed insert and 1  4.5 µl
puriﬁed plasmid backbone were mixed together with 1 µl 10 x ligase buﬀer and 0.5 µl T4
DNA ligase in a 10 µl reaction. Ligation reactions were incubated 3  5 hours at room
temperature or over night at 16°C. Subsequently, 0.5  2 µl (electroporation) or the complete
10 µl reaction (heat-shock transformation) were used for transformation into bacteria (see
also sections 2.2.2.2 and 2.2.2.4).
2.2.3.7 DNA family shuing of AAV capsids
AAV cap ampliﬁcation and DNA fragmentation via DNaseI digest
For the generation of a shued AAV capsid library, the cap composition of the library was
selected based on the further application. Subsequently, the selected capsids were PCR am-
pliﬁed with the primers #827 and #828 from plasmids #1452  1463 or #1492  1495 which
contained the appropriate cap genes. The latter were ﬂanked with standardized sequences
containing binding sites for the primers SAFor (#459) and SARev (#460) and the restriction
enzymes PacI and AscI which allowed later cloning steps. Table 2.18 depicts the PCR reaction
and PCR program that were used in order to yield high amounts of DNA for the following
fragmentation. PCR products were run on a 1 % agarose gel and puriﬁed with the QIAquick
Gel Extraction Kit. For DNA fragmentation, 4 µg of cap DNA were mixed with each serotype
being represented in equal amounts. In addition, the reaction contained 6 µl 10 x DNase re-
action buﬀer, 0.3 µl DNaseI enzyme and water up to a total volume of 60 µl. Importantly,
Table 2.18: PCR mix and reaction for AAV cap ampliﬁcation from pBS vectors
PCR reaction PCR program
Components Amount Temperature Time
Cap plasmid 200 ng 95°C 5 min
Primer #827 (M13For) 2 µM 94°C 15 sec
Primer #828 (M13Rev) 2 µM 57°C 30 sec 40 cycles
5x polymerase buﬀer 10 µl 68°C 3 min
HotStar HiFidelity Polymerase 2 µl 72°C 10 min
H2O Filled up to 50 µl 4°C ∞
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DNaseI has to be added as last component to the mixture followed by immediate ﬂicking (3 x)
of the tube, a short centrifugation step and an incubation of the reaction between 1.5 and
2.5 min at 25°C. The exact incubation time had to be determined in pre-experiments in order
to create optimal DNA fragment sizes between 100 and 1200 bp. The reaction was stopped
via addition of 6 µl 25 mM EDTA and 10 min incubation at 75°C. Next, 9 µl H2O and 15 µl
6 x loading dye were added to the mixture and the DNA was separated on a 1 % agarose
gel. DNA fragments between 100 and 1200 bp were cut out, puriﬁed with the QIAquick Gel
Extraction Kit and eluted in 30 µl nuclease-free water.
DNA fragmentation via Covaris
Since DNase digestion is highly error-prone and it is thus diﬃcult to generate DNA fragments
of equal quality and size, DNA fragmentation with a Covaris focused-ultrasonicator S2 ma-
chine was assessed as an alternative. Therefore, 4 µg cap DNA were mixed in nuclease-free
water (total volume: 50 µl), and transferred to a Covaris reaction tubes (microTUBE AFA
Fiber Snap-Cap 6 x 16 mm). Depending on the aimed fragment size, diﬀerent Covaris pro-
grams were used to shear the DNA (see table 2.19). Next, the DNA was separated on a 1 %
agarose gel, fragments were cut out and puriﬁed with the QIAquick Gel Extraction Kit and
eluted in 30 µl H2O. To compare Covaris versus DNase-treated samples, DNA was analyzed
on an Agilent 2100 Bioanalyzer Chip. The used DNA 1000 kit depicted a size range between
25  1000 bp. Sample preparation and chip run were performed according the manufacturer's
protocols.
Table 2.19: Covaris settings for DNA fragmentations of diﬀerent sizes
Fragment size [bp] 150 300 800
Duty cycle 10 % 10 % 5 %
Intensity 5 4 3
Cycles per burst 200 200 200
Time [s] 500 120 80
Re-assembly PCR (1st PCR) and 2nd PCR
After DNA fragmentation, cap sequences were re-assembled in a primerless PCR reaction (1st
PCR) which is based on partial homology between the parental AAV sequences. Therefore,
500 ng puriﬁed DNA fragments, 10 µl 5 x HF buﬀer, 1.5 µl DMSO, 1 µl 10 mM dNTPs and
0.5 µl Phusion Hot Start II DNA polymerase were mixed in a 50 µl PCR reaction together
with H2O. PCR conditions were: an initial denaturation at 98°C for 30 sec, 40 cycles of 10 sec
denaturation at 98°C, 30 sec annealing at low temperature (42°C) to foster self-priming and
generation of chimeric sequences, and 45 sec elongation at 72°C. The PCR was ﬁnished with a
ﬁnal extension step at 72°C for 10 min. PCR products were directly used without puriﬁcation
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as DNA template for the subsequent 2nd PCR. Two µl of DNA were added to a reaction
containing 2 µM SAFor (#459) and 2 µM SARev (#460) primer, 10 µl 5 x polymerase buﬀer,
0.5 µl 25 mM MgSO4, 2 µl HotStar HiFidelity Polymerase (Qiagen) and 33.5 µl H2O. In order
to obtain enough DNA for further cloning steps and a highly diverse library, 16 x 50 µl PCR
reactions were set up for one AAV cap library. For small-scale production and analysis of
shuing eﬃciencies 4 x 50 µl reactions were prepared. PCR conditions were 5 min at 95°C,
40 cycles of 15 sec at 94°C and 3 min at 68°C, and a ﬁnal extension step at 72°C for 10 min.
PCR products were run on a 1 % agarose gel. Re-assembled cap fragments with a size of
∼ 2.2 kb were cut out and puriﬁed with the QIAquick Gel Extraction Kit.
AAV cap library cloning and electroporation
After puriﬁcation of the re-assembled cap fragments, DNA was digested with the restriction
enzymes PacI and AscI (25 U each) in the appropriate buﬀer over night at 37°C. The next
day, the DNA was run on a 1 % agarose gel and fragments were puriﬁed with the QIAquick
Gel Extraction Kit. AAV cap library fragments were then cloned into an AAV single-strand
plasmid backbone containing the AAV2 rep gene ﬂanked by two ITR2 sequences (plasmid
#778 or #1608). For the ligation, 3 x more cap fragment DNA than plasmid backbone DNA
(molar ratio) was used. In detail, 861 ng vector backbone DNA, 1139 ng cap DNA, 4 µl
10 x ligase buﬀer and 4 µl T4 DNA ligase were mixed in a 40 µl ligation reaction (resulting
in a concentration of 50 ng DNA per µl) and incubated over night at 16°C. After ligation,
DNA was transformed into electro-competent bacteria. Therefore, 600 µl bacteria were pooled
and carefully mixed with the complete ligation reaction. Thirty-two µl of the mixture were
transferred to a chilled electroporation cuvette, pulsed (see 2.2.2.4), resuspended in 1 ml pre-
warmed SOC media and transferred to a 1.5 ml reaction tube. The procedure was repeated
20 times. After 1 hour shaking at 37°C, reactions were pooled again and 100 µl bacteria
suspension were plated on antibiotic-containing LB agar plates. Additionally, 1:10 and 1:100
dilutions were prepared and plated in order to determine library diversity on the next day
and to characterize chimeric clones (see paragraph below) through picking of single colonies.
The rest of the bacterial suspension was used to inoculate 400 ml of antibiotic-containing
LB media, and was processed for DNA preparation with the NucleoBond® Xtra Maxi Kit
after incubation at 37°C over night. In order to create a back-up of the generated library,
800 µl of bacterial suspension were mixed with 200 µl glycerol and stored at -80°C. For a
small-scale library production only a 10 µl ligation reaction was prepared with one fourth of
the above mentioned components. Moreover, only 1 x 30 µl bacteria were electroporated and
no suspension culture was inoculated.
Analysis of shued sequences with the Salanto program
For AAV library characterization normally 12  20 single colonies were picked after electro-
poration. DNA was isolated as described above (see 2.2.3.2) and sent for sequencing with
the primers #36, or #37, #822 and #823. Therefore, DNA was prepared according the
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company's instructions (GATC Biotech). From the resulting data sets, full-length AAV cap
sequences were assembled since one sequencing reaction covered only a third of the shued
capsid. Next, a DNA alignment of parental and chimeric sequences was generated with the
program Vector NTI and its AlignX function. Alternatively, the freeware ClustalX was used.
Subsequently, a FASTA ﬁle was created from the alignment and manually corrected for mis-
aligned nucleotides in case it was needed. The resulting ﬁle could be opened by Salanto and
analyzed with the integrated tools. For example, proportions of parental capsids in the AAV
library were determined, numbers of cross-over events within the clones or in the complete
library were calculated, and position-wise assignments of chimeras to parental sequences were
displayed. The latter was further processed with the Microsoft Excel program, i.e. chimeras
were colored according to the parental sequences (see supplementary table 1 for the used
macro). More details about Salanto, its function and tools as well as the newest version can
be found here: https://bitbucket.org/benderc/salanto/wiki/Home. See also supplementary
ﬁgure 2 for used features and generated diagrams described in this work.
2.2.3.8 RNA extraction
For RNA extraction, HEK293T cells were seeded in a 6-well plate format with 0.5 x 106 cells
in 2 ml media per well, transfected one day later (see 2.2.5.2) and harvested 48 hours after
transfection. Therefore, cells were washed with PBS, resuspended in 600 µl RLT buﬀer
(RNeasy Mini Kit) and transferred to 1.5 ml reaction tubes. Samples were stored at -80°C until
further processing. Subsequently, RNA was puriﬁed according to the manufacturer's protocol
(section Puriﬁcation of Total RNA from Animal Cells using Spin Technology) with inclusion
of the on-column DNase digestion step. Finally, RNA concentrations were determined using
the NanoVue spectrophotometer.
2.2.3.9 cDNA synthesis and quantitative PCR (qPCR)
To measure mRNA copy numbers in the extracted RNA samples, 5 µg RNA were transcribed
with the Tetro cDNA Synthesis Kit using the random hexamer primers according to the
manufacturer's protocol. cDNA was then diluted 1:500 and 1 µl was used in a 10 µl qPCR
reaction (see table 2.20). qPCR was performed with the SensiMixTM SYBR No-ROX Kit and
reactions were run in a Rotor-Gene 6000 machine using the following program: 95°C 10 min,
40 cycles of 95°C 15 sec, 58°C 15 sec, 72°C 15 sec, and a ﬁnal melting step from 50°C to
99°C in 5-second steps of 1°C each. Samples were measured in duplicates and normalized
to a GAPDH housekeeper (primers #1117/#1118). For ﬁnal analysis, sample values were
calculated according to the 2-∆∆CT method [198].
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Table 2.20: Composition of one 10 µl reaction for qPCR analysis (using the SensiMixTM SYBR
No-ROX Kit)
Component Volume [µl]
2x SensiMixTM SYBR No-ROX 5
10 µM forward primer 1.25
10 µM reverse primer 1.25
cDNA template (1:500 diluted) 1
H2O 1.5
2.2.4 Protein biochemistry methods
2.2.4.1 Immunoprecipitation (IP)
HEK293T cells were seeded in 6 cm dishes (1.4 x 106 cells per dish, 4.5 ml media) and trans-
fected 24 hours later with PEI (see 2.2.5.2). Twenty-four hours after transfection old media
was removed and fresh media containing the proteasome inhibitor MG-132 (ﬁnal concentra-
tion 2 µM) was added. After additional 24 hours cells were harvested in media and centrifuged
for 10 min at 1500 x g and 4°C. The supernatant was discarded and 1000 µl PBS containing
protease inhibitors (PBSPI; 1 tablet protease inhibitor cocktail was dissolved in 50 ml PBS)
was added. Centrifugation was repeated, the supernatant was discarded and the cells were
resuspended in 1200 µl PBSPI. Cells were then lysed by 5 x freeze-thaw cycles (2 min liquid
nitrogen / 5 min 37°C), sonicated for 1 min and cell debris was removed by centrifugation for
5 min at 10000 x g, 4°C. The supernatant was transferred into a new tube and the volume
adjusted to 1300 µl with PBSPI. Subsequently, 50 µl of the samples were aliquoted for later
Western blot analysis and served as IP input. Next, speciﬁc antibodies were added to the
lysate: 115 µl B1 antibody hybridoma supernatant were used to pull down AAV VPs, 0.4 µl
anti-Ubiquitin antibody FK2 were used for IP of mono- and polyubiquitinated proteins, and
either 1 µl anti-Oct3/4 or 1 µl anti-SSEA1 antibody served as control antibodies. The lysate-
antibody mixtures were incubated for ∼ 5 hours under rotary agitation at 4°C. Afterwards,
50 µl of Protein A/G PLUS Agarose beads were added per sample and incubated over night
at 4°C under rotary agitation. The next day, samples were centrifuged for 3 min at 2500 x g
and 50 µl of supernatant were aliquoted for Western blot analysis to serve as non-bound frac-
tion. At this step, proteins of interest should be speciﬁcally bound to the antibodies coupled
to the beads. The supernatant was then carefully removed from the beads and discarded.
Beads were washed four times with ice-cold PBS to remove non-speciﬁcally bound proteins.
Therefore, samples were gently mixed with PBS and centrifuged for 3 min at 2500 x g, 4°C.
After the last washing step, as much buﬀer as possible was removed and the bead pellet
was resuspended in 50 µl 2 x SDS buﬀer. For dissociation of the immunocomplexes from
the beads, samples were incubated for 10 min at 95°C. Beads were then collected by 2 min
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centrifugation at 2500 x g, and the supernatant was transferred to a new tube and stored at
-20°C until Western blot analysis. Every step during the IP was performed on ice to avoid
protein degradation and de-ubiquitination.
2.2.4.2 Immunostaining
HEK293T cells were seeded three days prior to immunostaining in either 96-well glass plates
suitable for confocal microscopy with a density of 2.8 x 104 cells per well or in LabTek formats.
The latter were ﬁrst coated with 1 % gelatine for 30 min at 37°C and then ﬁlled with the same
cell number per well. One day later cells were transfected using polyethylenimine (see 2.2.5.2).
Therefore, 172.5 ng of an adeno-viral helper construct, a rep-cap helper which encodes for the
AAV capsid and plasmid #714 (unless mentioned otherwise) carrying the transgene ﬂanked
by ITRs were transfected in equal amounts. In addition either 44.2 ng of AAP plasmid or
44.2 ng stuﬀer DNA were added to the mixture. Forty-eight hours after transfection, cells were
washed with 200 µl (LabTek) or 100 µl (96-well) ice-cold PBS, air-dried for ∼ 2 min and ﬁxed
with 100 % methanol for 10 min at -20°C. After 2 x 5 min washing with IF blocking buﬀer,
cells were incubated for 1  2 hours at 37°C with 150 µl (LabTek) or 50 µl (96-well) primary
antibodies diluted in blocking buﬀer (see table 2.9 for dilutions). Subsequently, cells were
washed 3 x 5 min with IF blocking buﬀer and incubated for 1 hour at 37°C with secondary
antibodies diluted in blocking buﬀer (see table 2.10 for dilutions). For quantiﬁcation of B1
and A20 stainings an anti-mouse AF647-labeled secondary antibody was used. The anti-
HA antibody was detected with an anti-mouse AF488-labeled secondary antibody (unless
mentioned otherwise). In case of the concurrent use of the anti-AAP2 antibody with either
the B1 or the A20 antibody, anti-rabbit AF568 and anti-mouse AF488 antibodies were added
to the samples. Next, cells were washed 2 x 5 min with IF blocking buﬀer, incubated for
5 min with Hoechst stain 33258 diluted 1:3000 in PBS and washed again 2 x 5 min with
PBS. For long-term storage, LabTeks were embedded in three drops of mounting media and
covered with a cover slip. 96-well plates were stored at 4°C in the dark containing 100 µl PBS
per well. In case of time-course experiments, samples were ﬁxed with methanol, washed once
with IF blocking buﬀer and stored in blocking buﬀer at 4°C until staining procedures were
continued as described above.
2.2.4.3 Microscopy and picture quantiﬁcation
In order to quantify the immunostaining of the abovementioned samples, pictures were taken
with an Olympus inverted ﬂuorescence microscope IX-81. Table 2.21 depicts the microscope
settings for each color channel. Microscopy pictures were quantiﬁed with the open-source
software CellProﬁler. The implemented protocols are described in supplementary tables 2 
4. To obtain more detailed pictures a Leica confocal microscope TCS SP5 was used. The
program Fiji was used to further process the captured microscopy pictures (e.g. z-stack
projections, scale bar insertions).
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Table 2.21: Microscope settings for the Olympus inverted ﬂuorescence microscope IX-81.
Channel Filter cube Exposure
time
Intensity Excitation
ﬁlter
Blue (Hoechst) DAPI 10 ms 100 % empty
Green
(GFP/AF488)
GFP 200  500 ms 50  100 % empty
Red (AF568) DAPI/FITC/TxRed 1000 ms 50 % TxRed 572/23
Dark red (AF647) Cy5 100 ms 100 % empty
2.2.4.4 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
For analysis of viral proteins, samples were ﬁrst mixed with 2 x SDS sample buﬀer and
denaturated for 5  10 min at 95°C. Next, samples were loaded with a Hamilton syringe on
either 8 % (VP1, VP2, VP3, actin) or 12 % (AAP) resolving sodium dodecyl sulfate (SDS)
polyacrylamide gels for separation by their molecular weight. Gels were prepared as described
in table 2.22 with the Mini-PROTEAN® tetra cell casting module. In detail, one-millimeter
spacer plates were assembled with short glass plates. After ensuring that the setup was
tight and leakproof, the resolving gel was poured between the two glass plates and overlaid
with isopropanol. Once the resolving gel was polymerized, the isopropanol was removed, the
stacking gel was poured and a comb with the required number of wells (10 or 15) was inserted.
As soon as the stacking gel was polymerized, the gel was transferred to the electrophoresis
chamber and samples were loaded together with a standard protein ladder (PageRulerTM plus
prestained protein ladder). Electrophoresis was performed in 1 x TGS buﬀer for 2  2.5 hours
at 90 V. After the run had ﬁnished the gels were processed for Western blotting (see 2.2.4.5).
Table 2.22: SDS polyacrylamide gel composition for one gel
Stacking gel 5 % Resolving gel 8 % 12 %
Component Volume
[ml]
Component Volume
[ml]
Volume
[ml]
H2O 1.46 H2O 2.65 2.15
Stacking gel buﬀer (pH 6.8) 0.25 Running gel buﬀer (pH 8.8) 1.25 1.25
40 % Acrylamide-
Bisacrylamide
0.25 40 % Acrylamide-
Bisacrylamide
1.0 1.5
10 % SDS 0.02 10 % SDS 0.05 0.05
TEMED 0.02 TEMED 0.05 0.05
10 % APS 0.002 10 % APS 0.003 0.002
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2.2.4.5 Western blotting
After proteins were separated via SDS-PAGE (see 2.2.4.4), they were transferred to a nitro-
cellulose membrane through semi-dry blotting. Therefore, gels were removed from the glass
plates, the stacking gel was cut oﬀ and the resolving gel as well as the nitrocellulose membrane
and an appropriate amount of blotting papers were equilibrated in transfer buﬀer. Next, four
blotting papers, the membrane, the SDS gel and another four blotting papers were assembled
on a Trans-Blot® SD Semi-Dry Transfer Cell followed by 1  1.5 hours of blotting at 150 
300 mA at 4°C. The eﬃciency of the transfer was determined through Ponceau S staining of
the membrane. Afterwards, membranes were washed with 1 x TBS-T buﬀer and blocked for
at least one hour at room temperature with either 5 % milk or 1 % albumin fraction V in
TBS-T. Primary antibodies were diluted according to table 2.9 in the corresponding blocking
buﬀer (except for the anti-actin antibody all antibodies were diluted in 5 % milk blocking so-
lution) and incubated with the membrane over night at 4°C. The membranes were cut around
the 55 kDa ladder band ahead of blocking, in case viral proteins (VPs) and actin were co-
stained on one gel. The next day, membranes were washed 3 x 10 min with TBS-T buﬀer and
incubated for at least 1 hour at room temperature with a horseradish peroxidase-conjugated
secondary antibody diluted in blocking buﬀer (see table 2.10 for dilutions). After 3 x 10 min
subsequent washing steps in TBS-T buﬀer, membranes were incubated for 1 min with West-
ern Lightning Plus-ECL reagent to visualize bound antibodies via chemiluminescence and
exposed to X-ray ﬁlms. The latter were developed in an X-OMAT 2000 processor.
2.2.5 Cell culture methods
2.2.5.1 Cell culture
All cell lines were cultured under standard sterile growth conditions and incubated at 37°C
with 5 % CO2. HEK293T, MCF-7 and SF-539 cells were cultured in Dulbecco's Modiﬁed Eagle
Medium (DMEM) media with GlutaMAXTM supplemented with 10 % FCS and 100 U/mL
Penicillin-Streptomycin. Additionally, Huh7 media contained 1 % non-essential amino acids.
Cells were split every two to four days at 80  100 % conﬂuency (see table 2.23).
Table 2.23: Split conditions for several cell lines
Cell line Split factor Split frequency
HEK293T 1:8  1:12 2-3 days
Huh7 1:3  1:6 3-4 days
MCF-7 1:8  1:12 3-4 days
SF-539 1:6  1:10 3-4 days
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2.2.5.2 Transfection with polyethylenimine (PEI)
For transfection, HEK293T cells were seeded 24 hours before PEI transfection in a required
well / plate format and transfected as soon as they reached an optimal conﬂuency of 60 
75 %. For transfection, a PEI mix and a DNA mix were prepared separately (see table 2.24
for composition of mixtures). Both were mixed together and incubated for 10 min at room
temperature to allow the formation of DNA-PEI complexes. Finally, the complete mix was
added dropwise to the cells. Forty-eight to 72 hours post-transfection cells were processed for
further experiments.
Table 2.24: Composition of PEI and DNA mixes for transfections with PEI in diﬀerent cell culture
(well-) plate formats. Amounts are calculated for one well or one dish, respectively.
Plate format
PEI mix DNA mix
PEI H2O 300 mM
NaCl
DNA H2O 300 mM
NaCl
96-well (normal) 1.7 µl 2.1 µl 3.8 µl 200 ng 3.8 µl 3.8 µl
96-well (glass) 2.55 µl 3.15 µl 5.7 µl 300 ng 5.7 µl 5.7 µl
LabTek 1.83 µl 2.25 µl 4.08 µl 216.7 ng 4.08 µl 4.08 µl
6-well 22 µl 27 µl 49 µl 2.6 µg 49 µl 49 µl
6 cm dish 50.8 µl 62.3 µl 113.1 µl 6.0 µg 113.1 µl 113.1 µl
15 cm dish 352 µl 438 µl 790 µl 44 µg 790 µl 790 µl
2.2.6 Virological methods
2.2.6.1 Cell seeding, transfection and harvest for large-scale AAV production
Four million HEK293T cells were seeded in 22 ml of media per 15 cm dish two days be-
fore transfection. Normally, 10 dishes per vector for iodixanol gradient puriﬁcation, or 40 
60 dishes per vector for cesium chloride puriﬁcation, were transfected according to table 2.24.
For virus production, equal amounts of an adeno-viral helper construct, a rep-cap helper which
encodes for an AAV capsid and a plasmid carrying the transgene ﬂanked by ITRs were trans-
fected (14.67 µg each per dish). In case of AAV productions supplemented with AAP, 11.7 µg
of the abovementioned plasmids were transfected in addition with either 9 µg of an AAP
construct or 9 µg of stuﬀer (sheared salmon sperm) DNA. For shued AAV libraries, 22 µg of
adeno-viral helper plasmid and 22 µg library plasmid were transfected per dish. Three days
after transfection cells were scraped oﬀ the plates, transferred to tubes, centrifuged for 10 min
at 400 x g and washed with 1 x PBS. Finally, cell pellets were resuspended in benzonase buﬀer
(5 ml per 10 dishes) and AAVs were puriﬁed through iodixanol or cesium chloride gradients
(see chapter 2.2.6.2 and 2.2.6.3).
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2.2.6.2 AAV puriﬁcation through iodixanol density gradient centrifugation
Cell pellets produced as depicted in chapter 2.2.6.1 were lysed by 5 x freeze-thaw cycles and
1 min soniﬁcation followed by a benzonase digest (150 U / ml) for 1 hour at 37°C. Samples
were carefully mixed every 10  20 min to ensure complete degradation of free DNA and
RNA. Then, samples were adjusted to 7 ml and centrifuged for 15 min at 4000 x g and 4°C.
The supernatant was transferred to a new tube and centrifuged again. During centrifugation,
iodixanol solutions (15  60 %) were prepared according to table 2.4. To pour the solutions into
an ultracentrifugation tube, a Pasteur capillary pipette was put into the tube. Next, virus-
containing supernatant was transferred into the ultracentrifugation tube, followed by 1.5 ml of
each iodixanol solution in the order 15 % / 25 % / 40 % / 60 %. Tubes were ﬁlled completely
with benzonase buﬀer and sealed after removal of remaining bubbles. Gradients were run in
a ﬁxed-angle 70.1Ti Beckman rotor for 2 hours at 50000 rpm and 4°C in an Optima L-90K
ultracentrifuge. Afterwards, the 40 % iodixanol phase was collected with a syringe from the
side of the gradient while taking care not to transfer the 25 % phase which contained empty
particles. Therefore, tubes were placed in a burette clamp ﬁxed at a triangular support with
rod. Puriﬁed virus was aliquoted and stored at -80°C until further use.
2.2.6.3 AAV puriﬁcation through cesium chloride density gradient centrifugation
Samples were produced as described in section 2.2.6.1 and treated as detailed in the beginning
of chapter 2.2.6.2 to disrupt the cells and degrade free DNA and RNA. After benzonase
digest, samples were centrifuged for 15 min at 4000 x g, and the supernatant was transferred
to a new tube. Subsequently, 1/39 volumes of 1 M calcium chloride solution were added
(ﬁnal concentration 25 mM) to separate high molecular weight impurities [199]. Samples
were then incubated for 1 h on ice and centrifuged for 15 min at 10000 x g and 4°C. Next,
1/4 volumes of 40 % PEG / NaCl solution were added to the sample, which was carefully
mixed and incubated 3  5 hours or over night on ice to precipitate AAV particles. Afterwards,
samples were centrifuged at 2500 x g / 4°C for 30 min and carefully resuspended in 10 ml
Na-HEPES resuspension buﬀer with a pipette. In case precipitation was performed for 3 
5 hours, resuspension of the pellet took place over night at 4°C on a tube rotator. In an
additional centrifugation step (2500 x g, 4°C, 30 min) remaining precipitates were removed,
the supernatant was transferred to a new tube and Na-HEPES buﬀer was added to a volume
of 24 ml. After addition of 13.2 g cesium chloride, the solution temperature dropped and
samples were incubated until they reached room temperature again. In the meanwhile the
refraction index (RI) of the cesium chloride topping solution was assessed and  if necessary
 adjusted to 1.3710. Next, the RI of the samples was also adjusted with either Na-HEPES
buﬀer (RI > 1.3710) or cesium chloride (RI < 1.3710) to 1.3710, and samples were transferred
with a serological pipette to large OptiSealTM Ultracentrifuge tubes (26 x 77 mm). Bubbles
were removed, and the tubes were ﬁlled up with topping solution and closed with appropriate
lids. Gradients were run in a ﬁxed-angle 70Ti Beckman rotor for 23 hours at 45000 rpm and
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21°C in an Optima L-90K ultracentrifuge. After the centrifugation, tubes were placed in a
burette clamp ﬁxed at a triangular support with rod. Needles were used to create holes at the
top of the tube for air exchange and at the bottom for sample collection. Diﬀerent volumes of
fractions (3 / 3 / 0.5 / 0.5 / 0.5 / 5 / 0.5 / 0.5 / 0.5 / 3 ml) were collected in 15 ml tubes and
the RI of each fraction was determined. Fractions with a RI between 1.3711 and 1.3766 were
pooled, and the volume adjusted to 9 ml with PBS. Next, samples were transferred to a Slide-
A-Lyzer dialysis cassette and dialyzed against 1 x PBS at 4°C with regularly buﬀer exchanges
(after 30 min, 1 hour, 2 hours, over night, 2 hours and 2 hours). Subsequently, samples were
concentrated in equilibrated Amicon® Ultra Centrifugal Filter Units to a volume of 500 
1200 µl using several centrifugation steps at 400 x g. Finally, puriﬁed virus was aliquoted and
stored at -80°C until further use.
2.2.6.4 AAV titration
To determine AAV titers, 10 µl cesium chloride or 10 µl iodixanol gradient-puriﬁed AAV
sample was diluted in 10 µl TE buﬀer and mixed with 20 µl 2 M NaOH followed by 30 min
incubation at 56°C for virus lysis. Samples were neutralized with 38 µl 1 M HCl and further
diluted with 922 µl H2O. In case of iodixanol-puriﬁed virus, samples were additionally diluted
1:10 in H2O since high iodixanol concentrations could inhibit the qPCR reaction. In each
titration one negative control with nuclease-free water and one AAV positive control with an
already known titer were included and treated as described above. In addition, a standard
curve containing an appropriate plasmid was prepared. The latter was 10-fold serially diluted
in order to obtain several dilutions with 5 x 103 to 5 x 109 molecules per reaction. Final
qPCR mixtures contained 1 x SensiMixTM II Probe No-ROX mix, 0.4 µM forward primer,
0.4 µM reverse primer, 0.1 µM qPCR probe, 1.43 µl treated sample and were ﬁlled up to 10 µl
reaction volume with nuclease-free water (see table 2.25 for primer and probe sequences).
Samples were measured in triplicates. PCRs were run in a Rotor-Gene 6000 machine with
the following program: denaturation for 10 min at 95°C, 40 cycles of 10 sec denaturation at
95°C and 20 sec combined annealing and extension at 60°C. After the run, CT values were
Table 2.25: Sequences of probe and primers used for AAV titrations. Probes were labeled 5' with
the ﬂuorophore FAM and 3' with the quencher BHQ1.
Name Probe (5` → 3`) 5` primer (5` → 3`) 3` primer (5` → 3`)
CMV AGTCATCGCTATTA
CCATGG
TGCCCAGTACATG
ACCTTATGG
GAAATCCCCGTGAG
TCAAACC
GFP ACGACGGCAACTACA GAGCGCACCATCT
TCTTCAAG
TGTCGCCCTCGAAC
TTCAC
Rep TGATCGTCACCTCC
AACA
AAGTCCTCGGCCC
AGATAGAC
CAATCACGGCGCAC
ATGT
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translated into molecule numbers based on the standard curve (expected r2 value > 0.985)
and ﬁnal sample concentrations were calculated by multiplying the obtained values by 7 (since
1.43 µl sample were added to 10 µl reaction), 100 (dilution through alkaline lysis), 100 (for
up-scaling from 10 µl to 1 ml), 2 (only for single-stranded genome viruses) and 10 (only for
iodixanol gradient-puriﬁed samples which were additionally diluted 1:10).
2.2.6.5 Determination of empty and full AAV capsids
First, cesium chloride gradient puriﬁcation was performed until the centrifugation step as
described above (see 2.2.6.3). Subsequently, the ﬁrst 5 ml of the gradient were discarded and
0.5 ml fractions were collected. In total, 40 fractions were taken and their RI was determined.
Fractions with RIs between 1.3638 and 1.3780 were used for the following experiments. For
determination of infectious particles, 5 µl of each fraction were used to transduce HEK293T
cells seeded one day before with 2.5 x 104 cells per well in 96-well plates. Viral dilutions of
1:10 and 1:100 reduced sample toxicity which was caused by the high cesium chloride con-
centrations. Cells were analyzed 48 hours later by ﬂow cytometry (see 2.2.6.7). Assembled
viral particles were determined by AAV2 Titration ELISA (PROGEN Biotechnik). There-
fore, every second fraction was diluted between 1:100 and 1:10000 and measured against a
provided standard sample. The ELISA was performed according to the manufacturer's pro-
tocol. Finally, measured absorbance values were normalized to a blank and AAV particle
concentrations were calculated with the help of a standard curve which was included in the
kit.
2.2.6.6 AAV crude cell lysate production
HEK293T cells were seeded in 6-well plates with 0.45  0.50 x 106 cells in 2 ml media per
well one day before transfection. For transfection, PEI was used as transfection reagent
(see 2.2.5.2). In case of normal virus production, equal amounts of an adeno-viral helper
construct, a rep-cap helper which encodes for an AAV capsid and a plasmid carrying the
transgene (normally a CMV promoter-driven GFP, unless mentioned otherwise) ﬂanked by
ITRs were transfected (866.67 ng each per well). When AAP was added during production,
690 ng per construct were transfected together with either 530 ng of AAP plasmid or 530 ng
stuﬀer DNA. Forty-eight hours after transfection, cells were harvested in media with a pipette
and centrifuged for 10 min at 1500 x g. The supernatant was discarded and the cell pellet
resuspended in 1 ml PBS. After a second centrifugation, the pellet was resuspended in 500 µl
PBS. Sixty µl of this suspension were transferred to a new tube and diluted with 40 µl PBS
for later Western blot analysis (see 2.2.4.5). The remaining cell suspension (440 µl) was lysed
by 5 x freeze-thaw cycles (37°C / liquid N2) and 1 min soniﬁcation. Cell debris was removed
through 10 min centrifugation at 16100 x g and AAV particle containing supernatant was
transferred to a new tube. AAV crude cell lysates were stored at -20°C for later transduction
of diﬀerent cell lines.
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2.2.6.7 Crude cell lysate transduction and ﬂow cytometry analysis
Cells were seeded in 96-well plates 24 hours ahead of AAV crude lysate transduction (see table
2.26 for cell line speciﬁc cell densities). Normally, HEK293T cells were used to test AAV2
constructs, MCF7 cells for AAV4 vectors and SF539 cells for AAV5 particles. Since crude cell
lysates cannot be titered due to containing intracellular components which could interfere with
the qPCR reaction, equal volumes of vector were used for transduction. Accordingly, 5 µl or
10 µl AAV crude lysate were added per 96-well for adherent or suspension cells, respectively.
Additionally, cells were transduced with vector dilutions of 1:10 and 1:100. Forty-eight hours
post-transduction, cells were processed for ﬂow cytometry analysis. In detail, cell culture
media was discarded and cells were washed with 100 µl PBS. After 5 min incubation at 37°C
with 30 µl trypsin, cells were resuspended in 170 µl 1 % BSA in PBS (ﬁnal volume = 200 µl).
The amount of transduced cells was determined through the measurement of GFP-positive
events in ﬂow cytometry. Therefore, size and granularity of the cells were monitored by
forward and sideward scatter whereby a cutoﬀ gate was set in order to exclude cell debris.
Within the displayed events a `Living cells' fraction was deﬁned and had to be adapted for
each cell line. GFP expression of the `Living cells' fraction was detected in the green channel
and plotted against the red channel which was expected to be negative. With the help of a
non-transduced sample, the amount of background ﬂuorescence was determined and a `GFP
positive' gate set. Transduction rates were calculated as percentage of positive cells out of
all events in the `Living cells' gate. In total 15000 events were measured or detection was
stopped after 1 min acquisition, respectively, when the number of events fell below 15000. All
data were acquired with a FC500 MPL ﬂow cytometer and the accompanying MXP software
in a 96-well plate format. Recorded data were further processed with an Excel macro (see
supplementary table 5) to extract all relevant values. For ﬁnal analysis, the crude lysate
dilution was selected in which the AAV wild-type control showed less than 95 % positive cells
in order to avoid the analysis of oversaturated data. Subsequently, all values were normalized
to this control which was set to 1.0 and compared with other measurements.
Table 2.26: Cell densities of diﬀerent cell lines for AAV crude lysate transduction (96-well plate
format)
Cell line Cell numbers per well
HEK293T 1.5  2.0 x 104 cells
Huh7 0.7 x 104 cells
MCF7 0.5 x 104 cells
SF539 0.4 x 104 cells
59

3
Results
3.1 Optimization of DNA family shuing
3.1.1 DNase digest outperforms Covaris fragmentation
Previous studies showed successful generation of chimeric AAV capsids using DNA family shuf-
ﬂing as a method for molecular evolution [133,136]. However, DNA family shuing includes
critical steps which, when performed improperly or without suﬃcient training, can inﬂuence
the quality of the generated library. Amongst others, one crucial procedure during shuing is
the fragmentation of input DNA. Normally, enzymatic DNaseI digests are performed in order
to generate DNA fragments < 1000 bp [133136]. Yet, DNase digest is highly dependent on
the enzyme amount used and on the incubation time of the mixture (ﬁgure 3.1a). Slightly
decreased incubation times already result in undesirable large fragments, while higher enzyme
quantities increase fragmentation to an unfavorable extent, respectively. Moreover, enzyme
stocks can vary in their activity and therefore have to be tested before each fragmentation
approach.
Thus, we aimed to improve DNA fragmentation and compared enzymatic DNase digest with
physical treatment regarding their fragment generation and shuing eﬃciency. In detail, we
applied DNA shearing with a Covaris focused-ultrasonicator machine which is widely used for
e.g. next generation sequencing [200, 201]. The system uses acoustic energy to create cavita-
tion zones through which DNA double-strand breaks are generated. By modifying diﬀerent
parameters (e.g. intensity or time) it is possible to deﬁne variable fragment lengths. We chose
settings to create fragments of 150, 300 and 800 bp and compared them with DNase-treated
DNA on an Agilent Bioanalyzer DNA 1000 chip. As input we used AAV capsids of the
serotypes 1, 7, 8, 9 and rh10 (from hereon referred to as 1789rh10 AAV cap library). Figure
3.1b-c clearly depicts the diﬀerence between both methods: Controlled fragmentation with fo-
cused ultrasonication yielded deﬁned DNA pieces of speciﬁc length depending on the machine
settings (ﬁgure 3.1c). In contrast, DNase digestion generated a wide range of fragment sizes
without a deﬁned peak (ﬁgure 3.1b). We next puriﬁed the generated fragments in order to
check their ability to reconstitute intact AAV cap genes and used them as input for the ﬁrst
primer-less re-assembly PCR reaction, followed by a second PCR with ﬂanking primers (see
methods section for details). Figure 3.2a shows the result of the second PCR after its separa-
tion on an agarose gel. Interestingly, only the DNase-treated sample and the 800 bp fragmen-
tation yielded suﬃcient amounts of re-assembled capsid genes of ∼ 2.2 kb. With 150 or 300 bp
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a
DNase digestion
Covaris fragmentation
b
0.3 Units DNase 0.5 Units DNase
Time [min:sec] 1 1:30 2 1 1:30
3000
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[bp]
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Figure 3.1: Optimization of DNase di-
gest conditions and comparison with
controlled fragmentation. a) Examples
for DNase digests at 25°C with diﬀerent
incubation times and varying amounts of
DNase enzyme, respectively. The optimal
condition for DNase digestion is marked
with a star and created a wide range of
fragments between 100 and 1000 bp (white
square). b)  c) Schematic depiction of
random DNA fragmentation via DNase en-
zyme (b - left) and controlled focused acous-
tic DNA fragmentation (c - left). Chro-
matograms show fragmented DNA analyzed
with an Agilent Bioanalyzer DNA 1000 chip.
Characteristically, DNase treatment gener-
ated a broad range of diﬀerent DNA sizes
without a distinct peak whereas physically
treated samples show deﬁned DNA peaks
with the intended lengths (150, 300 and
800 bp). Signals at 15 and 1500 bp are
marker bands included in the chip. The
chromatogram of the DNase digest was gen-
erated by N. Schürmann.
DNA fragments no or only a slight capsid DNA band could be detected, respectively. There-
fore, we continued library production only with the successfully assembled samples, cloned
the capsid fragments into our generated pSSV9_Pac_Asc construct (see section 2.2.1.1) and
sequenced 20 library clones after transformation into electro-competent bacteria. Analysis of
the shued sequences was performed with the Salanto program (see supplementary ﬁgure 1
and 2). On top of the previously published tools [195], additional Salanto functions were im-
plemented in order to allow deeper analysis of shued AAV cap libraries. In detail, the tools
Crossover analysis, Fragment length analysis, Show homology and Show Crossovercount
were developed and validated in close collaboration with Christian Bender. The latest version
of Salanto can be found at https://bitbucket.org/benderc/salanto/wiki/Home. The created
1789rh10 cap libraries were further analyzed with the Fragment length analysis tool which
allows for the determination of number and length of shued cap fragments within the library.
As depicted in ﬁgure 3.2b-c, number and length of the generated fragments diﬀered between
physically or enzymatically treated samples. In general, DNase digest resulted in a library
with smaller fragments (average length = 148.9 bp) which entailed a higher fragment number
(average count = 43.5 within the 20 analyzed clones). In contrast, controlled fragmentation
with the Covaris resulted in 1.45-fold longer fragments (Ø 216.5 bp) and hence in 1.48-fold
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Figure 3.2: Capsid re-assembly after enzymatic or physical DNA treatment and com-
parison of fragment length and number within generated chimeras. a) Second shuing
PCR reaction with diﬀerent DNA inputs. From left to the right: 150, 300 or 800 bp fragments
created by Covaris treatment or DNase-digested DNA were used as template DNA. PCR reactions
were separated on a 1 % agarose gel. Only the DNase treated sample and the 800 bp fragmentation
yielded enough DNA for further cloning steps. b)  c) Comparison between fragment lengths and
numbers of 20 shued and analyzed chimeras of a 1789rh10 AAV cap library after DNase treatment
(black bars in b) or 800 bp Covaris fragmentation (grey bars in b). Red arrows indicate the resulting
fold-change of the analyzed values between the two methods (c). Analysis of chimeric clones was
done with the Salanto program and the "Fragment length analysis tool. "Indet" denotes regions in
chimeras which could not be assigned unequivocally.
decreased fragment numbers (Ø 29.3). Of note, these data reﬂect the DNA input characteris-
tics at the beginning of the shuing reaction. Eight hundred bp fragmentation lacked DNA of
smaller size and mainly contained longer fragments whereas the DNase-treated sample showed
a broad range of DNA fragments between 100 and 1000 bp (see again ﬁgure 3.1b-c). Our data
suggest that the fewer small fragments are present in the re-assembly reaction, the lower are
the crossover rate and thus the fragment length in the ﬁnal clones. Since we generally aim
to create highly diverse AAV cap libraries with many crossovers, we conducted that DNase
digest outperformed 800 bp Covaris treatment in our set up. Although Covaris treatment
was more robust upon individual experiements, we decided to continue with DNase digestion
as fragmentation method for all upcoming AAV shuing reactions in order to guarantee the
highest possible shuing eﬃciency.
3.1.2 Rate of sequence homologies inﬂuence shuing eﬃciency
During our aforementioned experiments we not only observed a correlation between input
fragment size and crossover rate but also between homology of parental capsids and crossover
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Figure 3.3: Correlation of sequence homology and crossover frequency. a/c) Correlation
between crossover frequency (black) and homology (red) of the input capsids after generation of the
AAV libraries 1789rh10 (a) and 1-9 (c). Twenty clones per library were analyzed with the Salanto
program tools "Crossover analysis" and "Similarity to reference sequences". Grey arrows highlight
the low homology and reduced crossover rates of AAV cap 4 and 5 to other capsids. b) Sequence
identities between AAV capsids 1  9, rh10, po.1 and 12.
frequency in the created 1789rh10 library (ﬁgure 3.3a). Therefore, we analyzed the cap se-
quences of AAV1  9, rh10, po.1 and 12 regarding their similarity with the Salanto program.
Calculated homologies ranged between 56.6 and 97.1 % (ﬁgure 3.3b). The lowest similarity
was obtained for AAV cap po.1 and cap 12, the highest for AAV cap 1 and cap 6. Overall,
AAV cap 1, 2, 3, 6, 7, 8, 9 and rh10 are very similar to each other whereas AAV cap 4, 5, po.1
and 12 diﬀer the most. To further investigate the correlation between homology and crossover
rate, we generated in addition to the 1789rh10 library an AAV library consisting of capsids
1  9. Again we observed the same correlation as described above. The higher the homology
between capsids, the more likely they recombine during the shuing procedure (compare the
red and black lines in ﬁgure 3.3c). Of note, AAV cap 4 and 5 showed the lowest recombination
rate amongst all capsids (see grey arrows in ﬁgure 3.3c).
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3.1.3 Sequence optimizations of AAV cap 4 and 5 increase shuing eﬃciency
The low recombination rate of AAV cap 4 or 5 prompted us to investigate whether increasing
capsid homology will enable more crossover events. Therefore, we modiﬁed both capsids and
adapted them to the cap sequence of AAV2. In detail, single nucleotides of AAV4 or 5,
respectively, were adjusted to AAV2 without changing the amino acid sequence of all three
VPs. Figure 3.4a schematically depicts the process for cap 4. Full sequences of the optimized
cap variants can be found in supplementary ﬁgure 3 and 4. Through optimization, homologies
between cap 2 and 4 or 5 (named from here on cap 4O and 5O), respectively, increased by
13 % (ﬁgure 3.4b-c). Additionally, the similarity between cap 4O and 5O improved by 11 %.
Moreover, capsids 4O and 5O showed increased homologies to all other capsids ranging between
0.4 and 4.7 % except for cap 12 (cap 4O) or po.1 (cap 5O), respectively.
Next, we investigated the shuing potential of the optimized cap sequences and generated a
library containing wild-type AAV capsids 2, 4 and 5 (short: 245) as well as a library containing
cap 2, 4O and 5O (short: 245O). Per library 20 randomly picked clones were sequenced and
analyzed with the Salanto tools "Show precise type assignment", "Number of crossovers per
clone" and "Crossover analysis". Figure 3.5a shows the colored precise type assignment of the
chimeras generated by the program and processed with Microsoft Excel (see section 2.2.3.7
for details). Both libraries clearly diﬀered from each other. The 245 library showed low
amounts of crossovers (Ø 3.3 per clone) which clustered preferentially at the 5' part of the
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Figure 3.4: Sequence optimization of AAV cap 4 and 5. a) Schematic depiction of the op-
timization process for AAV cap 4. From top to bottom: AAV cap 2 sequence, optimized AAV4O
sequence with adapted nucleotides, wild-type AAV cap 4 sequence, amino acid sequence of AAV cap
4 and 4O VPs. Note that amino acids do not change between wild-type and optimized gene version.
b)  c) Increase of sequence homologies between AAV cap 4/4O (b) and 5/5O (c), respectively, to
capsids 1  9, rh10, po.1 and 12. Red arrows mark the intended improvement between cap 2/4O,
2/5O as well as 4O/5O.
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Figure 3.5: Comparison of AAV cap libraries 245 and 245O. a) Precise type assignment of
AAV cap libraries 245 and 245O. Twenty clones per library were analyzed with the Salanto program
(see text for details). Use of cap 4O and 5O yielded higher crossover numbers in comparison to the
wild-type library, especially in the 3' part of the cap gene. b) Detailed crossover analysis between the
single cap genes in libraries 245 and 245O. Crossover numbers increased in the range of 20  49 events
within the 245O library. c) Correlation of sequence homology and crossover events. Higher crossover
numbers (compare white and red) are related to regions with increased sequence homology (compare
black and white). Homology calculations between the parental capsids 2, 4 and 5 or 2, 4O and 5O
were performed with the "Show homology" tool of Salanto and coloured with Excel. Position-related
crossover analysis was done with the "Show crossovercount" tool.
cap gene. In contrast, the 245O library contained on average 8.2 crossovers per clone which
were distributed almost equally throughout the complete sequences. A detailed analysis of the
crossover numbers revealed 20  49 more events between the single serotypes after sequence
optimization compared to the wild-type capsids (ﬁgure 3.5b). Importantly, the location of
crossovers correlated with the homology of the capsids. The higher the similarity between
the capsid DNA sequences, the more likely crossovers appeared in these regions (ﬁgure 3.5c).
Altogether, sequence optimization of cap 4 and 5 yielded higher shuing eﬃciency within a
245O library in direct comparison to the wild-type counterpart.
In order to determine the inﬂuence of increased DNA homologies in a more complex library,
we ﬁrst decided to combine the commonly used AAV capsids 8 and 9 with cap 2, 4 and 5
(short: 24589) or 4O and 5O (short: 24589O), respectively. Again, we observed a higher
shuing eﬃciency especially in the 3' part of the gene when the sequence-optimized versions
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Figure 3.6: Comparison of AAV cap libraries 24589 and 24589O. Precise type assignment
of AAV cap libraries 24589 and 24589O. Twenty clones per library were analyzed with the Salanto
program. Use of cap 4O and 5O yielded higher crossover numbers in comparison to the wild-type
library, especially in the 3' part of the cap gene.
of cap 4 and 5 were used (5.9 versus 9.2 crossovers per clone, see ﬁgure 3.6). Detailed analysis
revealed higher crossover numbers between cap 2, 4O and 5O among each other (see table 3.1
for details). Moreover, recombination rates between AAV cap 5O and 8 or 9 were increased.
Secondly, we combined cap 4/4O and 5/5O with capsids other than cap 2 and generated a
145689 or 145689O library. In addition, we used our modiﬁed capsid genes in a complex library
that contained cap genes of the AAV serotypes 1  9 (short: 1-9O) and compared it to the
wild-type counterpart (1-9). Table 3.1 summarizes the results of the abovementioned libraries
(precise type assignments can be found in supplementary ﬁgure 8). In general, we determined
Table 3.1: Comparison of crossover numbers between capsids in cap 4 / 4O and 5 / 5O containing
libraries. Twenty clones per library were analyzed with the tools "Numbers of crossovers per clone"
and "Crossover analysis" of the Salanto program.
Shued library 24589 24589O 145689 145689O 1-9 1-9O
Average number of
5.9 9.2 9.5 10.1 14.9 16.1
crossovers per clone
Crossover
from →
to
2 → 4 12 38 n/a n/a 6 8
2 → 5 1 25 n/a n/a 0 3
4 → 5 5 16 0 14 0 4
4 → xa 31 22 27 43 26 25
5 → xa 3 20 7 10 3 13
a Any capsid in library other than 2, 4 or 5
n/a = not applicable
increased crossover rates between cap 4O and 5O in all generated libraries. Besides, cap 5O
recombined more frequently with all other capsids than AAV5 wild-type. In line with library
24589O, crossover numbers per clone slightly improved also in libraries 145689O and 1-9O.
Taken together, our results show that sequence optimization of capsids yields higher crossover
67
3 Results
numbers and better shuing in the 3' part of the cap gene. Moreover, this eﬀect persisted
even in highly complex libraries.
3.1.4 AAP expression can be reconstituted in sequence-optimized capsids and
knock-out mutants
During sequence optimization of AAV cap 4 and 5 the ﬁrst ORF remained unaﬀected and VP
protein sequence was not changed. However, at the same time the second ORF was modiﬁed
inadvertently and thereby the assembly-activating protein (AAP) mutated (see also section
2.2.1.3 for a more detailed description). As a result, AAV4O and 5O were not able to assemble
functional viral particles any more (see also ﬁgure 3.8, second bar of b/c). In order to study
whether the functionality of AAP can be restored upon trans-complementation, we generated
an AAV2-AAP knock-out mutant (named AAV2mut from hereon) which lacks the AAP2 start
codon and contains a stop codon 66 bp downstream of the modiﬁed start (ﬁgure 3.7a). Of
note, the AAV2mut construct was unable to produce functional viral particles (ﬁgure 3.7b,
second bar from the left).
In parallel to the AAV2 mutant, we cloned an AAP2 expression vector. In detail, the AAP2
start codon was exchanged from CTG to ATG and the DNA sequence was placed behind a
CMV promoter. Moreover, AAP2 was N-terminally linked to a FLAG- and an HA-tag in order
to allow detection through Western blotting and microscopy. To investigate the functionality
of the construct, we tested which amounts of AAP2 plasmid were necessary to restore assem-
bly of the AAV2 mutant. Therefore, we produced AAV crude cell lysates by transfection of
HEK293T cells in 6-well format with diﬀerent amounts of AAP2 plasmid ranging from 0.0625
to 0.65 µg per well. DNA amounts were supplemented with stuﬀer (sheared salmon sperm)
DNA in order to achieve comparable transfection conditions. As a reporter a GFP-encoding
transgene was packaged. To test production of assembled and functional viral particles, crude
lysates were used to transduce new HEK293T cells. Forty-eight hours later GFP expression
was analyzed via ﬂow cytometry. Already the lowest amount of supplemented AAP2 plasmid
(0.0625 µg per well) was able to recover AAV2mut assembly by up to 50 % compared to
wild-type. The most potent rescue could be observed with 0.5 µg AAP2 DNA which yielded
as many GFP-positive cells as AAV2wt (ﬁgure 3.7b). Therefore, we decided to use this ratio
of AAP2 and helper plasmids for all upcoming experiments (see also section 2.2.6.6).
Next to the crude lysate transduction, we also determined the amount of viral proteins and
AAP2 in the cell lysate after transfection via Western blotting. Interestingly, we observed
a reduction of VP amounts for AAV2mut which could be restored to wild-type levels upon
AAP2 supplementation (see also section 3.2.1). At the same time Rep protein levels stayed
constant (ﬁgure 3.7c). AAP2 could be detected only for the highest amounts of the trans-
fected plasmid with an anti-HA tag antibody.
The successful recovery of AAV particle assembly after AAP knock-out prompted us to inves-
tigate the eﬀect of AAP4wt or 5wt addition during transfection of AAV4O or 5O constructs,
respectively. In order to test the produced crude lysates, MCF7 cells (AAV4 particles) or
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Figure 3.7: Generation of AAV2-AAP knock-out mutant and recovery with AAP2 sup-
plemented in trans. a) Schematic depiction of introduced AAV2 cap modiﬁcations in order to
knock-out AAP2. The AAP2 start codon CTG was exchanged to CCG and a stop codon was
inserted 66 bp downstream. VP1-3 protein sequences were not inﬂuenced by the mutations. b)
Trans-complementation assay of the AAV2mut construct with diﬀerent amounts of AAP2 compared
to AAV2wt. HEK293T cells were transfected (6-well format) for the production of GFP-encoding
AAV crude cell lysates and supplemented with diﬀerent amounts of AAP2 plasmid (0.0625 - 0.65 µg
per well). Crude cell lysates were subsequently used to transduce new HEK293T cells and GFP
expression was measured 48 hours after transduction via ﬂow cytometry. Values were normalized to
the AAV2wt control. As statistical analysis one-way ANOVA with Bonferroni's multiple comparisons
test was performed. c) Western blot analysis of cell lysates 48 hours after transfection described in
b). Next to the viral proteins VP1-3, AAV Rep proteins as well as AAP2 were detected. The latter
was stained with an anti-HA tag antibody. Relative VP levels (depicted below the actin staining)
were quantiﬁed with the Fiji program and double-normalized to actin and the AAV2wt control. n.s.
= not signiﬁcant, *** p < 0.001, n = 3 (Trans-complementation assay).
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Figure 3.8: Repair of AAV4O and 5O capsid genes and trans-complementation assays with
AAP4wt and 5wt. a) Schematic depiction of repaired AAV4O and 5O cap sequences. Nucleotides in
red mark the mutations that led to an AAP knock-out or the deletion of the rep stop codon in AAV5O,
respectively. The corrected nucleotide triplets are shown below. b/c) Trans-complementation assays
of AAV4 (b) and AAV5 (c) constructs with or without AAP4wt or 5wt, respectively. Crude cell
lysates were tested in MCF7 cells (AAV4) or SF539 cells (AAV5). GFP-positive cells were quantiﬁed
via ﬂow cytometry and normalized to the wild-type controls. As statistical analysis one-way ANOVA
with Bonferroni's multiple comparisons test was performed. n.s. = not signiﬁcant, *** p < 0.001, n
= 3.
SF539 cells (AAV5 particles) were transduced. Couriously, we detected only a partial recov-
ery of AAV assembly up to 35 % compared to wild-type after AAP supplementation (ﬁgure 3.8
b/c, compare bar one to three). Therefore, we repaired the introduced mutations in AAV4O
and 5O resulting in cap sequences AAV4O repaired and 5O_rep / 5O repaired (see ﬁgure 3.8a). In
addition, we corrected the deleted stop codon of AAV5O which led to extended Rep40 and
Rep68 protein sequences (see supplementary ﬁgures 5  7 for DNA sequences) and tested the
new constructs again with or without trans-complementation of AAP (ﬁgure 3.8b/c). For
AAV4O the repair of all modiﬁed nucleotides only led to an 8 % increase of GFP positive
cells after crude lysate transduction. However, after addition of AAP4wt during transfection,
AAV4O functionality achieved 81 % of wild-type level. Expression of AAV5O repaired alone
achieved already 71 % GFP-positive cells compared to wild-type which could be increased
to 99 % by addition of AAP5wt during AAV particle production. Of note, co-expression of
AAV5O_rep together with AAP5wt recovered virus functionality to 96 % of wild-type.
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Altogether, we could show that AAP functionality could be restored by either repair of modi-
ﬁed nucleotides (AAV5O repaired) or addition of AAP wild-type (AAV4O repaired). Importantly,
in all cases achieved levels of GFP expressing cells were comparable to wild-type AAV particle
transductions.
3.1.5 AAP does not inﬂuence AAV shuing
Since the AAP frame can be disrupted not only by sequence optimization but also during the
AAV shuing process, we wanted to examine the functionality of individual shued AAPs
and the role of AAP in a complete library. Towards this aim, we produced the aforementioned
AAV cap libraries 24589 and 24589O as viral stocks and puriﬁed them through an iodixanol
density gradient. During production we supplemented both libraries with a mixture of all
wild-type AAPs present in the libraries, i.e., AAP2, 4, 5, 8 and 9. Subsequent qPCR titra-
tion of the virus stocks revealed that AAP addition did not inﬂuence virus titers (table 3.2).
Analysis of the shued AAPs within 20 randomly selected and sequenced clones showed that
in library 24589 all AAPs are theoretically functional (intact start and stop codon, normal
AAP length). In contrast, 12 / 20 are not functional in library 24589O due to missing start or
stop codons, or newly created early stops. However, trans-complementation with AAP during
virus production did not increase genome-containing particle numbers for library 24589O. In
parallel, also AAP supplementation during crude lysate production of 15 individual, shued
24589O library clones, which contained mainly non-functional AAPs, did not lead to the for-
mation of functional AAV particles (see supplementary ﬁgure 9).
Based on this observation, we assumed that AAP shuing is not critical and that other
factors inﬂuence virus production after AAV shuing to a larger degree. To further inves-
tigate this hypothesis, we cloned 46 randomly selected, shued and theoretically functional
AAPs from ﬁve diﬀerent AAV cap libraries with diﬀerent homologies and complexities into
our CMV expression vector backbone (named AAP-X1 to AAP-X47, see supplementary ﬁgure
10 for protein type assignments). Since these libraries also contained AAV capsids 1, 3, 6, 7,
8, 9 and rh10, we initially determined the recovery potential of their AAPs with the corre-
sponding AAP knock-out mutants in SF539 cells. Figure 3.9a displays the successful rescue
of all mutants after trans-complementation with their serotype-speciﬁc AAPs. Moreover, we
Table 3.2: Genomic titers of AAV cap libraries 24589 and 24589O with or without supplementation
of an AAP mixture of serotypes 2, 4, 5, 8 and 9 during virus production.
AAV cap library AAP addition Titer [vg/ml]
24589  8.20 x 1011
24589 + 7.72 x 1011
24589O  1.85 x 1011
24589O + 1.78 x 1011
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Figure 3.9: Trans-complementation assays with various AAV serotypes and AAP cross-
reactivity with AAV2mut. a) Trans-complementation assays of AAP-deﬁcient AAV1, 3, 6, 7, 8,
9 and rh10 constructs with their corresponding AAPs. Produced crude cell lysates were tested in
SF539 cells. Values were normalized to the AAVwt controls. b) Cross-reactivity test of all cloned
wild-type AAPs together with the AAV2mut construct. Samples were tested in HEK293T cells and
values were normalized to AAV2wt. Positive cells were determined via ﬂow cytometry. As statistical
analysis one-way ANOVA with Bonferroni's multiple comparisons test was performed in a and b. n.s.
= not signiﬁcant, *** p < 0.001, n = 3.
investigated the potential cross-reactivity of the cloned wild-type AAPs with the AAV2mut
construct. Interestingly, all AAPs except for AAP4 and 5 were able to recover AAV2mut
functionality between 45 and 96 % compared to AAP2 (ﬁgure 3.9b).
We therefore tested the selected shued AAPs ﬁrst with the AAV2mut construct and, if no
recovery was observed, either the AAV4O repaired or the AAV5O_rep capsid were used in fur-
ther trans-complementation assays. We found 37 of 46 AAPs to be functional with AAV2mut
(ﬁgure 3.10) and classiﬁed them as high performers (50 %  100 % AAV2mut rescue abil-
ity compared to AAP2) or intermediate performers (5 %  50 % AAV2mut rescue ability
compared to AAP2). AAPs with less than 5 % recovery potential were estimated as non-
functional. Apart from the 37 AAV2mut-compatible variants, two more AAPs showed func-
tionality with AAV5O_rep (AAP-X19 and AAP-X46, data not shown). AAP-X44 also reached
higher recovery rates with AAV5O_rep than with AAV2mut. In total, 84.8 % of the tested
AAPs were functional. Of note, the highest degree of defect AAPs was observed in libraries
which contained less homologous capsids (i.e., cap 4 and 5). Library 24589O revealed the
lowest number of active AAPs (67 %). Another defect AAP appeared in the complex 1-9
library. In summary, we conclude from these results that AAP shuing does not inﬂuence
AAV capsid shuing to a major extent.
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Figure 3.10: Test of randomly picked shued AAPs. Trans-complementation assays using
the AAV2mut construct together with 46 randomly selected shued AAPs (AAP-X1 to AAP-X47).
AAPs originate from AAV cap libraries 24589 and 24589O (a) or 289, 1789rh10 and 1-9 (b) as
indicated above the diagrams. Cap library 289 was generated by A.K. Herrmann. Out of 46 tested
AAPs 37 were functional with AAV2mut. Two additional AAPs only showed functionality with
the AAV5O_rep construct (marked with triangles). Non-functional AAPs are highlighted with a red
square. The cut-oﬀ value for AAP functionality was set at 5 % of GFP positive cells (dark grey
background) compared to AAV2mut supplemented with AAP2. AAP-X9, -X11, -X14, -X31 and -X44
are AAPs with an intermediate rescue ability which was deﬁned between 5 and 50 % GFP positive cells
compared to the control (light grey area). Crude cell lysates were tested in HEK293T cells, positive
cells were determined by ﬂow cytometry and values were normalized to AAV2mut supplemented with
AAP2. Numbers in brackets indicated the percentage of working (high and intermediate phenotype)
AAPs per library. Error bars represent experimental diﬀerences after three independent transductions
of the same crude lysate.
3.1.6 Successful AAV virus production with repaired optimized cap genes
In order to prove that our generated shued libraries with cap 4 and 5 can yield func-
tional virus particles, we produced iodixanol-puriﬁed virus stocks and titered them via qPCR.
Moreover, we compared libraries containing the wild-type version of AAV4 and 5 with their
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sequence-optimized containing counterparts. For the latter we repeated the shuing pro-
cedure and included the repaired versions of cap 4O and 5O to overcome inadvertent AAP
limitations caused by the sequence adaption (libraries are accordingly labeled with Or). DNA
type assignments of the new libraries can be found in supplementary ﬁgure 11 and resulting
titers are depicted in table 3.3. Notably, virus titers were comparable for wild-type and Or
libraries with the exception of the 245/245Or libraries. In detail, 245Or virus titers were
more than 100-fold lower compared to its wild-type counterpart. AAV particle amounts of
the other libraries ranged between 1011 and 1012 particles per milliliter with 24589±Or being
10-fold lower than 145689±Or titers. Altogether, shued libraries with sequence-optimized
AAV cap variants generated normal amounts of viral genome-containing particles except for
245Or which was not able to yield high titers.
Table 3.3: Genomic titers of diﬀerent AAV cap libraries ± 4 / 5Or capsids.
AAV cap librarya Titer [vg/ml]
245 1.2 x 1012
245Or 7.1 x 109
24589 7.1 x 1011
24589Or 7.7 x 1011
145689 2.7 x 1012
145689Or 3.2 x 1012
ar indicates that the repaired versions of sequence-optimized AAV cap 4 and 5 were used
3.2 AAP biology
3.2.1 AAP knock-out leads to VP degradation
The fact that AAP biology is still unexplored to a large extent prompted us to investigate
this protein in more detail. In particular, we were interested in following up our unexpected
observation that AAP knock-out led to a reduction of VP levels in the cell lysate detected
by Western blotting (see ﬁgure 3.7c). The VP signal could be recovered completely by addi-
tion of AAP during crude cell lysate production. Since the protein sequence of the VPs was
not inﬂuenced by our introduced mutations we ﬁrst hypothesized that VP reductions were
caused by a dysregulation on mRNA levels. We therefore isolated mRNA of HEK293T cells
after transfection (similar to crude lysate productions) and performed quantitative PCR after
reverse transcription. In order to measure the diﬀerent transcripts of the AAV genome, we
designed four primer pairs (#1107  #1114, see table 2.1) binding at diﬀerent positions in
the viral mRNAs (arrows in ﬁgure 3.11a  right side). Data were analyzed according to the
2-∆∆CT method [198] and normalized ﬁrst to the house-keeper GAPDH and second to the
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Figure 3.11: VP quantiﬁcation on mRNA and protein levels. a) Quantitative PCR of AAV
genome transcripts. Relative expression levels of the diﬀerent viral mRNAs are displayed in the
diagram. Arrows in the scheme at the right side depict the binding sites of the used primer pairs within
the diﬀerent transcripts. Values were analyzed according to the 2-∆∆CT method and normalized to
GAPDH as house-keeper as well as the AAV2wt control. b/c) Quantiﬁcation of AAV-VPs (b)
or assembled AAV2 particles (c) in microscopy pictures of cells stained with B1 or A20 antibody,
respectively. Schemes on the right side display the speciﬁcity of the antibodies. Six pictures per
condition were analyzed with the CellProﬁler program in order to determine the percentage of positive
cells and the mean integrated intensity of the stained cells 48 hours after transfection.
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AAV2wt control. As depicted in ﬁgure 3.11a, we could not observe a signiﬁcant dysregulation
of mRNA levels after knock-out or supplementation of AAP during AAV production. Hence,
we conducted that VP reduction is not caused on mRNA level.
Next, we quantiﬁed the amount of VPs and assembled viral particles 48 hours after trans-
fection in the cells via immunostaining. For detection we either used the A20 antibody [190]
which only binds assembled AAV2 particles (see scheme in ﬁgure 3.11c) or the B1 anti-
body [190] which is speciﬁc for linear, non-assembled AAV VP1, VP2 and VP3 (scheme
in 3.11b). For each condition, six microscopy pictures were analyzed with the open-source
software CellProﬁler (see also supplementary table 2). Next to the percentage of positively
stained cells also the mean integrated intensity of the signals was determined. Consistent
with the mRNA data, we again detected no major diﬀerences in numbers of positive cells and
intensities between AAV2wt and AAV2mut ± AAP2. As expected, A20 staining gave no sig-
nal for the AAV2mut construct without AAP supplementation. Based on these observations,
we hypothesized that the levels of free VP proteins in the cells stay constant independent
of AAP2. Hence, increasing VP levels after AAP2 addition by Western blotting potentially
revealed from assembled AAV2 particles which got denaturated and detectable with the B1
antibody upon sample treatment. To test whether VPs are degraded in the absence of AAP2,
we added the proteasome inhibitor MG-132 (ﬁnal concentration in the media: 2 µM) ﬁve or
24 hours after transfection to the cells (see scheme in ﬁgure 3.12a), performed Western blot
analysis 48 hours after transfection (ﬁgure 3.12b) and quantiﬁed the visible bands with the
Fiji software. Indeed, we determined increasing VP levels with the AAV2mut construct after
MG-132 treatment. When the inhibitor was already supplemented to the media ﬁve hours
after transfection, protein amounts of AAV2mut were comparable to the AAV2 wild-type
control. Twenty-four hours after transfection 44 % VP proteins compared to wild-type could
be detected whereas without treatment only 12 % of VPs were present in the cell lysate.
Importantly, AAV crude lysates generated from the MG-132 treated cells showed comparable
transduction eﬃciencies relative to the AAV2wt control (ﬁgure 3.12c). These results (I) prove
that although VPs accumulate in the cell, they are not able to assemble functional virus parti-
cles in the absence of AAP2 and (II) indicate that VPs are degraded through the proteasome
pathway when not assembled into AAV particles. Interestingly, we also observed a slight, ad-
ditional band at ∼ 200 kDa only for the AAV2mut construct after MG-132 treatment (ﬁgure
3.12b, red square) which led us to speculate that these bands might be ubiquitinated viral
proteins that were not degraded by the blocked proteasome. In our next experiments we tried
to detect this possible VP ubiquitination via a VP-IP or a Ubiquitin-IP. However, thus far, we
could not prove our hypothesis due to insuﬃcient pull-down eﬃciencies or unspeciﬁc binding
in the IP (data not shown). Nevertheless, the additional band after MG-132 treatment could
be robustly reproduced in all conducted experiments.
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Figure 3.12: MG-132 treatment and quantiﬁcation of VP signals by Western blotting.
a) Schematic depiction of the AAV crude cell lysate production with MG-132 treatment ﬁve or
24 hours after transfection. Samples were harvested 48 hours after transfection and processed for
Western blot analysis or cell transductions. b) Western blot analysis of cell lysates after AAV crude
lysate production. Cells were treated with MG-132 ﬁve (left panel) or 24 hours (middle panel) after
transfection and compared to untreated samples (right panel). Viral proteins were detected with
the B1 antibody, quantiﬁed with the Fiji program and normalized ﬁrst to actin and second to the
AAV2wt control without AAP2. The red square in the middle panel marks an additional, slight
band of ∼ 200 kDa which was detected only for AAV2mut. c) Relative GFP expression of HEK293T
cells 48 hours after transduction with crude lysates from samples shown in b). Positive cells were
measured via ﬂow cytometry and values normalized to the AAV2wt control without AAP2. AdH =
adeno helper plasmid, Fl.R. = ﬂuorescence reporter plasmid encoding for GFP, R/C = AAV rep-cap
helper plasmid.
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3.2.2 Detection of endogenous AAP2 during AAV2 production
Next to the eﬀect of AAP2 on VP expression (see previous chapter), we were also interested
in the endogenous expression of AAP and the protein localization in the cell. To further
investigate this question, we ordered a polyclonal anti-AAP2 antibody from the company
Perbio. In detail, the company immunized rabbits with the previously published short pep-
tide GKDSSTTTGDSDPRDSTS (AAP2: aa 121-138) [25] and aﬃnity-puriﬁed the resulting
antibody. We used this antibody in immunostainings and detected AAP2 together with VPs
Viral proteins (VPs) AAP2 Nucleus Merge
AAV2 particles AAP2 Merge
a
b
Nucleus
AAP2 Nucleus Merge
AAV2 particles AAP2 MergeNucleus
Viral proteins (VPs)
B1
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A20
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A
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 A
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Figure 3.13: Validation of the anti-AAP2 antibody. AAV2mut-transfected HEK293T cells
supplemented with stuﬀer DNA a) or an AAP2 expression construct b) were immunostained after
48 hours with the new anti-AAP2 antibody together with the B1 (ﬁrst row) or A20 (second row)
antibody, respectively. Transfections and immunostainings were performed in LabTek format. Nuclei
were stained with Hoechst. Scale bar = 50 µm.
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or assembled particles after cell transfection with an AAV2wt rep-cap helper, a transgene
(luciferase) and the adenohelper construct. To control for the speciﬁcity of the antibody
we stained AAV2mut-transfected cells with A20 or B1 antibodies, respectively, and moni-
tored unspeciﬁc binding or cross-reactivity. As expected, we did not detect any signal in
the AAV2mut-transfected cells which do not express AAP2 (ﬁgure 3.13a). However, when
AAP2 was co-transfected together with AAV2mut a clear signal was seen with the anti-AAP2
antibody (ﬁgure 3.13b) and assembly could be detected with the A20 antibody (second row
in ﬁgure 3.13b). In order to detect endogenous AAP2 we transfected cells with the AAV2wt
construct and quantiﬁed the amount of positive cells at diﬀerent time points in the captured
microscopy pictures (four pictures per condition) with the CellProﬁler software (see supple-
mentary tables 3  4 for protocols). Diagrams in ﬁgure 3.14 show the expression of AAP2
and VPs (a) or assembled viral particles (b) over time, respectively. In general, we observed
that not all cells which are positively stained for VPs are also positive for AAP2. In contrast,
the number of AAP-positive cells which also contained assembled AAV2 particles was almost
equal except after 48 hours where more AAV particles were detected. For a more detailed
analysis of the AAP localization we also captured images with a Leica confocal microscope.
Again we found cells that stained positive for VPs but not for AAP (ﬁgure 3.15). However,
as soon as VPs accumulated in the nucleus they co-localized with AAP2. In contrast, AAV2
particles and AAP2 always co-localized (ﬁgure 3.16). Twenty-four hours after transfection
both localizations were limited to the nucleus and expanded throughout the complete cell
from 30 hours on. Interestingly, AAP showed a more dispersed phenotype once more parti-
cles were detected in the cytoplasm. In summary, AAP2 could be successfully detected with
the generated anti-AAP2 antibody and showed diﬀerent localizations in the cell during virus
production.
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Figure 3.14: Quantiﬁcation of AAP2-, VP- or virus particle-immunostainings over time.
a) Quantiﬁcation of VP- and AAP2-expressing HEK293T cells. b) Quantiﬁcation of AAP2-
expressing and AAV2 particle-containing HEK293T cells. Numbers of positive cells were determined
24, 30, 36 or 48 hours after transfection of an AAV2wt rep-cap helper, a transgene (luciferase) and
the adenohelper construct in LabTek format. Antibodies B1 (a), A20 (b) and anti-AAP2 (a/b) were
used for immunostaining. Four pictures per time point were analyzed with the CellProﬁler program.
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48 h
Viral proteins (VPs) AAP2 Nucleus Merge
30 h
24 h
36 h
Figure 3.15: Immunostaining of viral proteins and AAP2 at diﬀerent time points during
AAV2 virus production. HEK293T cells were transfected with an AAV2wt rep-cap helper, a
transgene (luciferase) as well as the adenohelper construct and ﬁxed for immunostaining at the
indicated time points. Arrows exemplify the nuclear localization of VPs only when AAP2 is expressed.
The triangle in the second row depicts one cell without AAP2 and a distinct nuclear exclusion of
VPs. Stainings were performed with the new anti-AAP2 antibody and the VP-detecting antibody
B1. Transfections and immunostainings were performed in LabTek format. Pictures were captured
with a TCS SP5 confocal microscope. Scale bar = 10 µm.
3.2.3 Localization of AAP4, 5, 8 and 9 diﬀer from AAP2
Next to the intracellular localization of AAP2, we also examined the expression pattern of
AAP4, 5, 8 and 9 in the cell. Due to the N-terminal fusion of all cloned AAPs to an HA-
tag it was possible to detect the proteins with an anti-HA tag antibody via immunostaining.
Analysis of the captured images revealed that localizations between the various serotype
AAPs diﬀer greatly from each other. AAP2 displayed a very distinct nucleolar localization
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Figure 3.16: Immunostaining of assembled AAV2 particles and AAP2 at diﬀerent time
points during AAV2 virus production. HEK293T cells were transfected with an AAV2wt rep-cap
helper, a transgene (luciferase) as well as the adenohelper construct and ﬁxed for immunostaining at
the indicated time points. Arrows depict the distinct nucleolar co-localization of AAP2 and assembled
particles at early time points during virus production. Assembled viruses spread throughout the cell
with ongoing time; in parallel AAP2 localized in the nucleoli as well as the nucleoplasm (triangle)
or became fully excluded from the nucleoli (rhombus). Stainings were performed with the new
anti-AAP2 antibody and the assembled AAV2 particle-detecting antibody A20. Nuclei were stained
with Hoechst. Transfections and immunostainings were performed in LabTek format. Pictures were
captured with a TCS SP5 confocal microscope. Scale bar = 10 µm.
(ﬁgure 3.17) which goes in line with our above described results and published observations by
Sonntag et al. [25]. However, all other investigated AAPs showed diﬀerent localizations. AAP8
and 9 were localized in the nucleus but did not accumulate in the nucleoli like AAP2. AAP4
resembles a nucleolar accumulation but was also detected in the cytoplasm. AAP5 appeared
predominately only in the cytoplasm and diﬀered the most from AAP2. In this regard,
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Figure 3.17: Immunostaining of AAPs of diﬀerent AAV serotypes. AAPs of AAV serotypes
2, 4, 5, 8 and 9 were transfected together with a corresponding rep-cap helper, a transgene (luciferase)
and the adenohelper construct into HEK293T cells and stained with an anti-HA tag antibody 48 hours
after transfection. Transfections and immunostainings were performed in either LabTek (AAP2) or
96-well (AAP4, 5, 8 and 9) format. Scale bar = 30 µm.
more detailed investigations and stainings are planned to validate nucleolar localizations of
e.g. AAP4 and gain further insights into the process of capsid assembly for the single AAV
serotypes.
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Discussion
4.1 Optimization of AAV cap DNA family shuing on the
technical and molecular level
4.1.1 Comparison of physical and enzymatic fragmentation reveals new
prerequisites for successful DNA shuing
Gene therapeutic approaches which treat genetic disorders like hemophilia, SCID or cystic
ﬁbrosis have recently shifted more and more into the focus of researchers and public atten-
tion. Due to the rapid gains in knowledge and techniques it is becoming increasingly feasible
to treat inherited disorders but also to apply gene therapy to patients suﬀering from cancer
or acquired neurological disorders. In this context, one of the most promising therapeutic
delivery tools are AAVs. Their non-pathogenicity, simple vector design and low risk of in-
tegration make them very attractive for use in humans [1, 2, 5]. This was evidenced in 2012
when the ﬁrst AAV-based gene therapeutic drug (Glybera®) was approved in the Western
world [11]. The successful admission of Glybera® represents a milestone in AAV research and
will certainly result in the positive evaluation of more clinical trials. Thus, an increasing need
for new AAV serotypes with special characteristics for further therapeutic approaches is ex-
pected. The requirements for novel capsids are (I) less cross-reactivity to pre-existing or newly
evolved antibodies, (II) a deﬁned tissue tropism for new cell types and (III) concurrently a
low transduction eﬃciency in non-target cells. In order to meet these demands, several meth-
ods for capsid modiﬁcation have been published during the last years [133,150,158,173,175].
Amongst these, peptide display and DNA family shuing (DFS) are the most eﬃcient means
to generate AAV particles with new properties [133136,140,150,151].
This thesis focused on DFS as a technique for capsid modiﬁcation which is based on recombi-
nation of partially homologous genes into chimeric sequences after controlled fragmentation.
Within this work we aimed to provide an optimized protocol for DFS which can be easily
adapted by other laboratories. Especially, we wanted to improve the critical step of DNA
fragmentation which can inﬂuence the quality of the generated shued library. Normally,
fragmentation is achieved by using the enzyme DNaseI. However, we know from our expe-
rience that DNase is very sensitive to external inﬂuences such as shearing forces and that
diﬀerent stocks can have varying activities. Moreover, we could show that small changes
in the protocol (e.g. an increase of incubation time or enzyme amount) can already lead to
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diﬀerent fragment sizes (ﬁgure 3.1). This hampers the reproducibility of the approach and
requires optimization experiments ahead of each shuing reaction. To overcome these lim-
itations, we considered implementing the method of ultrasonication-based DNA shearing in
our shuing protocol and aimed to compare it with DNase treatment side-by-side. Physical
DNA fragmentation is a widely used method for e.g. next generation and ChIP-sequencing
and produces DNA fragments with pre-deﬁned sizes. Although the fragmentation process is
not completely unbiased but rather seems to be sequence-dependent [202] it is a robust way
to cleave DNA in a controlled manner. Depending on the machine settings, various lengths of
DNA fragments can be generated, e.g. 150, 300 and 800 bp which were used here for shuing.
In contrast, DNase digest results in a broad range of DNA fragments (100  1000 bp) without
a speciﬁc peak size. Interestingly, we observed that physically generated fragments of 150 or
300 bp led to no or ineﬃcient recovery of full-length genes. Only 800 bp and DNase-treated
samples were able to re-anneal eﬃciently. These observations go in line with a publication
from Maheshri and Schaﬀer who predicted the re-assembly eﬃciency of AAV1 and 2 cap genes
in silico [203]. They described a reduction in re-assembly depending on the average fragment
size. One hundred bp fragments showed a more than 6-fold reduced re-assembly in comparison
to 400 bp fragments. On the other hand, smaller fragments generated 4-fold more crossover
events than bigger fragments. Similarly, our 800 bp library contained fewer crossover events
and 1.45-fold longer fragments than the DNase-treated library (7.8 versus 12.1 crossovers).
This indicates that smaller fragments generated by DNase digest act as primers during the
re-assembly PCR and thereby mediate homologous recombination. However, at the same time
bigger fragments seem to be needed for the re-assembly process since the exclusive use of small
fragments (150 / 300 bp) failed to result in full-length AAV cap sequences. They potentially
function as a template for the annealing reaction but can also recombine among each other
in regions of overlapping homology. As a conclusion, it appears beneﬁcial for the shuing
reaction to include a mixture of smaller and bigger DNA fragments. Indeed, also other AAV
shuing approaches used a mixture of fragments between 50 and 1200 bp for re-assembly
PCRs [133135]. Thus, one possibility to overcome the limited recombination capacity of
long fragments generated by ultrasonication could be to mix 150 and 800 bp fragments prior
to re-assembly in order to mimic enzymatic conditions. Future experiments should verify
the feasibility and eﬃciency of this attempt in order to further optimize the DFS protocol.
Until then, we conclude that DNase digest outperformed ultrasonication-based DNA shearing
in terms of crossover eﬃciency in this work even if the physical method is less sensitive to
external and experimental inﬂuences and hence more reproducible.
4.1.2 Extension of the Salanto toolbox facilitates analysis of shued libraries
For all analyses conducted during this study the previously published Salanto (Shuing
alignment analysis tool) program [195] was used and further extended by several additional
tools in close collaboration with Christian Bender. Speciﬁcally, the newly implemented func-
tions facilitate the crossover analysis within a generated library. It is important to note that
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Crossover analysis, Show crossovercount and Fragment length analysis are based on the
Type assignment. Importantly, the latter assigns a crossover at the ﬁrst diﬀering base be-
tween parent x or y whereas e.g. Coco et al. mark crossovers in the middle of a homologous
region [204]. Next to an extended crossover analysis, the new feature Show homology allows
for the position-wise comparison of chimeric and parental sequences regarding their homology.
The tool Show crossovercount combines the position-wise homology analysis with the type
assignment in order to enable a correlation of crossover appearance with identical nucleotides.
Overall, to our best knowledge Salanto is the only published toolbox so far which is able to
automatically analyze complex alignment ﬁles and to allow detailed conclusions about chimera
composition, homology and recombination frequencies.
4.1.3 Sequence-optimization broadens shued AAV cap library diversity
As already mentioned before, crossover frequency correlates with the quality of a generated
shued library and determines its diversity. Importantly, crossovers preferentially occur
within regions with sequence identities of at least 5  15 nt [205]. Therefore, it is favor-
able for the shuing process if parental sequences exhibit homologies greater than 65 %.
With homologies below 50 % almost no recombination events can be obtained [206]. AAVs
show homologies above 55 % which make them very suitable for shuing approaches. How-
ever, sequence identities between capsids range from 56.6  97.1 % and result in diﬀerent
crossover rates. Previously, Joern et al. observed that similar parents tend to pair among
each other [207] which reduces recombination between parental sequences of lower identity.
Indeed, we obtained a correlation between crossover events and capsid homology ranging from
43 crossovers between AAV1 and AAV6 (97 % identical) to zero crossovers between AAV4
and AAV5 (59 % identical) in a 1-9 cap library. Thus, the incorporation of serotype 4 and 5
capsids into a shued library is limited which simultaneously lowers the theoretical library
diversity.
To overcome this problem, we sequence-optimized AAV cap 4 and 5 by adapting their se-
quences to the one of AAV2 and achieved a homology improvement of 13 %. Comparison
of a wild-type 245 cap library and its optimized counterpart revealed nearly 2.5-fold more
crossovers per clone in the latter. Of note, detailed sequence analyses showed that crossovers
in the 245O library appeared especially in regions with increased nucleotide identity. We addi-
tionally determined the incorporation of cap 4 and 5 into more complex libraries ranging from
ﬁve to nine shued serotypes. All of them showed enhanced recombination rates between cap
2 and 4 / 5 as well as other serotypes with overall crossover numbers being less inﬂuenced
in libraries with increasing complexity. Our data suggest that homology-dependent shuing
limitations can be alleviated by increasing sequence identities of individual capsids.
Interestingly, in parallel to a higher shuing eﬃciency, we detected a > 100-fold lower virus
titer in library 245Or in comparison to the wild-type counterpart. These observations indi-
cate that improved recombination can be at the cost of virus ﬁtness. Although Joern et al.
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did not observe a correlation between loss-of-function and crossover numbers in their gener-
ated protein chimeras, they found clones with higher percentages of one parent to be more
functional than chimeras of equal parental proportions [207]. Mechanistically, it is therefore
likely that the interaction between dissimilar domains can hinder proper AAV capsid assem-
bly, stability and / or genome packaging. Indeed, previous publications observed a partial
impairment of AAV assembly and genome packaging upon domain swapping between diﬀerent
AAV serotypes. Especially, the surface exposed GH loop which encompasses VR-IV to VIII
was substantially sensitive for speciﬁc modiﬁcations, i.e., AAV1-to-AAV2 or AAV2-to-AAV8
domain exchanges [208,209]. In addition, DiPrimio et al. reported an essential role for the HI
loop in particle assembly and DNA packaging [210]. Although loopexchanges from AAV2 to
AAV1 or AAV8, respectively, were tolerated, swapping to AAV4 and AAV5 resulted in a lower
packaging eﬃciency and no capsid assembly for the latter [210]. The complex interaction of
capsid surface regions is further illustrated by another publication from 2014. In this report
rational aa substitutions in the VRs of AAV2 yielded only a low-titer library [211]. Detailed
investigations could show that combinations of modiﬁed VR-VIII with VR-III or -VII do
not result in AAV particles. Moreover, substitutions in VR-III, -VI, and -IX are less toler-
ated [211]. Notably, VR-III and -IX are located at the capsid order's two-fold symmetry axis
which is assumed to be involved in capsid assembly [212]. Taken together, it seems plausible
that combinations of low-homology capsids like 2, 4 and 5 can reduce the ﬁtness of a chimeric
AAV. Likewise, our data indicate that detrimental structural eﬀects are less pronounced the
more similar capsids are present in the library. Virus titers did not drop once serotypes other
than 2, 4 or 5 were shued (i.e. cap library 24589, 145689). Of note, this can also indicate
a dilution of capsids containing non-compatible cap fragments while more vital chimeras
outgrow the others. Former shuing approaches by various groups point in this direction as
well [133136,179,180]. Although all of them included at least cap 4 in their shued libraries,
only two ﬁnally reported a functional chimera containing AAV4 regions after selection. Con-
spicuously, cap 4 parts preferentially appeared in the 5' region of the selected clones [134,136]
which is located at the inner part of the assembled capsid and not involved in cell surface
receptor binding but contributes in one case (AAV-LK03) to the PLA2 domain of VP1 [136].
Generally, the low frequency of AAV4 or 5 occurrence could originate from an overall low
incorporation of cap 4 and 5 into the libraries but could also be a result of reduced ﬁtness of
AAV4/5-containing chimeras. Despite these potential hurdles, sequence-optimization of less
homologous capsids and their improved integration into shued libraries represents a useful
tool for future applications. Especially, it will enable to investigate AAV structure-function
relationships in more detail and potentially yield new capsids with unique properties.
Next to eﬃcient transduction, promising AAV vector candidates ideally also display a low
immunogenicity. This is beneﬁcial since pre-existing neutralizing antibodies can reduce the
eﬃcacy of applied AAVs. It is reported that 40  70 % of the human population already have
neutralizing antibodies against speciﬁc AAV serotypes [79]. However, so far no publication
has reported a prevalence of anti-AAV4 antibodies in the human population. A closely related
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AAV cap variant named rh32.33 which was also isolated from NHP likewise lacked speciﬁc
anti-capsid antibodies in humans [81]. Hence, AAV4 capsid chimeras are highly interesting
for gene therapy in terms of reduced immunogenicity. Our approach opens new avenues for
the generation of cap 4-containing vectors with new properties.
4.1.4 AAV DNA family shuing is not restricted by inadvertent
recombination of AAP
In 2010, an essential factor for AAV particle assembly called assembly-activating protein
(AAP) was described [25]. Since then, it has been assumed that AAP acts as a scaﬀold or
chaperone for VPs in order to mediate correct particle formation. In this context, the ques-
tion arose whether shued AAP chimeras are impaired in functionality which, if true, would
lead to limitations for AAV capsid shuing. Importantly, we obtained evidence in this work
that previous concerns may be unfounded. Out of our randomly tested and representative
46 shued AAPs, 39 (84.8 %) were functional. In this context, cross-complementation eﬃ-
ciencies of functional AAPs varied between 7 and 100 % indicating either diﬀerent protein
activities or limited interactions with the tested AAV2 knock-out mutant. Interestingly, li-
braries containing the capsids AAV4 and 5 comprised the highest amount of deﬁcient AAPs.
It is assumed that AAP interacts with as of yet unknown VP domains within the AAV cap-
sid [213]. Comparison of AAP sequences additionally revealed a low homology between AAP4
/ 5 and AAP1  3b or 6  10, respectively [213]. Therefore, it seems plausible that AAV4
and 5 VPs, which display the lowest homology between the common AAV serotypes, cannot
interact with AAPs of other origin and vice versa. Indeed, two of the shued AAPs were only
functional with our AAV5O_rep construct and not compatible with AAV2mut. Additionally,
only AAP4 and 5 failed to support AAV2 assembly in a trans-complementation assay with
our generated AAV2mut construct whereas all other AAPs were interchangeable. These re-
sults are in accordance with a publication of Sonntag et al. who already reported successful
cross-complementation between AAV-AAP1, 2, 8 and 9 but not AAP5 [213]. Here, we further
extended this data set with AAV-AAP3b, 4, 6, 7 and rh10. Except for AAP4 all tested AAPs
were able to stimulate AAV2 assembly to various degrees.
The above-described data prompted us to investigate whether AAPwt trans-complementation
during virus production can overcome the serotype speciﬁc limitations in case AAV4 and / or
5 are present in a shued library. Interestingly, we could not detect an increase in virus titers
of our 24589 libraries in the presence of an AAPwt mixture. One explanation could be that
cross-complementation of AAPs encoded within the library already counteracts restrictive
eﬀects during production. Thus, further AAP addition cannot enhance assembly to a higher
extent. On the other hand, non-functional shued 24589O capsid chimeras with inactive AAP
could not be recovered after AAP addition. The latter data point more into the direction
that the function of AAP itself is not the restrictive factor in shuing. The high functionality
of our individually tested AAPs further supports this assumption. We rather hypothesize
that the AAP binding site within the AAV capsids is inﬂuenced by the shuing process. To
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date, published data only reported that the VP C terminus interacts with AAP and is criti-
cal for the assembly process [212]. Especially the point mutations I682S and K688A/K692A
abolished VP-AAP interaction and blocked capsid formation [212]. Furthermore, other muta-
tions aﬀecting capsid assembly indicate an interplay of AAP with VP domains at the capsid's
two-fold symmetry axis [64, 141, 212]. It is therefore likely that AAP binding could be im-
paired due to unfavorable VP domain combinations of incompatible AAV serotypes during
capsid shuing which results in assembly-deﬁcient particles. On the other hand, also sterical
hindrances within the capsid can potentially lead to non-functional particles independent of
AAP. However, neither of these possibilities can be circumvented during AAV capsid shuing.
Conversely, stringent selection of shued cap libraries yielded functional AAV particles with
intact AAP sequence. For instance, AAV-DJ encodes a shued AAP which encompasses
AAV serotypes 2-9-2-9-8 whereas AAV-LK03 contains only AAP3b [133,136]. Hence, natural
sifting during virus production and further selection enriches functional AAV particles with
intact AAPs.
Apart from the generation of novel AAV capsids, DFS can also be exploited to gain more
insights into structure-function relationships of proteins. In 2013 work from our group demon-
strated the power of DFS by discovering a function-related motif in the human Argonaute
protein 2 [195]. There, the shuing of Argonaute 2 and 3 resulted in the identiﬁcation of
slicing-competent domains. Intriguingly, the described motif contains two small important
regions separated by 85 aa and was thus unlikely to be identiﬁed through normal site-directed
mutagenesis. Knowing that DFS is able to elucidate structure-function relationships, AAP
shuing has the potential to shed light on (I) important AAP domains which are necessary
for capsid assembly and (II) the interplay between AAP and VPs in order to resolve their
exact binding sites.
4.2 New knock-out model system enables novel insights into
AAV biology
4.2.1 AAP stabilizes VPs and prevents proteasomal degradation
After the discovery of the assembly-activating protein AAP, only a few studies have further
investigated its role as scaﬀold or chaperone for AAV particle formation [25, 212, 213]. Thus,
little is known about general AAP biology and its inﬂuence on other steps of the AAV life
cycle. Hence, we aimed to shed more light on the features of AAP and its importance for
AAV.
Up to now all previous AAP studies obtained insights into AAP biology through a VP3-based
model system [25, 212, 213]. There, instead of a full-length cap gene, a VP3-only expression
vector driven by a CMV promoter was used. This construct was based on the observation
that VP3 subunits are able to form non-infectious virus particles which are morphologically
indistinguishable from the wild-type capsids [168, 214]. Notably, these results were obtained
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in the presence of AAP whose sequence starts 80 nt upstream of the VP3 start codon and
was not aﬀected by introduced mutations. However, once these 80 nt are deleted virus-like
particles can only be formed in the presence of AAP supplemented in trans [25]. Despite
the simplicity and usefulness of the VP3 model system, it neither reﬂects (I) the endogenous
VP expression due to the used CMV promoter nor (II) the interplay between AAP and VPs.
Sonntag et al. performed only one experiment with the full-length, AAP-deleted AAV genome
at the beginning of their study [25]. With our newly developed full-length AAV model sys-
tem we can overcome the abovementioned limitations and were able to study AAP biology in
more detail. Of note, we not only modiﬁed the AAV2 genome but also generated AAP-lacking
AAV1, 3b, 6, 7, 8, 9 and rh10 constructs. Therefore, we deleted the AAP start codon CTG
and inserted a stop codon 66 nt upstream of the AAP start. Both mutations did not change
the VP1-3 sequence but were able to completely abolish formation of infectious virus particles.
In line with previous publications, AAP supplementation could recover virus formation for all
tested serotypes which proved the general applicability of the system to other AAV capsids.
Interestingly, the cross-complementation and recovery of infectious particles was dose-de-
pendent for the tested AAV2mut construct suggesting that AAP is a limiting factor during
virus assembly. Furthermore, we unexpectedly detected a drastic reduction of AAV2 VP
levels in cell lysates lacking AAP2 after Western blotting. Intriguingly, Sonntag et al. also
observed an alteration of the VP expression pattern with their full-length mutant in the ab-
sence of AAP but did not follow up on the phenomenon [25]. We could show in this work
that the loss of VP signal is not caused by an alteration of mRNA levels. Moreover, we saw
no signiﬁcant diﬀerences in VP levels of the AAV2mut construct in comparison to AAV2wt
in microscopy. Thus, we concluded that the decline of VP signal in Western blots is caused
by a reduction of assembled particles. At the same time, VPs do not seem to accumulate in
the cell but rather are degraded in the absence of virus assembly. Indeed, after addition of
the proteasome inhibitor MG-132 AAV2mut protein amounts became comparable to AAV2wt
indicating a post-translational modiﬁcation of VPs and subsequent degradation. Strong ad-
ditional support for this conclusion was the detection of an additional, VP-speciﬁc band of
higher molecular weight in AAV2mut-treated cells only after MG-132 treatment. These results
led us to postulate a potential ubiquitination of cap proteins which is congruent with previous
publications. Generally, ubiquitination of proteins is an important mechanism within the cell
to e.g. target proteins for degradation or change their intracellular localization [215,216]. This
process requires several steps which include (a) an activation of the ubiquitin molecule by the
enzyme E1, (b) the transfer to the E2 enzyme and (c) its cross-linking to the ﬁnal target pro-
tein through the ubiquitin ligase E3. Finally, ubiquitinated proteins can be degraded by the
26S proteasome complex [215, 216]. AAVs were shown to interact with ubiquitin for the ﬁrst
time in 2000, when Duan et al. reported an increase of ubiquitinated AAV VP proteins after
transduction in human airway epithelia cells treated with proteasome inhibitor LLnL [31]. Two
years later the same group conﬁrmed these results and further described in vitro ubiquitina-
tion studies with AAV2 and AAV5 particles [34]. Interestingly, heat-denaturated capsids were
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better substrates for the conjugation of ubiquitin than intact viruses. Additionally, several
publications reported an increase of virus transduction after elimination of tyrosine residues
at the capsid surface [217219] which were shown to be phosphorylated by the epidermal
growth factor receptor protein tyrosine kinase (EGFR-PTK) and thereby mediate ubiqui-
tination of the viral capsid [220]. Moreover, Nayak et al. described a ubiquitin-dependent
proteasomal degradation of transfected AAV5 VPs mediated by the adenovirus 5 E4Orf6 pro-
tein [221]. Altogether, these data support our hypothesis that non-assembled VPs undergo
post-translational modiﬁcations leading to degradation. However, we always detected only
one or two very distinct bands of ∼ 200 kDa after Western blot analysis of MG-132-treated
cells. This is contradictory to patterns of protein ubiquitination normally observed which are
characterized by a protein smear. Intriguingly, the pattern of our described bands resembles
the denaturated (10 min, 95°C) AAV particles reported by Yan et al. [34]. One can assume
that due to the absence of AAP in the cells and inhibited proteasomal degradation, VPs ag-
gregate similar to the heat treatment leading to these high-molecular weight clusters that are
resistant to denaturing conditions in SDS-PAGE. Since only the heat-denaturated particles
were shown to be substrates for ubiquitination [34] also aggregated cellular VPs could be po-
tential targets for ubiquitin. Furthermore, preliminary Western blot results of a collaboration
partner showed a similar VP staining which argues against an artifact. In contrast to our
system, M. Penaud-Budloo in the group of E. Ayuso tested the aforementioned AAV2mut
modiﬁcations in a baculovirus-based AAV production system. In line with our results, they
observed a reduction of VP protein levels in Western blot analysis and no assembly of infec-
tious particles in the absence of AAP2. Additionally, AAV2mut-expressing insect cells showed
not only the high-molecular band we detected but also a smear of VP proteins with increased
size (unpublished data, M. Penaud-Budloo & E. Ayuso, IRS, Université de Nantes). The lat-
ter additionally supports our hypothesis of post-translational VP modiﬁcations. Yet, we were
not able to pull down ubiquitinated VPs in various IP attempts so far. Although this could
be a result of insuﬃcient protein amounts and problems with the IP per se, it could also hint
towards a ubiquitin-independent proteasomal degradation or other post-translational modiﬁ-
cations apart from ubiquitin. Recently, a siRNA screen associated the small ubiquitin-related
modiﬁer (SUMO) with AAVs [222]. SUMO belongs to the group of ubiquitin-like modiﬁers
and alters proteins similar to ubiquitin [223]. Instead of ubiquitination, SUMOylated pro-
teins are normally not degraded but play important roles in transcription, DNA repair or
signal transduction [215]. Nevertheless, SUMOylation can also target proteins for degrada-
tion. Holscher et al. observed that a knock-down of several members of the SUMO pathway
led to an increased AAV transduction eﬃciency [222]. However, these results were obtained
for incoming virus particles after transduction and could not dissect at which step of intra-
cellular vector processing SUMO is relevant. Hence, it remains unclear whether VPs interact
with SUMO before virus assembly since no publication has thus far determined SUMOylation
or ubiquitination of non-assembled VPs during virus production.
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4.2.2 Subcellular localization of AAP2 changes during virus production
AAP2 has been shown to contain several nuclear (NLS) and nucleolar localization signals
(NoLS) which eﬃciently translocate AAP2 to the nucleoli [58]. Mutations in these regions
lead to abnormal localization patterns and inﬂuence AAV capsid production. Thus, nucleolar
AAP2 plays an important role for virus assembly. However, all publications only investigated
the localization of transfected AAP2 driven by a CMV promoter. It remained unknown
whether localization of endogenous AAP shows the same pattern and expression levels. Thus,
we aimed to develop an anti-AAP2 antibody which enables the detection of endogenous AAP2
in the context of virus production. In parallel to AAP2, we also determined cellular expression
of either free non-assembled VPs or assembled AAV2 particles. Microscopic analysis showed
that endogenous AAP2 localized, similar to CMV promoter-driven AAP2 [25, 58], in the
nucleoli of the cells. Intriguingly, we observed an increasing de-localization from the nucleoli as
soon as viral particles were produced. Furthermore, quantiﬁcation of the microscopy pictures
revealed a decrease of AAP2-positive cells at later time-points (48 h) after transfection. These
data are in accordance with reduced AAP2 protein levels in Western blot analysis at later time
points of AAV virus production in insect cells (unpublished data, M. Penaud-Budloo & E.
Ayuso, IRS, Université de Nantes). Our observations indicate (I) that AAP is used up during
the assembly process and cannot be recycled and / or (II) that the nuclear localization signals
are surpassed by other molecular interactions. In this context, it could be possible that AAP2
remains associated with assembled virus particles since both signals always co-localized. Yet,
this has to be further investigated before drawing a conclusion.
In contrast to AAV2 particles, free VPs did not always co-localize with AAP. In detail, we
obtained cells which only expressed VPs but not AAP2. Quantitative analysis conﬁrmed this
observation and revealed more VP-positive cells than AAP-positive cells for all analyzed time
points after transfection. Notably, in the absence of AAP, VP signals mainly localized to
the cytoplasm. VPs only appeared in the nucleoli when cells were also positive for AAP2.
Sonntag et al. likewise reported a nucleolar exclusion of AAV2 VP3 without AAP which
turned into nucleolar accumulation and virus assembly after expression of the protein [25].
In this context, they also showed that nucleolar translocation of VPs fused to a NoLS is not
suﬃcient for assembly but requires AAP.
Collectively, our AAV2 protein stainings are in line with previously published time courses
of VP expression and particle assembly [57]. Furthermore, our data expand the knowledge
about endogenous AAP expression and can be easily combined with existing data. Thus, our
proposed model for the time course of AAV protein expression (see also ﬁgure 4.1) encompasses
a) the translation of AAV2 VPs 24 early after transfection followed by b) the onswitch of
AAP2 expression which leads to a translocation of VPs to the nucleoli due to the nucleolar
localization of AAP. Next, c) virus particles assemble in the nucleoli when AAP2 is present
and d) spread throughout the cell with time. The latter includes a decrease of AAP2 protein
levels and a translocation of the protein from the nucleoli.
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Figure 4.1: AAV2 protein expression model. Schematic depiction of the diﬀerent steps of
AAV2 protein expression during virus production. First (1), VPs are expressed and (2) subsequently
translocate to the nucleoli once nucleolar AAP2 is made by the cell. (3) Virus particles assemble in
the nucleoli and co-localize with AAP2. Finally (4), newly assembled particles spread throughout
the cell. In parallel, AAP2 protein levels are reduced and de-localize from the nucleoli.
4.2.3 Subcellular localization of AAP2 diﬀers from other serotypes
Next to the localization of AAP2, we also assessed intracellular AAP expression of other
AAV serotypes. In detail, we compared AAP2, 4, 5, 8 and 9 patterns after transfection
of the corresponding CMV-AAP expression plasmids together with other constructs needed
for virus production. Since our generated anti-AAP2 antibody showed only minimal cross-
reactivity with AAP8 and 9, and none with AAP4 or 5 (data not shown), we used an anti-HA
antibody for all AAP stainings. Interestingly, only AAP2 showed the nucleolar localization
above described whereas all other investigated serotypes behaved diﬀerently. AAP8 and 9
were not exclusively detected in the nucleoli but also in the nucleoplasm. AAP4 exhibited
mainly cytoplasmic localization but also seemed to accumulate in the nucleoli. In contrast
to all other AAPs, AAP5 showed no nucleolar localization but appeared in the nucleoplasm
and cytoplasm. Since all AAPs performed well in our conducted trans-complementation
assays, we could exclude an impairment of functionality by the varying localizations. Thus,
we hypothesize that nucleolar localization of AAP is not a pre-requisite for successful virus
assembly and is rather dependent on the AAV serotype. Our observations go in line with an
abstract presented at the Annual meeting of the American Society of Gene and Cell Therapy in
2015 where the authors also reported diﬀerent localizations of diﬀerent AAPs [224]. Notably,
Earley et al. speculated in their publication about the dependency of nucleolar localization on
the electric charge of basic regions within AAP [58]. They determined the electric charge of
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AAP2 to be above 12 which seems to be required for nucleolar localization. In contrast, with a
value of 8, AAP5 showed the lowest charge of all analyzed AAPs and led the authors to predict
a nucleolar exclusion of AAP5 [58]. Indeed, we could conﬁrm their hypothesis and detected
AAP5 only in the cytoplasm and nucleoplasm. Mechanistically, it is therefore likely that
AAV assembly does not exclusively appear in the nucleoli but at the site of AAP localization
depending on the AAV serotype. In turn, this would mean (and was already indicated by
Earley et al.) that no nucleolar factors are necessarily needed for assembly and nucleolar
localization is rather a side-eﬀect of the AAP sequence than actual function. However, these
are speculations and need further validation by future experiments.
4.3 Future perspectives
Within this work we provided several options for the optimization of AAV cap DNA family
shuing and discussed the inﬂuence of AAP on the method. Concurrently, we raised a series
of important new questions which should be addressed in the future.
First, although Covaris fragmentation is less sensitive to external and experimental inﬂuences
and hence more reproducible, DNaseI digest yielded better shuing eﬃciencies and crossover
numbers within a generated library. Thus, we recommend to further optimize ultrasonication-
based DNA shearing and test a mixture of small and big DNA fragments in order to mimic
enzymatic fragmentation. Successful implementation will increase the adaptability of the
method for other labs and, moreover, allow for a deliberate ﬁne-tuning of a shued library
by mixing diﬀerent DNA input sizes.
Second, our approach of sequence optimization of less homologous cap DNA will contribute
to an increasing diversiﬁcation of AAV libraries. In this context, optimization of other AAV
serotypes, which are genetically distinct to the commonly used serotypes (i.e. AAV2, 8 or 9),
oﬀers promising options. In particular, the incorporation of AAVs of bovine, porcine, avian
and caprine origin could potentially yield new AAV variants with improved immunogenic-
ity since they should not exhibit any prevalence for pre-existing antibodies in the human
population. Another possibility to increase library diversity would be the partial sequence
optimization of cap genes in regions of interest followed by the addition of only these parts in
the shuing reaction. This would minimize risks for potential negative eﬀects of recombina-
tion of non-compatible VP domains.
Third, optimized DFS cannot only yield new AAV capsids with ameliorated properties but
could also contribute to the elucidation of AAP functions. Considering the knowledge about
AAP remains very limited, DFS would allow for a more detailed investigation of AAP-VP
binding sites and / or the study of single AAP domains regarding their importance for func-
tionality. Since our analyzed shued AAPs showed varying eﬃciencies in the conducted
cross-complementation assays, we believe that they are especially suitable for initial structure-
function relation approaches. Additionally, our new AAP knock-out model system with the
generated mutants enables-serotype speciﬁc interaction studies between AAP and AAV cap
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proteins. Furthermore, microscopic analysis of these mutants will provide more details on the
localization of diﬀerent AAPs and can shed light on the question whether nucleolar localiza-
tion of AAPs is a pre-requisite for AAV capsid assembly which is, surprisingly, not supported
by our results. Finally, our reported data raised new questions about the causes of AAP
protein level reductions after AAV capsid assembly and the type of post-translational mod-
iﬁcation of VPs in the absence of AAP which have to be investigated in more detail in the
future.
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Figure 1: DNA type assignments of AAV cap library 1789rh10 produced with DNase or
ultrasonication-based fragmentation. a) Type assignment of 20 shued AAV cap chimeras after
DNaseI fragmentation. b) Type assignment of 20 shued AAV cap chimeras after ultrasonication-
based (Covaris) fragmentation. All sequences were analyzed with the Salanto program.
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Figure 2: Applied functions of the Salanto program. Screenshot of Salanto with opened and
analyzed data set (upper left). The shown type assignment analysis was colored with the Microsoft
program Excel to further indicate chimeric clone composition (colored panel in upper left). Addi-
tional used functions of Salanto are labeld with 1) - 7) and exempliﬁed with diagrams in the grey
boxes. 1) "Composition of clones" calculates percentages of parental sequences in the ﬁnal library.
2) "Distribution of reference sequence (position wise)" depicts the proportion of parents for each
nucleotide position in the analyzed library. 3) "Number of crossovers per clone" calculates crossover
events per chimera. 4) "Crossover analysis" determines crossover events between the single parents.
5) "Fragment length analysis" shows the number and length of shued gene fragments for each par-
ent along the complete library. 6) "Show homology" calculates position wise homologies of selected
parental and / or chimeric sequences. 7) "Show crossovercount" connects position wise homology
with the appearance of crossovers along the sequences. Calculations in 1)  5) and 7) are based on
the type assignment analysis.
110
PhD thesis, Stefanie Große
A T G A C C G AT G G T T A T CT T C C A G A TT G G C T C G AG G A C A A T CT C T C T G A AG G A G T A A GA G A G T G G TG G G
C G C T C C A AC C T G G C G CA C C A A A A CC A A A G G C CA A C C A G C AG C A T C A G GA C A A C G C CA G G G G T C TT G T
G C T T C C T GG G T A C A A GT A C C T C G GA C C C G G C AA C G G A C T CG A C A A G G GA G A G C C G GT C A A C G C GG C A
G A C G C C G CG G C C C T C GA G C A C G A CA A A G C C T AC G A C C A G CA G C T C A A GG C C G G A G AC A A C C C G TA C C
T C A A G T A CA A C C A C G CC G A C G C G GA G T T T C A GC A G C G C C TT C A A G G A GA T A C G T C TT T T G G G G GC A A
C C T C G G A CG A G C A G T CT T T C A G G CG A A A A A G AG G G T T C T TG A A C C T C TG G G C C T G GT T G A G C A AG C T
G G T G A G A CG G C T C C G GG A A A A A A GA G G C C G C TA A T C G A G TC T C C T C A GC A G C C A G AC T C C T C C AC G G
G A A T C G G AA A G A A G G GC A A G C A G CC T G C A A A AA A A A A A T TG G T T T T T GA G G A C G A GA C A G G C G CA G G
C G A C G G A CC T C C T G A GG G A T C G A CA T C A G G A GC C A T G T C TG A C G A T A GT G A G A T G CG T G C A G C CG C T
G G C G G A G CA G C G G T A GA G G G T G G CC A G G G C G CC G A C G G A GT G G G T A A TG C C T C G G GA G A T T G G CA T T
G C G A T T C CA C A T G G A GC G A G G G C CA C G T C A C CA C C A C C A GC A C C C G A AC C T G G G T CC T G C C C A CC T A
C A A C A A C CA C C T C T A CA A A C G A C TT G G C G A A TC C T T G C A GA G C A A T A CC T A C A A T GG C T T C A G CA C C
C C T T G G G GG T A T T T T GA C T T C A A CA G A T T C C AC T G C C A C TT T T C A C C AC G T G A C T GG C A A A G A CT C A
T C A A C A A CA A C T G G G GA A T G C G A CC C A A G G C AA T G A G A G TC A A G A T C TT T A A C A T TC A A G T C A AA G A
G G T C A C G AC G A G T A A CG G T G A G A CG A C G G T T GC C A A T A A CC T T A C C A GC A C G G T T CA G A T C T T TG C T
G A C T C G T CG T A C G A G CT C C C G T A CG T C A T G G AC G C G G G G CA G G A A G G AA G C C T C C CG C C G T T C CC A A
A C G A C G T CT T T A T G G TG C C A C A G TA T G G A T A CT G C G G C C TG G T C A C C GG G A A C A C AA G C C A G C AG C A
A A C A G A C CG C A A T G C CT T T T A C T GC C T G G A G TA C T T T C C TT C T C A G A TG C T G C G T AC C G G A A A CA A C
T T T G A G A TC A C C T A C TC T T T T G A GA A G G T T C CT T T C C A C AG C A T G T A CG C T C A C A GC C A G A G T CT G G
A C C G T C T CA T G A A T C CT C T C A T C GA C C A G T A CC T G T G G G GC T T G C A G AG C A C A A C CA C T G G A A CT A C
A C T C A A C GC G G G A A C GG C A A C G A CT A A C T T T AC T A A G C T CA G A C C G A CT A A C T T T AG C A A C T T CA A G
A A G A A C T GG C T T C C T GG A C C C T C TA T C A A G C AG C A G G G A TT C T C A A A GA C A G C T A AC C A G A A C TA C A
A G A T T C C AG C C A C G G GG T C T G A C AG C C T A A T AA A A T A C G AG A C C C A C TC C A C C C T CG A T G G C A GA T G
G T C T G C G CT G A C T C C GG G C C C T C CC A T G G C A AC C G C C G G GC C C G C T G AC T C A A A G TT T T C T A A CA G C
C A G C T T A TC T T C G C T GG G C C G A A AC A G A A C G GG A A C A C A GC T A C G G T CC C T G G A A CG C T C A T C TT T A
C A A G C G A AG A G G A A C TC G C G G C A AC C A A T G C CA C G G A T A CG G A C A T G TG G G G T A A TC T A C C T G GC G G
C G A C C A G AG C A A C A G CA A C C T A C CA A C T G T C GA C C G T C T CA C C G C A C TA G G C G C T GT T C C A G G CA T G
G T C T G G C AG A A C A G A GA T A T C T A CT A T C A G G GG C C C A T C TG G G C A A A GA T T C C A C AC A C G G A C GG A C
A T T T T C A CC C C T C T C CC C T C A T C GG T G G A T T CG G A C T T A AA C A C C C T CC T C C A C A GA T T T T C A TC A A
G A A C A C C CC G G T A C C TG C G A A T C CT G C G A C C AC C T T C A G TT C G A C A C CG G T T A A T TC C T T C A T CA C A
C A G T A C T CC A C G G G A CA G G T C A G CG T G C A G A TC G A C T G G GA G A T C C A GA A G G A A A GA A G C A A A CG C T
G G A A T C C CG A A G T T C AG T T C A C T TC C A A C T A CG G C C A G C AG A A T A G T CT G C T C T G GG C T C C G G AC G C
T G C T G G C AA G T A T A C AG A G C C T C GC G C C A T T GG C A C C A G AT A C C T G A CT C A T C A T CT G T A A
Figure 3:AAV cap 4O sequence. DNA sequence of the sequence optimized AAV4 capsid (AAV4O).
The AAP ORF is underlined. Modiﬁed nucleotides which lead to an AAP knockout are marked in
red.
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G G A T G G G CG A C A G A G TC G T C A C C AA G A G C A C CC G A A C C T GG G T C C T G CC C A G C T A CA A C A A C C AC C A
G T A C A G A GA A A T T A A GA G C G G A T CA G T A G A C GG C T C G A A CG C C A A T G CC T A C T T T GG C T A C A G CA C C
C C T T G G G GG T A T T T T GA C T T C A A CA G A T T C C AC A G C C A C TG G T C A C C AC G T G A C T GG C A A A G A CT C A
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G G T C A C G GT G C A G G A CA G T A C G A CG A C G A T T GC C A A T A A CC T T A C C A GC A C G G T T CA G G T G T T TA C T
G A C G A C G AC T A C C A G CT C C C G T A CG T C G T C G GC A A C G G G AC T G A A G G AT G C C T C C CG G C G T T C CC A C
C A C A G G T CT T C A C G C TG C C A C A G TA T G G A T A CG C C A C C C TG A A C A G A GA C A A C A C GG A G A A C C CA A C
A G A A C G C TC T T C A T T TT T C T G C C TG G A G T A C TT T C C T T C TA A G A T G C TG C G T A C C GG A A A C A A CT T T
G A G T T C A CC T A C A A T TT T G A G G A GG T T C C T T TC C A C A G C AG C T T C G C TC C C A G C C AG A A T C T G TT C A
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C T A A C A G GA T G G A G C TC G A G G G C GC A A G C T A TC A G G T G C CT C C G C A G CC G A A C G G GA T G A C C A AC A A
C C T C C A G GG A T C A A A CA C T T A T G CT C T G G A G AA C A C T A T GA T C T T T A AC A G C C A A CC C G C A A A CC C A
G G A A C A A CA G C T A C G TA C C T T G A AG G G A A C A TG C T G A T T AC A A G C G A AT C G G A A A CC C A G C C A GT C A
A T C G C G T GG C T T A C A AC G T G G G T GG T C A G A T GG C T A C C A AC A A C C A G AG C A G C A C CA C A G C A C CA G C
T A C C G G A AC T T A C A A CC T A C A A G AG A T T G T T CC A G G C A G CG T C T G G A TG G A G A G A GA T G T G T A CC T T
C A G G G G C CC A T C T G G GC A A A G A T TC C A G A G A CG G G C G C A CA T T T T C A CC C C T C T C CC G C C A T G GG T G
G A T T C G G AC T T A A A C AC C C T C C T CC A A T G A T GC T C A T C A AG A A C A C C CC G G T A C C TG G G A A T A TC A C
C A G C T T C AG T G A C G T AC C G G T T T CT T C C T T C AT C A C A C A GT A C T C C A CG G G A C A G GT C A C C G T GG A G
A T G G A G T GG G A G C T G AA G A A G G A AA A C A G C A AA C G C T G G AA T C C C G A AA T T C A G T AC A C T A A C AA C T
A C A A C G A CC C T C A G T TT G T G G A C TT T G C T C C GG A C T C T A CT G G C G A G TA T A G A A C GA C T C G C C CC A T
T G G C A C C AG A T A C C T GA C T C G T C CT C T G T A A
O
Figure 4: AAV cap 5O sequence. DNA sequence of the sequence optimized AAV5 capsid (AAV5O).
The AAP ORF is underlined. Modiﬁed nucleotides which lead to the deletion of the rep stop codon
and an AAP knockout are marked in red.
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A T G A C C G AT G G T T A T CT T C C A G A TT G G C T C G AG G A C A A T CT C T C T G A AG G A G T A A GA G A G T G G TG G G
C G C T C C A AC C T G G C G CA C C A A A A CC A A A G G C CA A C C A G C AG C A T C A G GA C A A C G C CA G G G G T C TT G T
G C T T C C T GG G T A C A A GT A C C T C G GA C C C G G C AA C G G A C T CG A C A A G G GA G A G C C G GT C A A C G C GG C A
G A C G C C G CG G C C C T C GA G C A C G A CA A A G C C T AC G A C C A G CA G C T C A A GG C C G G A G AC A A C C C G TA C C
T C A A G T A CA A C C A C G CC G A C G C G GA G T T T C A GC A G C G C C TT C A A G G A GA T A C G T C TT T T G G G G GC A A
C C T C G G A CG A G C A G T CT T T C A G G CG A A A A A G AG G G T T C T TG A A C C T C TG G G C C T G GT T G A G C A AG C T
G G T G A G A CG G C T C C G GG A A A A A A GA G G C C G C TA A T C G A G TC T C C T C A GC A G C C A G AC T C C T C C AC G G
G A A T C G G AA A G A A G G GC A A G C A G CC T G C A A A AA A A A A A T TG G T T T T T GA G G A C G A GA C T G G C G CA G G
C G A C G G A CC T C C T G A GG G A T C G A CA T C A G G A GC C A T G T C TG A C G A T A GT G A G A T G CG T G C A G C CG C T
G G C G G A G CA G C G G T C GA G G G T G G CC A G G G C G CC G A C G G A GT G G G T A A TG C C T C G G GA G A T T G G CA T T
G C G A T T C CA C A T G G A GC G A G G G C CA C G T C A C CA C C A C C A GC A C C C G A AC C T G G G T CC T G C C C A CC T A
C A A C A A C CA C C T C T A CA A A C G A C TT G G C G A A TC C T T G C A GA G C A A T A CC T A C A A T GG C T T C A G CA C C
C C T T G G G GG T A T T T T GA C T T C A A CA G A T T C C AC T G C C A C TT T T C A C C AC G T G A C T GG C A A A G A CT C A
T C A A C A A CA A C T G G G GA A T G C G A CC C A A G G C AA T G C G G G TC A A G A T C TT T A A C A T TC A A G T C A AA G A
G G T C A C G AC G A G T A A CG G T G A G A CG A C G G T T GC C A A T A A CC T T A C C A GC A C G G T T CA G A T C T T TG C T
G A C T C G T CG T A C G A G CT C C C G T A CG T G A T G G AC G C G G G G CA G G A A G G AA G C C T C C CG C C G T T C CC A A
A C G A C G T CT T T A T G G TG C C A C A G TA T G G A T A CT G C G G C C TG G T C A C C GG G A A C A C AA G C C A G C AG C A
A A C A G A C CG C A A T G C CT T T T A C T GC C T G G A G TA C T T T C C TT C T C A G A TG C T G C G T AC C G G A A A CA A C
T T T G A G A TC A C C T A C TC T T T T G A GA A G G T T C CT T T C C A C AG C A T G T A CG C T C A C A GC C A G A G T CT G G
A C C G T C T CA T G A A T C CT C T C A T C GA C C A G T A CC T G T G G G GC T T G C A G AG C A C A A C CA C T G G A A CT A C
A C T C A A C GC G G G A A C GG C A A C G A CT A A C T T T AC T A A G C T CA G A C C G A CT A A C T T T AG C A A C T T CA A G
A A G A A C T GG C T T C C T GG A C C C T C TA T C A A G C AG C A G G G A TT C T C A A A GA C A G C T A AC C A G A A C TA C A
A G A T T C C AG C C A C G G GG T C T G A C AG C C T A A T AA A A T A C G AG A C C C A C TC C A C C C T CG A T G G C A GA T G
G T C T G C G CT G A C T C C GG G C C C T C CC A T G G C A AC C G C C G G GC C C G C T G AC T C A A A G TT T T C T A A CA G C
C A G C T T A TC T T C G C T GG G C C G A A AC A G A A C G GG A A C A C A GC T A C G G T CC C T G G A A CG C T C A T C TT T A
C A A G C G A AG A G G A A C TC G C G G C A AC C A A T G C CA C G G A T A CG G A C A T G TG G G G T A A TC T A C C T G GC G G
C G A C C A G AG C A A C A G CA A C C T A C CA A C T G T C GA C C G T C T CA C C G C A C TA G G C G C T GT T C C A G G CA T G
G T C T G G C AG A A C A G A GA T A T C T A CT A T C A G G GG C C C A T C TG G G C A A A GA T T C C A C AC A C G G A C GG A C
A T T T T C A CC C C T C T C CC C T C A T C GG T G G A T T CG G A C T T A AA C A C C C T CC T C C A C A GA T T T T C A TC A A
G A A C A C C CC G G T A C C TG C G A A T C CT G C G A C C AC C T T C A G TT C G A C A C CG G T T A A T TC C T T C A T CA C A
C A G T A C T CC A C G G G A CA G G T C A G CG T G C A G A TC G A C T G G GA G A T C C A GA A G G A A A GA A G C A A A CG C T
G G A A T C C CG A A G T T C AG T T C A C T TC C A A C T A CG G C C A G C AG A A T A G T CT G C T C T G GG C T C C G G AC G C
T G C T G G C AA G T A T A C AG A G C C T C GC G C C A T T GG C A C C A G AT A C C T G A CT C A T C A T CT G T A A
O repaired
Figure 5: AAV cap 4O repaired sequence. DNA sequence of the repaired AAV4O capsid
(AAV4O repaired). The AAP ORF is underlined. Nucleotides which were repaired in order to re-
cover AAP expression are marked in blue.
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A T G T C T T TC G T T G A T CA T C C T C C AG A T T G G C TC G A G G A G GT T G G T G A AG G A C T A A GA G A G T T C TT G G
G G C T C G A AG C T G G C C CA C C A A A A CC A A A G C C CA A C C A G C AG C A T C A G GA C C A G G C CA G G G G T C TT G T
G C T T C C T GG G T A C A A CT A C C T C G GA C C C G G C AA C G G A C T CG A C A G G G GA G A G C C G GT C A A C C G GG C A
G A C G A G G TG G C C C G C GA G C A C G A CA T A T C C T AC A A C G A G CA G C T C G A GG C C G G A G AC A A C C C G TA C C
T C A A G T A CA A C C A C G CC G A C G C G GA G T T T C A GG A G A A G C TC G C A G A C GA T A C G T C TT T T G G G G GC A A
C C T C G G A AA A G C A G T CT T C C A G G CG A A A A A G AG G G T T C T TG A A C C T T TC G G C C T G GT T G A G G A AG G T
G C T A A G A CG G C T C C G AC A G G A A A GA G G A T T G AC G A C C A C TT T C C T A A GC G G A A A A AG G C C C G C AC G G
A G G A G G A CT C G A A G C CT T C A A C G TC T A G C G A CG C A G A G G C A G G A C C T AG C G G A T C CC A G C A G C TC C A
A A T C C C A GC A C A A C C CG C C T C T A GT C T G G G A GC T G A T A C GA T G T C T G CA G G C G G T GG C G G A C C AC T G
G G A G A C A AT A A C C A G GG C G C C G A CG G A G T G G GT A A T G C C TC G G G A G A TT G G C A T T GC G A T T C C AC A T
G G A T G G G CG A C A G A G TC G T C A C C AA G A G C A C CC G A A C C T GG G T C C T G CC C A G C T A CA A C A A C C AC C A
G T A C A G A GA A A T T A A GA G C G G A T CA G T A G A C GG C T C G A A CG C C A A T G CC T A C T T T GG C T A C A G CA C C
C C T T G G G GG T A T T T T GA C T T C A A CA G A T T C C AC A G C C A C TG G T C A C C AC G T G A C T GG C A A A G A CT C A
T C A A C A A CT A C T G G G GA T T C C G A CC C A G G A G CC T C A G A G TC A A G A T C TT T A A C A T TC A A G T C A AA G A
G G T C A C G GT G C A G G A CA G T A C G A CG A C G A T T GC C A A T A A CC T T A C C A GC A C G G T T CA G G T G T T TA C T
G A C G A C G AC T A C C A G CT C C C G T A CG T C G T C G GC A A C G G G AC T G A A G G AT G C C T C C CG G C G T T C CC A C
C A C A G G T CT T C A C G C TG C C A C A G TA T G G A T A CG C C A C C C TG A A C A G A GA C A A C A C GG A G A A C C CA A C
A G A A C G C TC T T C A T T TT T C T G C C TG G A G T A C TT T C C T T C TA A G A T G C TG C G T A C C GG A A A C A A CT T T
G A G T T C A CC T A C A A T TT T G A G G A GG T T C C T T TC C A C A G C AG C T T C G C TC C C A G C C AG A A T C T G TT C A
A G C T C G C GA A T C C T C TC G T C G A C CA G T A C C T GT A T C G C T TC G T C A G C AC A A A C A A TA C A G G T G GA G T
T C A G T T T AA T A A G A A CC T A G C G G GT C G C T A T GC G A A C A C GT A T A A G A AC T G G T T T CC T G G A C C CA T G
G G C C G C A CG C A G G G A TG G A A C C T GG G A T C T G GG G T T A A C AG A G C C A G TG T A T C C G CG T T C G C T AC A A
C T A A C A G GA T G G A G C TC G A G G G C GC A A G C T A TC A G G T G C CT C C G C A G CC G A A C G G GA T G A C C A AC A A
C C T C C A G GG A T C A A A CA C T T A T G CT C T G G A G AA C A C T A T GA T C T T T A AC A G C C A A CC C G C A A A CC C A
G G A A C A A CA G C T A C G TA C C T T G A AG G G A A C A TG C T G A T T AC A A G C G A AT C G G A A A CC C A G C C A GT C A
A T C G C G T GG C T T A C A AC G T G G G T GG T C A G A T GG C T A C C A AC A A C C A G AG C A G C A C CA C A G C A C CA G C
T A C C G G A AC T T A C A A CC T A C A A G AG A T T G T T CC A G G C A G CG T C T G G A TG G A G A G A GA T G T G T A CC T T
C A G G G G C CC A T C T G G GC A A A G A T TC C A G A G A CG G G C G C A CA T T T T C A CC C C T C T C CC G C C A T G GG T G
G A T T C G G AC T T A A A C AC C C T C C T CC A A T G A T GC T C A T C A AG A A C A C C CC G G T A C C TG G G A A T A TC A C
C A G C T T C AG T G A C G T AC C G G T T T CT T C C T T C AT C A C A C A GT A C T C C A CG G G A C A G GT C A C C G T GG A G
A T G G A G T GG G A G C T G AA G A A G G A AA A C A G C A AA C G C T G G AA T C C C G A AA T T C A G T AC A C T A A C AA C T
A C A A C G A CC C T C A G T TT G T G G A C TT T G C T C C GG A C T C T A CT G G C G A G TA T A G A A C GA C T C G C C CC A T
T G G C A C C AG A T A C C T GA C T C G T C CT C T G T A A
O-rep
Figure 6: AAV cap 5O_rep sequence. DNA sequence of the partially repaired AAV5O capsid
(AAV5O_rep). The AAP ORF is underlined. The nucleotide which was repaired in order to recover
the rep stop codon is marked in blue.
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A T G T C T T TC G T T G A T CA T C C T C C AG A T T G G C TC G A G G A G GT T G G T G A AG G A C T A A GA G A G T T C TT G G
G G C T C G A AG C T G G C C CA C C A A A A CC A A A G C C CA A C C A G C AG C A T C A G GA C C A G G C CA G G G G T C TT G T
G C T T C C T GG G T A C A A CT A C C T C G GA C C C G G C AA C G G A C T CG A C A G G G GA G A G C C G GT C A A C C G GG C A
G A C G A G G TG G C C C G C GA G C A C G A CA T A T C C T AC A A C G A G CA G C T C G A GG C C G G A G AC A A C C C G TA C C
T C A A G T A CA A C C A C G CC G A C G C G GA G T T T C A GG A G A A G C TC G C A G A C GA T A C G T C TT T T G G G G GC A A
C C T C G G A AA A G C A G T CT T C C A G G CG A A A A A G AG G G T T C T TG A A C C T T TC G G C C T G GT T G A G G A AG G T
G C T A A G A CG G C T C C G AC A G G A A A GA G G A T T G AC G A C C A C TT T C C T A A GC G G A A A A AG G C C C G C AC G G
A G G A G G A CT C G A A G C CT T C A A C G TC T A G C G A CG C A G A G G C T G G A C C T AG C G G A T C CC A G C A G C TC C A
A A T C C C A GC A C A A C C CG C C T C T A GT C T G G G A GC T G A T A C GA T G T C T G CA G G C G G T GG C G G A C C AC T G
G G A G A C A AT A A C C A G GG C G C C G A CG G A G T G G GT A A T G C C TC G G G A G A TT G G C A T T GC G A T T C C AC A T
G G A T G G G CG A C A G A G TC G T C A C C AA G A G C A C CC G A A C C T GG G T C C T G CC C A G C T A CA A C A A C C AC C A
G T A C A G A GA A A T T A A GA G C G G A T CA G T C G A C GG C T C G A A CG C C A A T G CC T A C T T T GG C T A C A G CA C C
C C T T G G G GG T A T T T T GA C T T C A A CA G A T T C C AC A G C C A C TG G T C A C C AC G T G A C T GG C A A A G A CT C A
T C A A C A A CT A C T G G G GA T T C C G A CC C A G G A G CC T C A G A G TC A A G A T C TT T A A C A T TC A A G T C A AA G A
G G T C A C G GT G C A G G A CA G T A C G A CG A C G A T T GC C A A T A A CC T T A C C A GC A C G G T T CA G G T G T T TA C T
G A C G A C G AC T A C C A G CT C C C G T A CG T C G T C G GC A A C G G G AC T G A A G G AT G C C T C C CG G C G T T C CC A C
C A C A G G T CT T C A C G C TG C C A C A G TA T G G A T A CG C C A C C C TG A A C A G A GA C A A C A C GG A G A A C C CA A C
A G A A C G C TC T T C A T T TT T C T G C C TG G A G T A C TT T C C T T C TA A G A T G C TG C G T A C C GG A A A C A A CT T T
G A G T T C A CC T A C A A T TT T G A G G A GG T T C C T T TC C A C A G C AG C T T C G C TC C C A G C C AG A A T C T G TT C A
A G C T C G C GA A T C C T C TC G T C G A C CA G T A C C T GT A T C G C T TC G T C A G C AC A A A C A A TA C A G G T G GA G T
T C A G T T T AA T A A G A A CC T A G C G G GT C G C T A T GC G A A C A C GT A T A A G A AC T G G T T T CC T G G A C C CA T G
G G C C G C A CG C A G G G A TG G A A C C T GG G A T C T G GG G T T A A C AG A G C C A G TG T A T C C G CG T T C G C T AC A A
C T A A C A G GA T G G A G C TC G A G G G C GC A A G C T A TC A G G T G C CT C C G C A G CC G A A C G G GA T G A C C A AC A A
C C T C C A G GG A T C A A A CA C T T A T G CT C T G G A G AA C A C T A T GA T C T T T A AC A G C C A A CC C G C A A A CC C A
G G A A C A A CA G C T A C G TA C C T T G A AG G G A A C A TG C T G A T T AC A A G C G A AT C G G A A A CC C A G C C A GT C A
A T C G C G T GG C T T A C A AC G T G G G T GG T C A G A T GG C T A C C A AC A A C C A G AG C A G C A C CA C A G C A C CA G C
T A C C G G A AC T T A C A A CC T A C A A G AG A T T G T T CC A G G C A G CG T C T G G A TG G A G A G A GA T G T G T A CC T T
C A G G G G C CC A T C T G G GC A A A G A T TC C A G A G A CG G G C G C A CA T T T T C A CC C C T C T C CC G C C A T G GG T G
G A T T C G G AC T T A A A C AC C C T C C T CC A A T G A T GC T C A T C A AG A A C A C C CC G G T A C C TG G G A A T A TC A C
C A G C T T C AG T G A C G T AC C G G T T T CT T C C T T C AT C A C A C A GT A C T C C A CG G G A C A G GT C A C C G T GG A G
A T G G A G T GG G A G C T G AA G A A G G A AA A C A G C A AA C G C T G G AA T C C C G A AA T T C A G T AC A C T A A C AA C T
A C A A C G A CC C T C A G T TT G T G G A C TT T G C T C C GG A C T C T A CT G G C G A G TA T A G A A C GA C T C G C C CC A T
T G G C A C C AG A T A C C T GA C T C G T C CT C T G T A A
O repaired
Figure 7: AAV cap 5O repaired sequence. DNA sequence of the repaired AAV5O capsid
(AAV5O repaired). The AAP ORF is underlined. Nucleotides which were repaired in order to re-
cover AAP expression as well as the rep stop codon are marked in blue.
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145689 library
Ø Crossovers: 10.1 per clone
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b
Figure 8: DNA type assignments of libraries with AAV cap 4 / 4O and AAV cap 5 / 5O.
a) DNA type assignments of libraries 145689 and 145689O. b) DNA type assignments of libraries 1-9
and 1-9O. Per library 20 clones were analyzed with the Salanto program. Average crossover numbers
per clone within the library are depicted below.
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AAV2 AAV4O AAV5O AAV8 Indet MutAAV9
5‘ 3‘
5
6
7
8
9
10
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12
13
14
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C
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DNA type assignment
a
b enil lleCenil lleC
AAV serotype AAP HE
K2
93
T
MC
F7
SF
53
9
AAV serotype AAP HE
K2
93
T
MC
F7
SF
53
9
AAV2 - 24589O clone 11 +
AAV4 - 24589O clone 11 -
AAV5 - 24589O clone 12 +
AAV8 - 24589O clone 12 -
AAV9 - 24589O clone 13 +
24589O clone 13 -
24589O clone 05 + 24589O clone 14 +
24589O clone 05 - 24589O clone 14 -
24589O clone 06 + 24589O clone 15 +
24589O clone 06 - 24589O clone 15 -
24589O clone 07 + 24589O clone 16 +
24589O clone 07 - 24589O clone 16 -
24589O clone 08 + 24589O clone 17 +
24589O clone 08 - 24589O clone 17 -
24589O clone 09 + 24589O clone 19 +
24589O clone 09 - 24589O clone 19 -
24589O clone 10 + 24589O clone 20 +
24589O clone 10 - 24589O clone 20 -
non-transduced cells + Negative control +
0%        100% 0%        100%
Figure 9: Test of 15 individual, shued 24589O clones with or without AAP supplemen-
tation. a) DNA type assignment of all tested 24589O library clones. Clone numbers are depicted
on the left side, circles on the right side mark clones which carry non-functional AAPs. Clones were
analyzed with the Salanto program and are already depicted in ﬁgure 3.6. b) Heat-map of AAV
transduction with the tested 24589O library clones in three diﬀerent cell lines. Crude cell lysates
were produced by transfection of HEK293T cells with the adeno-helper construct, a ﬂuorescence
reporter and a rep-cap helper encoding for either the wild-type AAV capsids 2, 4, 5, 8 or 9 or one of
the shued library clones. In additon, either an AAP mixture containing AAP2, 4, 5, 8, and 9 or
stuﬀer (salmon sperm) DNA was added during transfection (indicated with '+' or '-', respectively).
Next, HEK293T, MCF7 or SF539 cells were transduced with 5 µl crude lysate and analyzed via ﬂow
cytometry 48 hours later. Percentages of positive cells are color-coded from 0 % (black) to 100 %
(dark red). Out of 15 tested shued clones only two (clone no. 14 and 16) were able to transduce
cells. No clone was restored upon AAP supplementation.
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AAV1 AAV2 AAV4AAV3 AAV4O AAV5 AAV5O
AAV6 AAV7 AAV9AAV8 Indet Mut
X35
X36
X37
X38
X39
X40
X41
X42
7/8 AAPs functional (88 %)
‘3‘5
A
A
P 
cl
on
e
1-9 library
X23
X24
X25
X27
X28
X43
X44
X45
X46
7/9 AAPs functional (78 %)
‘3‘5
A
A
P 
cl
on
e
24589 library
X1
X2
X3
X4
X5
X6
X7
X18
X19
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Figure 10: Protein type assignments of all cloned shued AAPs. Colored protein type
assignment of AAP-X1  AAP-X47 which were randomly selected from ﬁve diﬀerent shued AAV
cap libraries (depicted on top of each assignment). In total 39/46 (84.8 %) of the tested AAPs were
functional in trans-complementation assays together with AAV2mut or AAV5O_rep. Non-functional
AAPs are marked with a circle. Sequences were analyzed with the Salanto program.
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Figure 11: DNA type assignments of cap libraries containing the repaired (r) versions of
cap 4O and 5O. Colored DNA type assignment of 245Or (a), 24589Or (b) and 145689Or (c) AAV
cap libraries. Twelve randomly selected clones per library were analyzed with the Salanto program.
Average crossover numbers per clone within the library are depicted below.
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2 Supplementary tables
Table 1: Microsoft excel macro for precise type assignment coloring
Protocol step
Sub color_precise_type_assignment_Salanto()
Dim Zelle As Range
For Each Zelle In ActiveSheet.UsedRange
If Zelle.Value = ">AAV1" Then
Zelle.Interior.ColorIndex = 16
End If
If Zelle.Value = ">AAV1" Then
Zelle.Interior.TintAndShade = 0.2
End If
If Zelle.Value = ">AAV2" Then
Zelle.Interior.ColorIndex = 3
End If
If Zelle.Value = ">AAV2" Then
Zelle.Interior.TintAndShade = 0.1
End If
If Zelle.Value = ">AAV3" Then
Zelle.Interior.ColorIndex = 51
End If
If Zelle.Value = ">AAV3" Then
Zelle.Interior.TintAndShade = 0.1
End If
If Zelle.Value = ">AAV4" Then
Zelle.Interior.ColorIndex = 44
End If
If Zelle.Value = ">AAV5" Then
Zelle.Interior.ColorIndex = 41
End If
If Zelle.Value = ">AAV5" Then
Zelle.Interior.TintAndShade = 0.1
End If
If Zelle.Value = ">AAV6" Then
Zelle.Interior.ColorIndex = 21
End If
If Zelle.Value = ">AAV6" Then
Zelle.Interior.TintAndShade = 0.7
End If
If Zelle.Value = ">AAV7" Then
Zelle.Interior.ColorIndex = 31
End If
If Zelle.Value = ">AAV7" Then
Zelle.Interior.TintAndShade = 0.1
End If
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If Zelle.Value = ">AAV8" Then
Zelle.Interior.ColorIndex = 29
End If
If Zelle.Value = ">AAV8" Then
Zelle.Interior.TintAndShade = 0.02
End If
If Zelle.Value = ">AAV9" Then
Zelle.Interior.ColorIndex = 11
End If
If Zelle.Value = ">AAV9" Then
Zelle.Interior.TintAndShade = 0.1
End If
If Zelle.Value = ">AAVrh10" Then
Zelle.Interior.ColorIndex = 52
End If
If Zelle.Value = ">AAVrh10" Then
Zelle.Interior.TintAndShade = 0.3
End If
If Zelle.Value = ">AAVpo.1" Then
Zelle.Interior.ColorIndex = 10
End If
If Zelle.Value = ">AAVpo.1" Then
Zelle.Interior.TintAndShade = 0.1
End If
If Zelle.Value = ">AAV12" Then
Zelle.Interior.ColorIndex = 43
End If
If Zelle.Value = ">AAV12" Then
Zelle.Interior.TintAndShade = 0.1
End If
If Zelle.Value = ">AAV4O" Then
Zelle.Interior.ColorIndex = 44
End If
If Zelle.Value = ">AAV4O" Then
Zelle.Interior.TintAndShade = 0.6
End If
If Zelle.Value = ">AAV5O" Then
Zelle.Interior.ColorIndex = 41
End If
If Zelle.Value = ">AAV5O" Then
Zelle.Interior.TintAndShade = 0.6
End If
If Zelle.Value = "indet" Then
Zelle.Interior.ColorIndex = 15
End If
If Zelle.Value = "indet" Then
Zelle.Interior.TintAndShade = 0.2
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End If
If Zelle.Value = "MUT" Then
Zelle.Interior.ColorIndex = 2
End If
Next Zelle
End Sub
Table 2: CellProﬁler protocol for the microscopy picture quantiﬁcation of nuclei and cells positively
stained with the B1- or A20-antibody.
Protocol step Setting
CellProﬁler Version,2014-07-23T17:45:00
6c2d896
Images
Filter images?: No ﬁltering
Metadata
Extract metadata?: No
NamesAndTypes
Assign a name to: Images matching rules
Select the rule criteria: and (ﬁle does contain "dapi.tif"")
Name to assign these images: DNA
Select the image type: Grayscale image
Set intensity range from: Image metadata
Select the rule criteria: and (ﬁle does contain "TxR.tif"")
Name to assign these images: TexasRed
Select the image type: Grayscale image
Set intensity range from: Image metadata
Crop
Select the input image: DNA
Name the output image: CropBlue
Select the cropping shape: Rectangle
Select the cropping method: Coordinates
Apply which cycle± cropping pattern?: First
Left and right rectangle positions: 1, 200
Top and bottom rectangle positions: 1, 200
Remove empty rows and columns?: Edges
IdentifyPrimaryObjects:
Select the input image: DNA
Name the primary objects to be identiﬁed: Nuclei
Typical diameter of objects, in pixel units (Min,Max): 11,40
Discard objects outside the diameter range?: Yes
Try to merge too small objects with nearby larger objects?: No
Discard objects touching the border of the image?: Yes
Threshold strategy: Global
Thresholding method: Background
Select the smoothing method for thresholding: Automatic
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Threshold correction factor: 1
Lower and upper bounds on threshold: 0,1
Method to distinguish clumped objects: Intensity
Method to draw dividing lines between clumped objects: Intensity
Automatically calculate size of smoothing ﬁlter for declumping?: Yes
Automatically calculate minimum allowed distance between local
maxima?:
Yes
Speed up by using lower-resolution image to ﬁnd local maxima?: Yes
Retain outlines of the identiﬁed objects?: Yes
Name the outline image: NucOutlines
Fill holes in identiﬁed objects?: After both thresholding and de-
clumping
Handling of objects if excessive number of objects identiﬁed: Continue
IdentifyPrimaryObjects:
Select the input image: TexasRed
Name the primary objects to be identiﬁed: B1_or_A20_positive_cells
Typical diameter of objects, in pixel units (Min,Max): 11,80
Discard objects outside the diameter range?: Yes
Try to merge too small objects with nearby larger objects?: No
Discard objects touching the border of the image?: Yes
Threshold strategy: Global
Thresholding method: Background
Select the smoothing method for thresholding: Automatic
Threshold correction factor: 1
Lower and upper bounds on threshold: 0,1
Method to distinguish clumped objects: Intensity
Method to draw dividing lines between clumped objects: Intensity
Automatically calculate size of smoothing ﬁlter for declumping?: Yes
Automatically calculate minimum allowed distance between local
maxima?:
Yes
Speed up by using lower-resolution image to ﬁnd local maxima?: Yes
Retain outlines of the identiﬁed objects?: No
Name the outline image: PrimaryOutlines
Fill holes in identiﬁed objects?: After both thresholding and de-
clumping
Handling of objects if excessive number of objects identiﬁed: Continue
MeasureObjectIntensity:
Select an image to measure: TexasRed
Select objects to measure: B1_or_A20_positive_cells
ExportToSpreadsheet:
Select the column delimiter: Comma ("","")
Output ﬁle location: Default Input Folder sub-folder
Add a preﬁx to ﬁle names?: No
Overwrite without warning?: Yes
Add image metadata columns to your object data ﬁle?: No
Limit output to a size that is allowed in Excel?: No
Representation of Nan/Inf: NaN
123
Supplementary information
Protocol step Setting
Calculate the per-image mean values for object measurements?: Yes
Calculate the per-image median values for object measurements?: Yes
Calculate the per-image standard deviation values for object mea-
surements?:
Yes
Create a GenePattern GCT ﬁle?: No
Export all measurement types?: Yes
Table 3: CellProﬁler protocol for the microscopy picture quantiﬁcation of cells positively stained with
A20- and anti-AAP2-antibodies.
Protocol step Setting
CellProﬁler Version,2014-07-23T17:45:00
6c2d896
Images
Filter images?: No ﬁltering
Metadata
Extract metadata?: No
NamesAndTypes
Assign a name to: Images matching rules
Select the rule criteria: and (ﬁle does contain "dapi.tif"")
Name to assign these images: DNA
Select the image type: Grayscale image
Set intensity range from: Image bit-depth
Select the rule criteria: and (ﬁle does contain
"AF488.tif"")
Name to assign these images: Green
Select the image type: Grayscale image
Set intensity range from: Image metadata
Select the rule criteria: and (ﬁle does contain
"AF568.tif"")
Name to assign these images: Red
Select the image type: Grayscale image
Set intensity range from: Image metadata
CorrectIlluminationCalculate
Select the input image: Red
Name the output image: IllumRed
Select how the illumination function is calculated: Background
Block size: 60
Rescale the illumination function?: Yes
Calculate function for each image individually, or based on all
images?:
Each
Smoothing method: No smoothing
Retain the averaged image?: No
Retain the dilated image?: No
CorrectIlluminationApply:
Select the input image: Red
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Name the output image: CorrRed
Select the illumination function: IllumRed
Select how the illumination function is applied: Divide
IdentifyPrimaryObjects:
Select the input image: DNA
Name the primary objects to be identiﬁed: Nuclei
Typical diameter of objects, in pixel units (Min,Max): 11,40
Discard objects outside the diameter range?: Yes
Try to merge too small objects with nearby larger objects?: No
Discard objects touching the border of the image?: Yes
Threshold strategy: Global
Thresholding method: Background
Select the smoothing method for thresholding: Automatic
Threshold correction factor: 1
Lower and upper bounds on threshold: 0,1
Method to distinguish clumped objects: Intensity
Method to draw dividing lines between clumped objects: Intensity
Automatically calculate size of smoothing ﬁlter for declumping?: Yes
Automatically calculate minimum allowed distance between local
maxima?:
Yes
Speed up by using lower-resolution image to ﬁnd local maxima?: No
Retain outlines of the identiﬁed objects?: Yes
Name the outline image: NucOutlines
Fill holes in identiﬁed objects?: After both thresholding and de-
clumping
Handling of objects if excessive number of objects identiﬁed: Continue
IdentifyPrimaryObjects:
Select the input image: Green
Name the primary objects to be identiﬁed: B1_or_A20_positive_cells
Typical diameter of objects, in pixel units (Min,Max): 10,50
Discard objects outside the diameter range?: Yes
Try to merge too small objects with nearby larger objects?: No
Discard objects touching the border of the image?: Yes
Threshold strategy: Global
Thresholding method: Background
Select the smoothing method for thresholding: Automatic
Threshold correction factor: 1
Lower and upper bounds on threshold: 0,1
Method to distinguish clumped objects: Shape
Method to draw dividing lines between clumped objects: Intensity
Automatically calculate size of smoothing ﬁlter for declumping?: Yes
Automatically calculate minimum allowed distance between local
maxima?:
Yes
Speed up by using lower-resolution image to ﬁnd local maxima?: Yes
Retain outlines of the identiﬁed objects?: No
Name the outline image: PrimaryOutlines
Fill holes in identiﬁed objects?: Never
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Handling of objects if excessive number of objects identiﬁed: Continue
IdentifyPrimaryObjects:
Select the input image: CorrRed
Name the primary objects to be identiﬁed: AAP
Typical diameter of objects, in pixel units (Min,Max): 10,50
Discard objects outside the diameter range?: Yes
Try to merge too small objects with nearby larger objects?: No
Discard objects touching the border of the image?: Yes
Threshold strategy: Global
Thresholding method: Background
Select the smoothing method for thresholding: Automatic
Threshold correction factor: 1.0
Lower and upper bounds on threshold: 0.0,1.0
Method to distinguish clumped objects: Shape
Method to draw dividing lines between clumped objects: Intensity
Automatically calculate size of smoothing ﬁlter for declumping?: Yes
Automatically calculate minimum allowed distance between local
maxima?:
Yes
Speed up by using lower-resolution image to ﬁnd local maxima?: Yes
Retain outlines of the identiﬁed objects?: No
Fill holes in identiﬁed objects?: Never
Handling of objects if excessive number of objects identiﬁed: Continue
ExportToSpreadsheet:
Select the column delimiter: Comma ("","")
Output ﬁle location: Default Input Folder sub-folder
Add a preﬁx to ﬁle names?: No
Overwrite without warning?: Yes
Add image metadata columns to your object data ﬁle?: No
Limit output to a size that is allowed in Excel?: No
Representation of Nan/Inf: NaN
Calculate the per-image mean values for object measurements?: No
Calculate the per-image median values for object measurements?: No
Calculate the per-image standard deviation values for object mea-
surements?:
No
Create a GenePattern GCT ﬁle?: No
Export all measurement types?: Yes
Table 4: CellProﬁler protocol for the microscopy picture quantiﬁcation of cells positively stained with
B1- and anti-AAP2-antibodies.
Protocol step Setting
CellProﬁler Version,2014-07-23T17:45:00
6c2d896
Images
Filter images?: No ﬁltering
Metadata
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Extract metadata?: No
NamesAndTypes
Assign a name to: Images matching rules
Select the rule criteria: and (ﬁle does contain "dapi.tif"")
Name to assign these images: DNA
Select the image type: Grayscale image
Set intensity range from: Image bit-depth
Select the rule criteria: and (ﬁle does contain
"AF488.tif"")
Name to assign these images: Green
Select the image type: Grayscale image
Set intensity range from: Image metadata
Select the rule criteria: and (ﬁle does contain
"AF568.tif"")
Name to assign these images: Red
Select the image type: Grayscale image
Set intensity range from: Image metadata
CorrectIlluminationCalculate
Select the input image: Red
Name the output image: IllumRed
Select how the illumination function is calculated: Background
Block size: 60
Rescale the illumination function?: Yes
Calculate function for each image individually, or based on all
images?:
Each
Smoothing method: No smoothing
Retain the averaged image?: No
Retain the dilated image?: No
CorrectIlluminationApply:
Select the input image: Red
Name the output image: CorrRed
Select the illumination function: IllumRed
Select how the illumination function is applied: Divide
IdentifyPrimaryObjects:
Select the input image: DNA
Name the primary objects to be identiﬁed: Nuclei
Typical diameter of objects, in pixel units (Min,Max): 11,40
Discard objects outside the diameter range?: Yes
Try to merge too small objects with nearby larger objects?: No
Discard objects touching the border of the image?: Yes
Threshold strategy: Global
Thresholding method: Background
Select the smoothing method for thresholding: Automatic
Threshold correction factor: 1
Lower and upper bounds on threshold: 0,1
Method to distinguish clumped objects: Intensity
Method to draw dividing lines between clumped objects: Intensity
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Automatically calculate size of smoothing ﬁlter for declumping?: Yes
Automatically calculate minimum allowed distance between local
maxima?
:Yes
Speed up by using lower-resolution image to ﬁnd local maxima?: No
Retain outlines of the identiﬁed objects?: Yes
Name the outline image: NucOutlines
Fill holes in identiﬁed objects?: After both thresholding and de-
clumping
Handling of objects if excessive number of objects identiﬁed: Continue
IdentifyPrimaryObjects:
Select the input image: Green
Name the primary objects to be identiﬁed: B1_or_A20_positive_cells
Typical diameter of objects, in pixel units (Min,Max): 10,50
Discard objects outside the diameter range?: Yes
Try to merge too small objects with nearby larger objects?: No
Discard objects touching the border of the image?: Yes
Threshold strategy: Global
Thresholding method: Background
Select the smoothing method for thresholding: Automatic
Threshold correction factor: 1
Lower and upper bounds on threshold: 0,1
Method to distinguish clumped objects: Shape
Method to draw dividing lines between clumped objects: Intensity
Automatically calculate size of smoothing ﬁlter for declumping?: Yes
Automatically calculate minimum allowed distance between local
maxima?:
Yes
Speed up by using lower-resolution image to ﬁnd local maxima?: Yes
Retain outlines of the identiﬁed objects?: No
Name the outline image: PrimaryOutlines
Fill holes in identiﬁed objects?: Never
Handling of objects if excessive number of objects identiﬁed: Continue
IdentifyPrimaryObjects:
Select the input image: CorrRed
Name the primary objects to be identiﬁed: AAP
Typical diameter of objects, in pixel units (Min,Max): 10,50
Discard objects outside the diameter range?: Yes
Try to merge too small objects with nearby larger objects?: No
Discard objects touching the border of the image?: Yes
Threshold strategy: Per object
Thresholding method: MoG
Masking objects: B1_or_A20_positive_cells
Approximate fraction of image covered by objects?: 0.01
Select the smoothing method for thresholding: Automatic
Threshold correction factor: 1.0
Lower and upper bounds on threshold: 0.0,1.0
Method to distinguish clumped objects: Shape
Method to draw dividing lines between clumped objects: Intensity
128
PhD thesis, Stefanie Große
Protocol step Setting
Automatically calculate size of smoothing ﬁlter for declumping?: Yes
Automatically calculate minimum allowed distance between local
maxima?:
Yes
Speed up by using lower-resolution image to ﬁnd local maxima?: Yes
Retain outlines of the identiﬁed objects?: No
Fill holes in identiﬁed objects?: Never
Handling of objects if excessive number of objects identiﬁed: Continue
ExportToSpreadsheet:
Select the column delimiter: Comma ("","")
Output ﬁle location: Default Input Folder sub-folder
Add a preﬁx to ﬁle names?: No
Overwrite without warning?: Yes
Add image metadata columns to your object data ﬁle?: No
Limit output to a size that is allowed in Excel?: No
Representation of Nan/Inf: NaN
Calculate the per-image mean values for object measurements?: No
Calculate the per-image median values for object measurements?: No
Calculate the per-image standard deviation values for object mea-
surements?:
No
Create a GenePattern GCT ﬁle?: No
Export all measurement types?: Yes
Table 5: Microsoft excel macro for ﬂow cytometry data extraction
Protocol step
Sub macro_FACS
Dim i As Integer
Dim j As Integer
Sheets.Add
ActiveSheet.Name = "result"
For i = 1 To 12
For j = 1 To 8
Worksheets("result").Cells(j, i).Value = Worksheets("Result 1").Cells(9 + ((i - 1) + (j - 1) * 12) * 7, 8)
Next
Next
Sheets.Add
ActiveSheet.Name = "result_positive cells"
For i = 1 To 96
'For j = 1 To 8
Worksheets("result_positive cells").Cells(i, 1).Value = Worksheets("Result 1").Cells(9 + ((i - 1)) * 7, 8)
'Next
Next
Sheets.Add
ActiveSheet.Name = "result_x-mean"
For i = 1 To 96
For j = 1 To 8
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Worksheets("result_x-mean").Cells(i, 1).Value = Worksheets("Result 1").Cells(9 + ((i - 1)) * 7, 10)
Next
Next
Sheets.Add
ActiveSheet.Name = "result_x-median"
For i = 1 To 96
For j = 1 To 8
Worksheets("result_x-median").Cells(i, 1).Value = Worksheets("Result 1").Cells(9 + ((i - 1)) * 7, 9)
Next
Next
End Sub
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